Home Blog Page 2

Centessa Pharmaceuticals Announces Appointment of Dr. Mathias Hukkelhoven to its Board of Directors

Centessa Pharmaceuticals plc

BOSTON and LONDON, 01 July. 10, 2022 (GLOBE NEWSWIRE) — Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a research and development (“R&D”) innovation engine that aims to discover, develop and ultimately deliver drugs effective for patients, today announced the appointment of Mathias Hukkelhoven, Ph.D., former Senior Vice President, Global Regulatory, Security and Biometrics at Bristol Myers Squibb (BMS), to its Board of Directors. Additionally, the company announced that Aaron Kantoff has resigned from the company’s board of directors, but will remain actively involved with the company as an advisor. Both amendments come into force on July 1, 2022.

“I am very pleased to welcome Math to the Centessa Board of Directors. Math’s deep industry experience in leading global regulatory efforts and developing new therapies will be extremely valuable as we continue to advance our rare disease and immuno-oncology pipeline of the best potential drugs for patients,” said Saurabh Saha, MD, PhD. , CEO of Centessa. “I also want to thank Aaron for his significant contributions to the Centessa Board of Directors, which have helped grow our company from its inception through our successful IPO to where we are today.”

“I am delighted to join Centessa’s Board of Directors at such a critical time for the company,” said Dr. Hukkelhoven. “I have been impressed with Centessa’s leadership team, vision and exciting portfolio, and look forward to working with the board and team to advance these potential therapies through readings from proof of concept with the ultimate goal of addressing unmet patient needs.”

Dr. Hukkelhoven is an experienced global leader in drug regulation and development. He previously served as Senior Vice President, Global Regulatory, Security and Biometrics at BMS and was also responsible for the R&D group at BMS China and the Clinical Pharmacology and Pharmacometrics group. In these roles, Dr. Hukkelhoven was responsible for establishing regulatory strategy and driving the execution of global regulatory and pharmacovigilance plans for BMS. Prior to joining BMS, Dr. Hukkelhoven served as Chairman of the Portfolio Stewardship Board at Novartis Pharmaceuticals and was Senior Vice President, Global Head Drug Regulatory Affairs at Novartis from 2001 to 2009. He also worked at Hoffmann LaRoche (Switzerland ) and Organon (The Netherlands). Dr. Hukkelhoven was chair of the PhRMA Regulatory Affairs Coordinating Committee, and most recently PhRMA negotiator for the PDUFA VII negotiations with the United States Food and Drug Administration (FDA). Dr. Hukkelhoven received his BSc and Ph.D. with honors in Biology and Biochemistry from the University of Nijmegen, The Netherlands. Dr. Hukkelhoven also sits on the board of directors of Compugen Ltd and is a senior advisor at McKinsey and an R&D strategy advisor at LianBio.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company with an R&D innovation engine that aims to discover, develop and ultimately deliver effective medicines to patients. Our programs range from discovery to advanced development and cover a range of high-value indications in rare diseases and immuno-oncology. We are led by a leadership team with extensive R&D experience, providing direct guidance to our program teams to rapidly progress our candidates from research through all stages of development. For more information, visit www.centessa.comwhich is not part of this version.

Forward-looking statements

This press release contains forward-looking statements. These statements can be identified by words such as “may”, “could”, “will”, “could”, “should”, “should”, “expect”, “intend”, ” plan”, “goal”, “anticipate”, “believe”, “estimate”, “predict”, “potential”, “continue”, “ongoing”, “aim”, “seek” and variations of these words or similar expressions that are intended to identify future- looking statements. Any statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements, including statements regarding the expected benefits of the Dr. Hukkelhoven’s service on the board of directors of Centessa; statements regarding the Company’s ability to deliver effective medicines to patients; the ability of our key executives to drive the execution of the Company’s program portfolio; our asset-centric business model t the advantages and benefits expected from it; and clinical research and development plans and timing. All forward-looking statements contained in this press release are based on our current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ. significantly and unfavorably from those established. contained in or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, risks related to the safety and tolerability profile of our product candidates; our ability to protect and maintain our intellectual property position; business (including commercial viability), regulatory, economic and competitive risks, uncertainties, contingencies and assumptions regarding the Company; risks inherent in the development of products and technologies; future results of our ongoing and planned clinical trials; our ability to obtain adequate financing, including through our financing facility with Oberland, to fund our planned clinical trials and other expenses; industry trends; the industry’s legal and regulatory framework, including obtaining and maintaining approvals to conduct or continue clinical trials; risks relating to future expenditures related to our asset-centric business model; the risk that one or more of our product candidates will not be successfully developed and/or commercialized; the risk that the results of preclinical studies or clinical studies will not be predictive of future results in future studies; geopolitical risks such as the Russian-Ukrainian war and risks related to the ongoing COVID-19 pandemic, including the effects of Delta, Omicron and any other variants. These and other risks relating to our programs and operations are described in more detail in our Quarterly Report on Form 10-Q for the three months ended March 31, 2022, and our other reports, which are filed with the Securities and Exchange Commission. United States. We expressly disclaim any obligation to update any forward-looking statements, except as required by law.


Kristen K. Sheppard, Esq.
SVP of Investor Relations
[email protected]

Apply for Scientific Officer and Analyst vacancies at MHRB

Applications are invited for various technical positions with the Medical and Health Recruitment Board (MHRB), Assam.

Medical and Health Recruitment Board (MHRB), Assam is inviting applications from eligible candidates for the positions of Principal Scientific Officer, Scientific Officer and Drug Testing Laboratory Analyst (AYUSH) at Government Ayurvedic College, Guwahati.

Name of position: Senior Scientific Manager – Botanical Section

Number of positions: 1

Salary Range: Rs. 12,000-40,000 with GP-6,100/- PM (PB-4)

Education: M.Sc. in Botany (Ph.D is preferred) or M. Pharm (Pharmacognosy is preferred)

Experience: At least 7 years of ASU&H government/government drug testing experience. recognized laboratory and should have experience in handling HPLC, HPTLC and AAS. Preference shall be given to the person working in the same position under APSC Rule 3(f)

Also Read: Assam Career: Apply for 20 Vacancies for Assistant Professor at Bhattadev University

Name of position: Scientific Officer – Botanical Section

Number of positions: 1

Salary Range: Rs. 12,000-40,000 with GP-5,400/- PM (PB-4)

Education: M.Sc. in Botany or M. Pharm

Experience: At least 5 years of ASU&H government/government drug testing experience. recognized laboratory and should have experience in handling HPLC, HPTLC and AAS. Preference shall be given to the person working in the same position under APSC Rule 3(f)

Job name: Analyst – Botany Section

Number of positions: 1

Salary Range: Rs. 8,000-35,000 with GP-4,500/- PM (PB-3)

Education: B.Sc. (Botany as main subject) or B.Pharm

Experience: At least 5 years of ASU&H government/government drug testing experience. recognized laboratory and must have experience in handling microscopy. Preference will be given to the person working in the same position under APSC Rule 3(f).

Position name: Principal Scientific Officer – Chemistry Section

Number of positions: 1

Read also: Assam Career: Cotton University Recruitment 2022

Salary Range: Rs. 12,000-40,000 with GP-6,100/- PM (PB-4)

Education Degree: M.Sc. in Chemistry (PhD is preferred) or M. Pharm (Pharmaceutical/Medicinal Chemistry is preferred)

Experience: At least 7 years of ASU&H government/government drug testing experience. recognized laboratory and should have experience in handling HPLC, HPTLC and AAS. Preference shall be given to the person working in the same position under APSC Rule 3(f)

Position name: Scientific Manager – Chemistry Section

Number of positions: 1

Salary Range: Rs. 12,000-40,000 with GP-5,400/- PM (PB-4)

Educational qualification: M.Sc. in Chemistry or M. Pharm

Experience: At least 5 years of ASU&H government/government drug testing experience. recognized laboratory and must have experience in handling GC, HPLC and AAS. Preference will be given to the person working in the same position under APSC Rule 3(f).

Job name: Analyst – Chemistry Section

Number of positions: 1

Salary Range: Rs. 8,000-35,000 with GP-4,500/- PM (PB-3)

Education: B.Sc. (Chemistry as main subject) or B.Pharm

Experience: At least 5 years of ASU&H government/government drug testing experience. recognized laboratory and must have experience in handling GC, HPLC and AAS. Preference will be given to the person working in the same position under APSC Rule 3(f).

Position name: Principal Scientific Officer – ISM Section

Also Read: Assam Career: Apply for PGT & TGT Vacancies at Kendriya Vidyalaya No.2, AFS Tezpur

Number of positions: 1

Salary Range: Rs. 12,000-40,000 with GP-6,100/- PM (PB-4)

Educational qualification: MD (Ayur) in Rasashastra or Dravyaguna Vigyan

Experience: At least 7 years of manufacturing/teaching/testing experience in ASU&H government/government drugs. recognized institute or in a reputable institute. Preference will be given to the person working in the same position under APSC Rule 3(f).

Age: Between 21 and 38 years old on 01/01/2022. Relaxation for the upper age will be considered according to the rules / government in force. notification.

How to register : Applicants can apply online for the above positions through the website https://nhm.assam.gov.in/ till 16th July 2022

Application fees : The application must be accompanied by the required application fee of Rs. 250/- (Rs. two hundred and fifty) only for General Category applicants and Rs. 150/- (Rs. One Hundred and Fifty) only for OBC/MOBC/ SC/ST(P)/ST(H). No application fee is required for applicants with GLP certificate and PWD certificate.

Detailed announcement : Click here

Apply online : Click here

Also Read: Assam Career: Numaligarh Refinery Limited Recruitment 2022

Hampton Roads Cannabis Businesses Diversify Awaiting Legal Retail Sales, But Future Unclear – The Virginian-Pilot

Although the sale of recreational marijuana is illegal in Virginia, more and more Hampton Roads entrepreneurs are getting into the industry.

A Google Maps search for “cannabis” returns results from at least nine local businesses. Dozens of other companies are popping up looking for “CBD”, a non-psychoactive compound found in cannabis.

The companies go beyond just selling CBD oils and creams. Now Hampton Roads businesses and organizations are helping customers grow their own plants, access medical marijuana cards, and build job skills to prepare for the eventual legalization of retail sales. It is uncertain whether the General Assembly will open the door to retail sales by 2024.

When former Governor Ralph Northam decriminalized marijuana possession in 2021, the law also allowed Virginia residents to grow up to four cannabis plants at their place of residence.

Norfolk resident Phil Jernigan’s new venture is helping aspiring pot growers break into the world of indoor growing. It opened Tidewater High Grow in May on Tidewater Drive just off the Interstate 64 interchange.

Inside the shop is everything from soil for growing lights to huge hydroponic setups. Jernigan, who says he has been growing for decades, hopes to start classes soon to educate beginners.

“Since the law came into effect, you’ve had a lot of new, entry-level producers,” Jernigan said. “It’s a huge new market.”

Growth is an investment, Jernigan said. He estimated that a decent hydroponic setup — a tent, fans, lights, and other materials — could cost upwards of $1,200.

He is also participating in a new trend – cannabis seed giveaways – as a way to promote his business. Aside from medical dispensaries, buying and selling marijuana is prohibited by 2021 law, but “adult sharing” or gifting is possible.

Michael Stoney began exploring marijuana after being shot twice in the arm and chest while working as a narcotics detective in Queens, New York.

Stoney suffered major pain episodes after the shooting, but he hated taking painkillers. After moving to Hampton Roads, Stoney realized weed and CBD could help him manage his pain, and he threw the opioids away.

Stoney, owner of the PROH wellness center in Norfolk, now helps clients obtain medical marijuana licenses. For $125, clients can meet with a nurse practitioner, who examines their symptoms and issues a written certificate of cannabis use. PROH had also helped patients register with the Virginia Board of Pharmacy, but legislation passed earlier this year ends that registration process effective July 1.

In addition to helping customers obtain medical marijuana cards, the company also offers life coaching classes – teaching good habits regarding diet, exercise and other factors.

“We want to talk to them a lot more about their lifestyle,” Stoney said.

Another group from Virginia focuses on integrating non-white residents of Hampton Roads into the cannabis industry in a variety of roles – from running a dispensary to growing cannabis to learning. professional skills for retail sales.

Called the Virginia Minority Cannabis Commission, the nonprofit is focused on creating meaningful economic change for those most affected by decades of unjust drug laws, said Paul McLean, founder and executive director.

The group has previously hosted several events in Hampton Roads where they attempt to bridge the cannabis education gap with religious and community leaders. The event also offers attendees a chance to learn how to get a head start on entering the industry before retail sales begin.

“It’s about creating opportunities and educating people,” McLean said.

Business owners recognized that they were operating in an industry with an uncertain legislative future. After Republicans claimed the Virginia House of Delegates and governorship in 2021, they addressed the issue of establishing cannabis retail sales. Democrats had set a goal of establishing a system by 2024, but then tried to push that date back into the 2022 session. Republicans blocked the attempt and offered no alternative, reports say. by Virginia Mercury.

Governor Glenn Youngkin and his allies also inserted language into the state budget that recriminalizes having 4 ounces but less than a pound of marijuana in public as a misdemeanor. Lawmakers approved the change as part of the budget, which was signed into law by Youngkin.

McLean said he’s not surprised lawmakers on both sides of the aisle are still trying to roll back marijuana laws.

“It’s a real concern,” he said.

McLean noted the stigma the drug still faces and the problems caused by legal drugs like prescription opioids and alcohol like addiction and drunk driving.

Inside business

Days of the week

Economic News for the Hampton Roads Area

Jernigan worried that the setback would deter new marijuana growers and entrepreneurs from entering the market.

Stoney said he thought, given the amount of money at stake, lawmakers would give in and establish a retail system. Still, he said he would continue to help his customers and had high hopes for the industry’s future.

“I want it to be a destination for tourists,” Stoney said. “I want Virginia to be proud.”

Tidewater High Grow is open 11 a.m. to 7 p.m. Monday through Saturday at 7441 Tidewater Drive in Norfolk.

The PROH Wellness Center is open from 11 a.m. to 7 p.m. at 223 E. City Hall Ave., Suite 327, in Norfolk.

The Virginia Minority Cannabis Commission’s next event is a free cannabis talk at 9 a.m. on July 23 at the Sixth Mt. Zion STREM Center at 1705 Aspenwood Drive in Hampton.

Trevor Metcalfe, 757-222-5345, [email protected]

New practice changes for general medicine


Updates to PBS subsidies, prescribing, and digital health services will go into effect July 1.

GPs should be aware of some changes to PBS prescribing and grants in the new fiscal year.

In addition to changes to the MBS from July 1, updates to other areas related to general medicine will be implemented from the new exercise.

Closing the Gap PBS Co-Pay Program
The new fiscal year marks the end of the grace period for reforming the PBS script’s Closing the Gap (CTG) metrics. The co-pay program was extended in July 2021, before further grace periods were extended through January and July 2022.

The CTG registration system for Aboriginal and Torres Strait Islander patients is operated by Services Australia and operates online through the Health Professional Online Services (HPOS) portal.

To date, the main benefits of the program include:


  • single registration
  • check-in should only be done via HPOS
  • any PBS prescriber (such as physicians, dentists, optometrists, midwives, nurse practitioners) or AHPRA-registered Aboriginal and Torres Strait Islander health practitioners registered with Medicare as provider can register eligible Aboriginal and Torres Strait Islander
  • people can be enrolled in the program regardless of where they live and their chronic disease status
  • prescriptions no longer need to be annotated with ‘CTG’.

However, the RACGP is concerned about some of the July 1 changes that mean patients who are not properly registered will pay more for PBS drugs.

Dr. Mary Belfrage has previously stated newsGP that it is not entirely the responsibility of general practitioners to register patients.

“While the changes to the program are positive … it is up to the individual prescriber to verify eligibility,” she said.

‘[But] it is also the responsibility of pharmacies to know this, because it is actually at the time of dispensing that this becomes a problem, and not at the time of prescription.

While many patients have been successfully transferred from the old CTG registration system, there are currently potentially thousands of eligible clients who are not properly registered on CTG, and GP clinical software systems may not provide a clear indication of a client’s CTG registration status.

Also, writing or printing “CTG” on a script or filling out PIP forms does not guarantee that a patient will receive CTG scripts – this can only be done through HPOS

To help maintain access to medicines for Aboriginal and Torres Strait Islander patients, the college recommends that GPs and practice teams consider:

  • ensure workflow and systems support both verification of Aboriginal and Torres Strait Islander patient registration status and registration of all eligible CTG clients
  • ask patients if they have had any problems accessing CTG drugs when they come to a pharmacy
  • Bulk SMS to Aboriginal and Torres Strait Islander patients with key information, if practice software allows.

As only ‘warnings’, not ‘rejections’, are issued at the pharmacy for customers who are not registered (before July 2022), GPs may also wish to contact their local pharmacies to check if they received numerous PBS “warnings” for their respective clients.

Health professional training resources are available on the Services Australia website, and NACCHO has developed a CTG Information and FAQs document for Indigenous community-controlled health organizations to better address issues linked to the new CTG reforms.

Provider Digital Access Account Requirements

From July 1, it will be mandatory for all physicians and medical practices to have and use a Provider Digital Access Account (PRODA).

When independent contract doctors work in a practice, each doctor must have their own PRODA account and issue invoices with their own ABN (and not that of the practice). If the doctor uses the firm’s PRODA account, this doctor cannot be considered an independent contractor.

When physicians are employed by the practice, they can use the practice’s PRODA account and ABN when invoicing. At this stage, electronic invoicing via PRODA will not be mandatory.

If GPs have specific questions about PRODA and e-billing, they can contact Services Australia or a finance/tax professional.

PBS Safety Net Thresholds

Beginning July 1, Pharmaceutical Benefit Scheme Safety Net thresholds will be reduced by the equivalent of 12 full-price scripts for concession card holders and the equivalent of approximately two full-price scripts for unpaid patients. concessionaires.

For concessional patients, the safety net threshold will be lowered from $326.40 to $244.80 – a reduction of $81.60 for concessional patients. This means that when a concession cardholder reaches the safety net threshold, after 36 full-price concession scripts, they will receive PBS drugs free for the remainder of the year.

For other patients, the general safety net threshold will be reduced from $1,542.10 to $1,457.10 – a maximum reduction of $85 for non-concessional patients, meaning that after the equivalent of approximately 34 general full-rate co-payments, general patients only pay the preferential rate. co-payment of $6.80 per PBS scenario (plus any applicable bonus) for the remainder of the year.

Further information can be found on the PBS website or in the Department of Health and Aged Care FAQ document.

Log in below to join the conversation.

Bridging the Gap EOFY Co-payment PBS Services Australia

newsGP weekly poll
Did any of your patients have problems accessing COVID antivirals (via PBS) after you prescribed them?

Understand and manage common drug interactions

Aris Saoulidis Senior Pharmacist, Hospital Pharmacy, Addenbrookes Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, England

Christianne Micallef Senior Pharmacist – Antimicrobials, Addenbrookes Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, England

Why you should read this article:
  • To deepen your knowledge of some of the mechanisms of drug interactions

  • To help you identify and manage common drug interactions in your practice

  • To count towards revalidation as part of your 35 hours of CPD, or you may wish to write a reflective report (UK readers)

  • To help with your professional development and local registration renewal requirements (non-UK readers)

Drug interactions are common in clinical practice and have a direct effect on patient morbidity and mortality. However, with the proper knowledge, they can be avoided. Medication administration is an essential nursing task and an increasing number of specialist nurses are also independent prescribers. This article details some of the common patterns of drug interactions and aims to help nurses optimize patient medication use.

Nursing standard.
do I: 10.7748/ns.2022.e11806

Peer review

This article has undergone external double-blind peer review and plagiarism check using automated software


[email protected]

Conflict of interest

None declared

Saoulidis A, Micallef C (2022) Understanding and managing common drug interactions. Nursing standard. doi:10.7748/ns.2022.e11806

Online: June 29, 2022

You want to know more ?

Already registered? Login


Unlock Full Access to RCNi Plus Today

Save over 50% on your first 3 months

Your subscription package includes:
  • Unlimited online access to the 10 RCNi journals and their archives
  • Customizable dashboard with over 200 topics
  • RCNi Learning with over 180 RCN accredited learning modules
  • RCNi Portfolio to build evidence for revalidation
  • Personalized newsletters tailored to your interests


RCN student member? Try Standard Nursing Student

Alternatively, you can purchase access to this article for the next seven days. Buy now


11th Annual SPDS International Conference, Disso India 2022 Online Inaugurated by Dr. Rajeev Raghuvanshi

Disso India 2022

MUMBAI, MAHARASHTRA, INDIA, June 29, 2022 /EINPresswire.com/ — Society for Pharmaceutical Dissolution Sciences (SPDS), had led the 11th Annual International Conference of the SPDS – Disso India 2022 –from June 23 to 25, 2022 in collaboration with the American Association of Pharmaceutical Scientists (AAPS). Held annually, this flagship conference of the Society for Pharmaceutical Dissolution Science (SPDS) brought together pharmaceutical R&D, QA and QC professionals as well as Indian and overseas scholars, involving speakers from the United States, Europe and Asia. The international conference took place online from June 23 to 25, 2022 (3:00 p.m. to 8:00 p.m. IST)

‘Advances in Dissolution Science’ was the theme of the conference. The Society for Pharmaceutical Dissolution Science (SPDS) has gained international recognition and acceptance in a short time.

Dr. Rajeev Raghuvanshi, Scientific Director-Secretary, Indian Pharmacopoeia Commission, opened the conference and delivered his keynote address. Dr. Rubina Bose, Deputy Comptroller of Medicines (India) was the guest of honor at the conference.

The 2nd edition of the Pharmaceutical Dissolution Science desk book was also released at the hands of chief guest Dr. Rajeev Raghuvanshi. Dr Ramaswamy has announced a special pre-print offer for Disso India delegates who can book their copy directly on www.spds.in

The Disso India 2022 Scientific Abstract Book has been officially released and will be made available on the SPDS website.

Disso India- 2022 Online organized around 20 lectures over a period of 3 days by eminent professionals working in the pharmaceutical industry across the globe as well as academia. More than two thousand professionals from pharmaceutical R&D, QA, QC and universities around the world attended this event on the first day.

The scientific sessions were programmed and executed under the chairmanship of Professor Arvind Bansal, Professor and Head of Department of Pharmacy, NIPER, SAS Nagar, and Co-Chairman-Dr. Vinod. P. Shah, ex-USFDA and pharmaceutical consultant, United States. A galaxy of prominent speakers enlightened attendees on current dissolution-centric technologies and science.

Teacher. Arvind Bansal (Dean, NIPER, SAS Nagar, India), Dr. Indu Bhushan (Steers Engineering), Dr. Rajashri Shinde (ABITEC), Prof. Padma Devarajan, (Institute of Chemical Technology, India), Prof. Dianne Burgess, (UCONN School of Pharmacy, Connecticut), Dr Jean Cardot, (University of Auvergne, France), Dr Vinod P. Shah (Pharmaceutical Consultant, USA), Dr Deanna Mudie (R&D, Lonza Inc, USA), Dr . Varsha Pradhan, (ICT Mumbai), Samir Haddouchi (SPS Pharma Services, Orléans, France), Dr Deirdre D’Arcy (Trinity College, Ireland), Kempf Jurgen (SOTAX AG, Switzerland), Dr Ajay Saxena (BMS, USA ), Dr Xujin Lu (BMS, USA), Sandeep Kulkarni (Image Provision Technology Pvt. Ltd. India), Holger Herman (SOTAX AG, Switzerland), Vijay Kshirsagar (TRAC Pharma Consulting, Mumbai), Dr Anant Ketkar (Scientific Lead-India, Simulation Plus, Inc.) were among the conferences that were part of Disso India 2022 Online.

The event was supported by companies like SOTAX and ACG who were Platinum partners of the event along with BASF, Electrolab, Steer Engineering, Abitec corp, Image Provision Technology and Inveniolife.

A registered NGO, Society for Pharmaceutical Dissolution Science (SPDS) was established on July 16, 2012 in Mumbai with the aim of promoting scientific and technological development in the field of dissolution science among pharmaceutical professionals, academics, students, regulatory bodies, etc. SPDS is the only professional body dedicated to Dissolution and its application in the world. SPDS envisions being one of the most important organizations focusing on dissolution science in the pharmaceutical industry and academia.

SPDS has proudly partnered with the American Association of Pharmaceutical Scientists (AAPS) for this year’s Disso India 2022 event. Founded in 1986, the American Association of Pharmaceutical Scientists (AAPS) is a professional scientific organization of approximately 7,000 individual members and more than 10,000 active stakeholders employed in academia, industry, government and other research institutes related to pharmaceutical sciences all over the world. The mission of AAPS is “to advance the ability of pharmaceutical scientists to develop products and therapies that improve global health.” It operates on five core values ​​- Learning, Innovation, Service, Inclusiveness and Integrity.

Dr Prakash Bhosale
+91 8097027355
write to us here
Visit us on social media:

The sad truth about online pharmacies

Are you tired of spending so much money on prescription drugs and you are browsing very professional online pharmacy websites. The premises, and the promises, are enticing. Save Money, Free Shipping, No Prescriptions Needed, No Doctor Visits Needed.

Except, if you don’t know what to look for, you could very well be buying fake fentanyl or methamphetamine pills from an international or domestic criminal network.

“Consumers are far too confident when it comes to buying services or products online, including medicines.”

— Libby Baney, Senior Advisor, Alliance for Safe Online Pharmacies

There’s Viagra for erectile dysfunction, drugs that promise to help you lose weight, and opioid painkillers like OxyContin and Vicodin. You are a cautious consumer. You’ve read the fine print, but it doesn’t seem to hurt to order from there. In fact, it sounds like a great idea.

According to the Drug Enforcement Administration’s 2021 Public Safety Alert, there is a huge increase in online sales of counterfeit death pills. Mass-produced in Mexico, smuggled into the United States, and sold on popular social media and e-commerce platforms, they resemble their legitimate counterparts and are sickening and killing Americans at an unprecedented rate.

Lily: Millions could lose health coverage if premium subsidies expire later this year, officials say

Many buy prescription drugs online

Americans of all demographics are shopping for a wide range of prescription drugs online, including drugs to treat persistent conditions such as asthma or diabetes, specialty drugs such as those for cancer, and frequently taken drugs like Adderall for ADHD (attention deficit/hyperactivity disorder).

According to the National Association of Boards of Pharmacy (NABP), of the approximately 35,000 online pharmacies worldwide, 95% are unregulated and fraudulent, selling products that may be substandard, contaminated or expired. Operating within US pharmacy laws and safety standards, they won’t necessarily cure what you’re suffering from and, in fact, they might even kill you.

“Data shows that online pharmacies are being used by increasing numbers of people, especially during the early stages of the pandemic when people weren’t entering physical stores,” says Libby Baney, senior adviser at the Alliance for Safe. Online Pharmacies (ASOP Global) and the ASOP Global Foundation.

She explains, “People use them for convenience, cost and easy access to medication. It can often be cheaper to buy medicine there, even if you have health insurance and are only responsible for a copayment. When legitimate and legal, providing you with the prescription medications your doctor has prescribed, online pharmacies can be a viable alternative to the pharmacy.

Legitimate is the key word. How to tell good online pharmacies and websites from bad ones is very confusing for consumers, Baney says. Even working in the field of health does not make it easier to separate the wheat from the chaff.

“These digital drug dealers know what consumers want and they deliver, their main goal being to sell you pills for profit,” Baney says.

Are you ordering from an online pharmacy because you don’t have time to go to the doctor? If there is no “real” doctor or pharmacist to chat with online, you may decide for yourself that you need a Z-pack or Cipro (types of antibiotics) for that sore throat persistent or this urinary tract infection. You will be asked to complete a questionnaire which is supposed to be reviewed by a pharmacist, and your medicine will be on its way soon.

The problem is, it may not be the right drug or dosage for your self-diagnosed problem, and you have no way of knowing if the drug you’re getting is produced in a shoddy facility or if it contains a much smaller amount of assets. ingredient than it should.

Misconceptions about online pharmacies

In addition to putting your health at risk, buying prescription drugs from fraudulent online pharmacies can compromise your financial and personal data, infect your computer with a virus, and allow your information to be spread to other illegal websites. and Internet scams.

Although both ship your medications directly to your home, your insurance plan’s mail-order pharmacy is different from an online pharmacy. Mail-order pharmacies that operate under your health plan require you to have a particular type of insurance, while online pharmacies are more like a pharmacy and may or may not accept insurance.

Read also : This couple swapped their house for an RV and paid off $200,000 in debt – then the money started rolling in

Do you think you are a wise consumer? The results of a May 2021 survey, “American Perceptions and Use of Online Pharmacies” by The Alliance for Safe Online Pharmacies (ASOP Global Foundation), were quite illuminating.

Some 45% of respondents mistakenly believe that all websites offering health services and prescription drugs via the Internet are safe, verified and approved by the United States Food and Drug Administration (FDA) or state regulatory agencies. This belief is even higher (59%) among those who have already purchased medication online.

A shocking 25% of consumers say they would accept a higher risk when buying from an online pharmacy for more savings or convenience. As many as 46% said they would be willing to buy prescription drugs from an online source that not Approved by the FDA if it gave them access to drugs they couldn’t otherwise get or drugs at cheaper prices.

Many people mistakenly believe that all Canadian drugs sold online are safe and legitimate.

Don’t miss: Three things to worry about when you retire – your future self will thank you

Better to be safe than sorry

Does that mean you shouldn’t use online pharmacies? No way. The savings can be substantial, especially if you or a family member takes a number of medications. What is that Is means you have to do your research carefully. There is a lot of information online (which is a bit of an oxymoron) that is educational and helpful.

Here are some great sites to bookmark and familiarize yourself with:

  • The Alliance for Safe Online Pharmacies allows you to download a list of safe pharmacy websites or search their site to see if the one you are considering is legit. There is also a Facebook page.

  • Your national pharmacy board, health care provider, and (legitimate, flesh-and-blood) pharmacist are great resources for learning how to buy and use medications safely.

  • Look for sites with the VIPPS (Verified Internet Pharmacy Practice Sites) seal that are accredited. Or use Check Before You Buy, a service from the Center for Safe Internet Pharmacies, or LegitScript.

  • Look for “.pharmacy” at the end of a web address. When a website ends in .pharmacy, it has been verified by NABP. Unlike logos, the pharmacy domain cannot be tampered with or tampered with.

  • Some of the best known and safest online pharmacies include Caremark Rx LLC, Costco Wholesale Corporation, GoodRx.pharmacy, and Walmart Inc.

  • Check Safe.pharmacy: sites not recommended for a full list of sites that NABP avoids.

Dangerous narcotics and fake pharmaceuticals are also widely available for purchase on social media platforms like Facebook META,
SNAP from Snapchat,
or Twitter TWTR,
According to the Alliance to Counter Online Crime, drug sales on these platforms fall into two categories: illegal narcotics such as heroin, cocaine and fentanyl, sold by individuals and criminal syndicates, and controls such as opioid painkillers sold over the counter by rogue online pharmacies.

Social media algorithms make it possible to target specific populations that are likely to want the products they sell.

Check: Best New Retirement Ideas

The dangers of a rogue pharmacy

Some red flags of a rogue online pharmacy include:

  • Prescription drugs are dispensed after the patient completes an online questionnaire, but there is no prescription submitted or contact with the doctor

  • There is no toll-free phone number or mailing address for the internet drug outlet on their website, and the only way to contact them is via email.

  • No pharmacist consultation is available either by phone or secure web communication

  • They ship prescription drugs worldwide or are located outside of the United States

  • Their prices seem incredibly cheap

“Consumers are far too confident when it comes to buying services or products online, including medicines. To speak to an anonymous supplier about safety and efficacy is to put your health in their hands, even if you have no idea who they are,” says Baney.

His advice? “Check before you buy and don’t buy drugs from social media companies and online marketplaces.”

Barbra Williams Cosentino RN, LCSW, is a psychotherapist in Queens, NY, and a freelance writer whose essays and articles on health, parenting, and mental health have appeared in The New York Times, Medscape, BabyCenter, and many other publications. nationally and online.

This article is reproduced with permission from NextAvenue.org© 2022 Twin Cities Public Television, Inc. All rights reserved.

More from Next Avenue:

Scientists create new fluorophores that could help fight cancer

Scientists from the Urals Federal University and the Urals branch of the Russian Academy of Sciences have created new fluorescent chemical compounds (fluorophores) for photodynamic therapy of cancerous tumors, the latest method of treating the cancer. The compound is suitable simultaneously for the diagnosis of tumor processes by staining the affected tissues and for their further treatment by destroying tumor cells without harming healthy cells. The results of the primary studies were published in the Dyes and Pigments log.

The synthesis of these fluorophores is characterized by low cost, due to the availability of all derivatives in the composition, as well as the absence of impurities that can cause side effects. The effectiveness of the fluorophore was tested on HeLa cells used as a model of cervical cancer. Now scientists are testing how the new compound interacts with other types of cancer cells.

Fluorophores are chemical compounds that emit visible light (photoluminescence) when exposed to ultraviolet or visible light. They are able to spread through biological tissues and stain cells prone to inflammatory processes. Thus, a new compound interacts with biomolecules of body tissues and, under UV or visible irradiation, colors the areas in which the tumor growth process takes place. This makes it possible to determine the size of the tumor in the body and to define its boundaries. During the experiments, scientists found that the new fluorophore performs a dual function: it not only stains diseased areas, but also begins to destroy them.

Initially, we only studied the tinctorial properties of the compound. The compound is able to accumulate in certain areas of the cell – the cell membrane and the reticulum (an intracellular organelle responsible for protein folding), and under ultraviolet or visible irradiation highlights the infected areas in bright green. However, it turned out that the fluorophore then functions as a photosensitizer. That is, under the influence of optical irradiation, it begins to interact with the surrounding cellular environment (oxygen, water, etc.) and generates free radicals, the so-called reactive oxygen species . These active particles enter into chemical interaction with the affected cells, starting their destruction, while practically not affecting healthy cells. It’s called photodynamic therapy, it’s a promising new method of treating cancer with high efficacy and minimal side effects.”

Grigory Zyryanov, co-author of the study and professor of the department of organic and biomolecular chemistry at UrFU

Scientists using the methods of heterocyclic chemistry created two experimental samples. Chemists synthesized a fluorophore based on naphthoxazole, an oxazole derivative used in the synthesis of medicinal and biochemical preparations, and a naphthalene fragment used as a platform and so-called antenna for more efficient perception of optical irradiation by a molecule. Additionally, the chemists added fragments of pyrene and anthracene, polynuclear aromatic hydrocarbons with a high fluorescent response, i.e. a bright glow, to the compound. The compound containing pyrene showed the highest fluorescent and anticancer activity.

“Pyrenes are very commonly used for bioimaging, anthracenes are less common,” says Grigory Zyryanov. “These compounds are promising for many reasons, including we were able to show that the pyrene-containing compound begins to glow even when irradiated with visible light, and this is visible even to the naked eye. This is very practical, including, for example, for surgical interventions, when it is still necessary in the treatment.”


Journal reference:

Slovenia, NV, et al. (2022) Synthesis of new polyarene-substituted water-soluble naphthos[1,2-d]oxazole-based fluorophores as fluorescent dyes and biological photosensitizers. Dyes and Pigments. doi.org/10.1016/j.dyepig.2022.110410.

Prof. Raimar Loebenberg receives Canadian Society for Pharmaceutical Sciences Leadership Award

VANCOUVER, BC and UTTENWEILER, GERMANY/ACCESSWIRE/June 27, 2022/X Phyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPyto” or the “Company”) is pleased to congratulate Professor Raimar Loebenberg as the 2022 recipient of the CSPS Award for Leadership in Canadian Pharmaceutical Sciences. Dr. Loebenberg is a professor in the Faculty of Pharmacy and Pharmaceutical Sciences at the University of Alberta (“UoA”), founder and director of the Drug Development and Innovation Center (DDIC), UoA, and is a director and founder of XPyto since 2018.

The CSPS Leadership Award in Canadian Pharmaceutical Sciences is given to an individual who has demonstrated leadership in advancing the cause of pharmaceutical research and development in Canada. Teacher. Dr. Loebenberg earned a Bachelor of Science in Pharmacy from Johannes Gutenberg University, Mainz, Germany and a Doctor of Pharmacy from Johann Wolfgang Goethe University, Frankfurt, Germany. He joined the University of Alberta in 2000 where he is the founder and director of the Center for Drug Development and Innovation in the Faculty of Pharmacy and Pharmaceutical Sciences. Professor Dr. Loebenberg’s research interests are in biopharmaceuticals to predict oral performance of drugs and plants and inhalable nanoparticles to treat lung diseases such as lung cancer, tuberculosis and leishmanase. He is a co-founder of RS Therapeutics Inc., a foam-based topical drug delivery company.

Recent notable positions of Prof. Dr. Loebenberg include: President of the Canadian Society for Pharmaceutical Sciences from 2014 to 2015; vice-chairman of the United States Pharmacopeia Dietary Supplement Expert Committee from 2016 to 2017; current member of the United States Pharmacopeia Expert Committee on Dietary Supplements; current Vice-Chair of the Traditional Chinese Medicine in Pharmacy Specialty Committee of the World Chinese Medicine Science Foundation; and a current member of Health Canada’s Scientific Advisory Committee on Pharmaceutical Sciences and Clinical Pharmacology and the Scientific Advisory Panel on Opioid Analgesic Abuse.

XPyto is proud to have Professor Dr. Loebenberg on its Board of Directors and to lead its psychedelic medicine program with a multi-pronged approach including GMP drug synthesis, proprietary drug delivery systems, new psychedelic analogue engineering and clinical validation.

About XPyto Therapeutics Corp.

XPyto Therapeutics Corp. is a diversified bioscience accelerator focused on next-generation drug formulation, diagnostics and new investment opportunities in active pharmaceutical ingredients, including: precision transdermal and oral soluble drug formulations; rapid and inexpensive diagnostic tests for infectious diseases and oral health; and the manufacture, standardization and evaluation of psychedelic compounds for the treatment of neurological disorders. The Company has research and development activities in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets.

X Phyto Therapeutics Corp.

Hugh Rogers, CEO and Director
Email: [email protected]
Telephone: +1 780-818-6422

Forward-looking statements

This press release contains statements that contain forward-looking information within the meaning of applicable Canadian securities laws (“forward-looking statements”). Forward-looking statements are frequently characterized by words such as “develop”, “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “potential”, “propose” and other similar words or statements that certain events or conditions “may” or “will” occur, and in this release include the statement regarding the company’s purpose to build a successful diagnostics, drug distribution and medical cannabis company. Forward-looking statements are only predictions based on the opinions and estimates of management as of the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results differ materially from those projected in the forward-looking statements, including: that the Company may not be successful in developing a commercial product; that selling products may not be a viable business; that the Company may not be able to expand its business; product liability risks; product regulatory risk; general economic conditions; adverse industry events; future legislative and regulatory developments; inability to access sufficient capital from internal and external sources and/or inability to access sufficient capital on favorable terms; currency risks; competition; international risks; and other risks beyond the Company’s control. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable law. expressly requires. Neither the CSE nor its Market Regulator (as that term is defined in the CSE policies) accepts responsibility for the adequacy or accuracy of this press release.

THE SOURCE: X Phyto Therapeutics Corp.

See the source version on accesswire.com:

8 marketing tips for home vets

I was super excited when Adam Christman, DVM, MBA, suggested I write an article on one of my favorite topics. There is so much to say about marketing for the home vet that I can only select a few to share with you today…but know that this is an incredibly rich and important topic. for mobile veterinarians.

This is especially important for people who are just starting out with their freelance home calling practices or for those who are relatively new business owners. As a good friend of mine said, “Let’s level the playing field a bit,” because these new national home calling practices have entire marketing departments, right? It can be a real challenge for big companies to market ethically, honestly and deliver on their promises, but I’m really proud to say that us small at-home vets tend to achieve this organically. Mobile practices owned by independent vets can also do a great job of marketing, and in our own way.

It is important to note that the marketing methods that will work best for your practice will depend on many unique individual factors. This includes your location, demographics, what sets you apart, and your skills (or investment in learning how to) market effectively in these ways. I go into much more detail on these topics in my online CE course, The House Call Vet Academy.1 But for now, I’ll leave you with my top 8 tips for marketing your practice:

1. Focus on your unique strengths.

Do you practice a unique service, such as acupuncture, chiropractic, or physiotherapy, in a place where few other vets do? Are you Fear Free certified? Do you offer concierge services (I do!) or another exciting and innovative way to give your customers and patients the best possible experience? Whatever it is, put it there.

2. Invest in a great search engine optimized website.

Your website is an essential tool for attracting new customers. You don’t want a cookie-cutter website that doesn’t reflect what makes your practice unique. And if you want potential customers who search the internet for you to find your website, it needs to be search engine optimized (SEO).

3. Word of mouth referrals are essential.

Word of mouth has a really special place in the home visit niche, more so than other types of businesses and veterinary practices. Even (and especially) if you only practice euthanasia at home.

Word of mouth referrals are essential for home vets for euthanasia, even though they are usually a single event, transaction or patient, because if you can keep those same customers in your loop, they are more likely to remember and refer to you when someone they know needs your services. Building rapport and relationships with local clinics, especially ERs, and local resources in your community is key to establishing a steady flow of patients to you, and without having to use Yelp if you don’t want to.

4. Your customer retention efforts must trump customer acquisitions (other than for IHE practices only).

Did you know that a 5% increase in customer retention can increase a company’s profitability by 75%?2 In other words, repeat customers are where they are. It’s so much easier (and more profitable) to attract customers you already have than to find new ones. That’s why the rest of these tips will focus primarily on marketing to your existing customers.

5. Take lots of photos of your patients (with their permission, of course).

One of the best things I did from day one of my practice, which also happens to be one of my top tips, is to take tons of pictures of your patients. First, make sure your clients are okay with it and get the necessary legal documents to post pictures of their pets on social media. Then you need to use all those photos of your beloved patients in social media posts (e.g. Instagram or Facebook) and newsletters to reconnect with current clients you haven’t heard from in a while. time.

People like to see photos of their own animals in your content. Use any excuse you can find to put these photos of your patients in the content you provide to existing and potential clients. For example, put tons of pictures of your patients in your communications about introducing new services, products, offers, wishing people happy holidays, etc.

6. Always stay ahead.

One of my mentors, Nicole Riccardo, taught me to always stay “on top”. When your customer has a question about their pet, you want them to think of you first – not Dr. Google; Not to the new cheap telemedicine offerings via the well-known online pharmacy giants and certainly not one of the giant non-veterinarian vetted corporate door-to-door chains. Not that your customers would ever consider those- here after tasting your incredibly personalized home services.

If your customers have recently heard of you in a message, newsletter or email, they will remember that you are always there for them. They will think of you right away when something comes up. And most importantly, they will remember that they need to come to your house for an in-home appointment or a telemedicine appointment.

This way they can get expert advice, continuity of care, truthful information (not alternate facts from who knows where) and information relevant to their pet based on their unique situation that only you can give them. provide.

7. Use calls to action in your marketing materials.

Another basic marketing principle is to use calls to action in your social media posts, newsletter, website, and any other content that your existing and potential customers will see. In other words, always add a button or link that they can press easily and quickly to perform the action you want them to take next. For example, add a cute little button to your newsletter or website that says, “Schedule your next appointment here” or “Apply to work with Dr. Eve!”

8. Make sure your customers know how much you love them.

My final tip is one of the most important to me, and that is to let your customers know how much you love them and their pets. I’m not saying lip service like companies do, but sincerely, since you actually know these people on a personal level. Thank them regularly for their loyalty and trust in you.

Ultimately, when people hire a home vet, they care about you and how you do things. The practice of home visitation has always been about authentic, genuine and irreplaceable relationships. Any old vet can come into their home and treat vomiting, diarrhea, give a vaccine, but what really sells in the practice of home visits is when your clients can see and feel your true love, your care and dedication to their animals.

As the popular saying goes, “People will forget what you said, people will forget what you did, but people will never forget how you made them feel.” So let your unique freelance home call firm create a feeling for your clients and patients that they can’t get enough of.

I wish you good luck with your marketing. Everywhere, humans and animals need you. You have this!


  1. Dr Eve Harrison. The Home Call Veterinary Academy. Accessed June 16, 2022. https://www.dreveharrison.com/house-call-vet-academy
  2. Reichheld F. Prescription to reduce costs. Bath & Company. Accessed June 1, 2022. https://media.bain.com/Images/BB_Prescription_cutting_costs.pdf

Bitcoin can fund equitable, high-quality healthcare for all

The current global healthcare system is broken

More than 6.2 million people have died from COVID-19-related deaths as of June 13, 2022. This is despite $8.9 trillion or 9.8% of global GDP spent on healthcare in 2019 in the world.

More broadly, half the world lacks access to essential health services. In addition, the current health system leaves out the most vulnerable groups of people, leading to health disparities and inequalities.

Health is a fundamental human right. It should be so for everyone.

Today, health care is delivered in one of two ways:

Insurance-based health systems: Generally, economically strong countries have insurance-based health systems that may or may not provide universal coverage. Furthermore, health disparities and inequalities are widespread, even among the best-covered groups of people. For example, in the United States, racial and ethnic minorities, economically weaker segments of the population, and people who live outside of large, outlying metropolitan counties continue to experience poorer quality health care. .

Direct healthcare systems: Economically weaker countries generally have reimbursable healthcare systems. It is important to note that even in economies with insurance-based healthcare systems, the most vulnerable group of people may still have to consume healthcare out of pocket. In much of the world where direct payment systems are common, corruption, patronage and lack of accountability are deeply rooted.

Both systems have a common attribute: intermediaries that control patient access or create inefficiencies, or both.

Bitcoin can make health a human right for all

The current healthcare system increases the cost of mediation. Like banks, mutuals are financial institutions that suffer from the inherent weakness of the trust-based model. More generally, current systems have led to additional intermediaries that add further inefficiencies into the healthcare system. For example, it is estimated that out of every $100 spent on prescription drugs purchased from a retail pharmacy using commercial insurance in the United States, more than $40 is recovered by intermediaries.

This high cost of mediation limits the minimum size of practical transactions, which has a disproportionate negative impact on preventive care. In direct health care systems, the societal cost of mediating in health care delivery networks is even higher, i.e. without an insurance safety net, groups of people most vulnerable are either completely left behind or underserved.

To quote Satoshi Nakamoto: “What is needed is an electronic payment system based on cryptographic evidence instead of trust, allowing two consenting parties to transact directly with each other without the need for a trusted third party.”

The best way to fix the currently broken healthcare system is to build a new integrated peer-to-peer (IHS) healthcare system between patients and providers that can deliver high-quality, equitable healthcare as well public easily accessible to all.

This new peer-to-peer IHS can work as follows:

  • First, an insurance-like product built on Bitcoin is required. Anyone registered for this product will be eligible to seek health care in the proposed IHS. Anyone with internet access should be able to register. The only “insurance premium” people will pay is their anonymized data on the determinants of health. Each member will retain ownership of their data in perpetuity.
  • Second, transparent, secure, and efficient supply chains must be built on Bitcoin. This will solve many critical challenges such as counterfeit drugs and artificially inflated drug prices to meet the needs of middlemen.
  • Third, healthcare providers should only be incentivized to optimize patient outcomes. This can be achieved by strongly encouraging the practice of evidence-based medicine, including an emphasis on preventive care.
  • Fourth, in addition to data provided by registered members, each health care provider should provide data collected during patient care.
  • Fifth, value-added services whose goal will be to promote long-term optimization of patient outcomes and maximization of system efficiencies can be created by anyone. A portion of the revenue generated by these services should be used to reduce out-of-pocket expenses or provide more incentives for providers to help patients achieve optimal outcomes.

This Bitcoin-based IHS can bring many transformative changes:

Universal health care: “It is safe to assume that every person on this planet will eventually have some means of accessing the open internet. We cannot make the same assumption about participation in the global financial system,” Jack Dorsey said recently. The same can be said of the Internet and the healthcare system. In the peer-to-peer IHS, anyone with internet access can become part of the system simply by providing their health determinants data.

Equitable and evidence-based health care for all: Because all each member pays in “premiums” is their data, and because provider incentives are tied to patient outcomes, everyone will have access to equitable healthcare of similar quality.

Acceleration of the development of new health technologies: Many of today’s medical technologies were discovered accidentally (eg, penicillin, x-rays, and pacemakers). Likewise, trial and error is a common strategy in today’s R&D efforts. If a data set consisting of all the determinants of health information of a population is available, the development of innovative health technologies will be accelerated.

Better allocation of the health budget: By 2030, the United States will spend $6.8 trillion a year on health care, according to the latest “official” estimates. Assuming that focusing on preventive care and the practice of evidence-based medicine can result in a 5-10% reduction in healthcare spending, this will translate into savings of $340-680 billion. This is enough to cover all health care expenses borne by the American population. The available evidence indicates how the proposed savings are achievable, even by implementing evidence-based care in the current system itself.

A call to action:

I believe that it takes a critical mass of three basic criteria for a new idea to be launched:

1. A well-thought-out concept that can bring about transformational change.

2. Technical expertise on how to execute it well.

3. The resources needed to make it happen are available.

This article summarizes my thoughts on the first point. I chose to do this because my current expertise is in the field of health. Through this article, I call on the Bitcoin community to explore ways in which we can achieve numbers two and three.

This is a guest post by Vishvas Garg. The opinions expressed are entirely their own and do not necessarily reflect those of BTC, Inc. or Bitcoin Magazine.

Marijuana laws change in Virginia

With the changing marijuana laws in the Commonwealth of Virginia, people are getting confused with the terms “decriminalization” and “legalization” of marijuana. Decriminalization is the process of removing criminal sanctions against an act, item, or behavior. Decriminalizing cannabis means it would remain illegal, but the court system would not prosecute a person for possession below a specified amount. Instead, penalties would range from no penalties at all to civil fines, drug education, or drug treatment.

Cannabis legalization is the process of removing all legal prohibitions against it. Each state in the United States would then have individualized legislation regarding use, sale, and possession. Cannabis would then be available to the general adult population (21+) for purchase and consumption at will, like tobacco and alcohol. Legalization allows each state to regulate and tax the use and sales of marijuana according to their specific laws. At the federal level, marijuana is still classified by the United States Drug Enforcement Administration as a Schedule 1 drug, which means 1) it currently has no accepted medical use and 2) it has a high potential for abuse.

In Virginia, some marijuana use has been decriminalized and legalized. The East Coast Community Services Board was recently led by the Virginia Department of Behavioral Health and Developmental Services to conduct a community readiness assessment for marijuana use. The purpose of the report was to capture community attitudes, perceptions, and knowledge about local marijuana use, partial decriminalization, and legalization of recreational marijuana in 2024 in Virginia. This assessment report was prepared by the Planning Board and can be accessed at https://escsb.org/resources/.

What is legal in the Commonwealth of VA? According to www.cannabis.virginia.gov, medical marijuana was legalized in 2017 and the current comprehensive laws on its use were put in place in 2020. Medical marijuana is currently only available from a pharmaceutical processor registered with the State. Patients must have a doctor’s referral to obtain a medical marijuana card and then apply to the State Board of Pharmacy to receive the card.

As for the recreational use of marijuana in Virginia, its laws are changing. On April 7, 2021, the Virginia General Assembly legalized possession and/or consumption of up to one ounce of cannabis sativa for recreational purposes by adults 21 and older on private property, and cultivation at home cannabis plants (up to four plants per household) for adults 21 years and older. Retail sales are scheduled to begin Jan. 1, 2024, giving the state three years to create comprehensive regulations.

As such, it is currently illegal for any person or business to sell or distribute marijuana, marijuana seeds, clones, flowers, or any other part of the marijuana plant in Virginia before 2024.

On June 1, 2022, the Virginia General Assembly approved the 2022-2024 budget. There were laws clarifying the possession of marijuana. The sentence makes it a misdemeanor for possession of more than four ounces of marijuana, adding a lower level offense before the felony charge that can come with possession of a pound or more. The language clarifies that possession limits do not apply to home-stored marijuana, clearing up some of the confusion created by the state legalizing home-grown marijuana for up to four plants, enough to potentially put someone over possession limits depending on how much the plants produce and how the law is interpreted.

More information about the new legislation can be found online at https://budget.lis.virginia.gov/


Broadwater Academy - Worth it!

Market research on screen-printed labels with teams from Suzhou, Dongguan Kaida Carbon Fiber Technology Co., Ltd, Kunshan Rucheng, Avery Dennison

A2z Market Research Announces Release of Report ‘ screen printed labels market Research report by category, form, product, type, end user, region – Global forecast to 2027. The main drivers of this growth are the growing need for market insights and the sustainability of key trends. The chemical and materials industry report further includes market gaps, stability, growth drivers, restraining factors, and opportunities over the forecast period. Our market research report provides an in-depth and comprehensive analysis of the global market, bringing you the latest insights from our leading analysts.

Get a sample report with table and charts: www.a2zmarketresearch.com/sample?reportId=582202

“The global Screen Printed Labels market size was estimated at reasonable USD Million in 2021 and is projected to reach healthy USD Million in 2022, and is projected to grow at a steady CAGR to get significant USD Million by 2027.”

The market has been studied through external screen printing label and internal screen printing label based on category. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure of Screen Printing Labels. Major companies in this report include: Suzhou Teams, Dongguan Kaida Carbon Fiber Technology Co., Ltd, Kunshan Rucheng, Avery Dennison, Amcor, CCL Industries, Berry Global, Multi-Color, Macfarlane Group, Graphic Arts Group, ITL Group ,

Screen Printed Labels Market Overview:

The Screen Printed Labels market research is an intelligence report with meticulous efforts to study the correct and valuable information. The data takes into account both the major existing players and the future competitors in chemicals and materials. The latest Global Forecast to 2027 report provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the Screen Printed Labels market. This market research report is an informative data compilation that gives an all-inclusive analysis of the current trend for the forecast period. Our report offers a comprehensive account of the current state of the market and also outlines its future prospects. We also illustrate how to develop future business plans based on our forecasts.


The report offers an in-depth assessment of the Screen Printed Labels market strategies, geographical and business segments of major market players, also provides information on current and future market trends, prominent regional market analysis and analysis of global and global market industrial chain. regional screen-printed label markets.


Pressure-sensitive, glued, heat-shrinkable and stretchable, in-mold labels


Food Application, Beverage Application, Home and Personal Care Application, Petroleum and Chemical Industry Application, Consumer Goods Application, Pharmaceutical Application, Office Products Application, Logistics and Transportation Application , retail application, other applications

The Screen Printed Labels Market has been studied across Americas, Asia-Pacific, Europe, Middle East & Africa based on region. The Americas are further explored in the Screen Print Label report in Argentina, Brazil, Canada, Mexico, and the United States. The United States is studied in more detail in the Screen Print Label report in California, Florida, Illinois, New York, Ohio, Pennsylvania and Texas. Asia-Pacific is further analyzed in the Screen Print Label report in Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan and Thailand . Finally, Europe, the Middle East and Africa are studied in more detail. Report on screen printing labels in France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates and United Kingdom.

Get a discount: www.a2zmarketresearch.com/discount/582202

Report on the cumulative impact of COVID-19 on screen printing labels:

Our ongoing research on the Screen Print Label report amplifies our research framework to ensure inclusion of underlying COVID-19 issues and potential pathways forward. Additionally, the updated study provides insights, analysis, estimates, and forecasts, considering the impact of COVID-19 on the Screen Printed Labels market.

The Porter Matrix evaluates and ranks screen printed label vendors in the market based on business strategy (industry coverage, business growth, financial viability, and channel support) and product satisfaction. screen-printed labels (ease of use, product features, value for money, and customer support) that helps businesses make better decisions and better understand the competitive landscape.

Screen Printed Labels Market Share Analysis: Knowing the Screen Print Label market share gives an idea of ​​the size and competitiveness of the vendors for the reference year. It reveals the characteristics of the screen printed label market in terms of accumulation, dominance, fragmentation and merger.

The report answers questions such as:

1. What is the Screen Printed Labels market size and global market forecast?

2. What are the inhibiting factors and impact of COVID-19 on the global Screen Printed Labels market during the forecast period?

3. In which products/segments/applications/areas to invest in during the forecast period in the Global Screen Printed Labels Market?

4. Which modes and strategic moves are suitable for entering the global screen printed labels market?

Buy exclusive reports: www.a2zmarketresearch.com/buy?reportId=582202

If you have any special requirements, please let us know and we will offer you the report you want.

Contact us:

Roger Smith


[email protected]

+1 775 237 4147

Related reports:

Big Data Analytics Market 2022: Business Development, Scaling, Sharing, Opportunity 2026IBM, Google, Oracle – Digital Journal

Scope and overview of the book market, to be developed

Metabolomics Market Expected to Witness Huge Growth by 2027

Pharmacist-based clinic, first of its kind in Alberta

Justin Jenson, the pharmacist who will run the walk-in clinic, says there will be only one pharmacist at the clinic to begin with, but more pharmacists may be brought in as demand grows.

“We are going to start with a single pharmacist. I won’t be the only gentleman here. We will be an interdisciplinary team within the community and we will certainly, of course, expand based on demand and as more pharmacists become available,” Jenson said. “We hope to achieve integration with at least the University of Alberta. If this is not possible, aspiring international pharmacy graduates, to help them gain additional experience in other countries or other communities where professional services are not as well defined or extensive. This will provide them with an excellent learning opportunity so that they can start to “get their feet wet” in clinical services, not just in a clinic. »

Due to the lack of doctors in Lethbridge, many people do not have a family doctor. Jenson is confident that if there is high demand at the clinic, they can handle it effectively.

“Rest assured, we have plans underway to scale up. We already have several pharmacists engaged in Lethbridge and surrounding areas. We are in discussions with other pharmacies in the area and are also communicating with pharmacists in the Calgary area,” Jenson said. “If the demand requires it, we will expand. If the demand is a little low, we are there to help those in need as soon as possible, but we will be there to help Canadians live their lives well.

Jenson mentioned that the clinic is not an emergency room and some services must be attended by a physician.

“Examples that may fall outside our scope of practice: narcotic drugs. This would not fall within the scope of practice of pharmacists. It would be more up to the doctors,” Jenson said.

Alberta Health Minister Jason Copping also attended the ribbon-cutting ceremony at the Lethbridge clinic. Copping says pharmacists have provided much-needed support during the pandemic, and this pilot project will help improve health service delivery.

“Over the past two years, pharmacists have also provided essential support during the pandemic. Now, this pharmacist walk-in clinic builds on the broad scope of practice and empowers pharmacists to provide more care in an accessible and safe way,” Copping said. “With the knowledge gained from this pilot project, we can continue to improve healthcare delivery by pharmacy teams and stay on the cutting edge of pharmacy practice in Canada.

At the event, Copping also provided an update on research to bring more doctors to Lethbridge. Copping confirmed 11 doctors are expected to open practices in Lethbridge by September, with the potential for even more.

“AHS has worked hard to bring new doctors to Lethbridge, and there are new doctors on the way. Copping said. “There are 11 family physicians committed to working in Lethbridge, pending a practice readiness assessment, and they are expected to begin work in September and log on to provide services over the remainder of the year. year.

Copping said five more physicians are currently being recruited, bringing the total number of potential physicians coming to Lethbridge to 16.

The clinic’s pilot program is expected to last 12 months in Lethbridge before eventually expanding to other regions.

Chula researchers find large amounts of THC in cannabis-flavored drinks Public warned, government urged to impose stricter controls

Newswise – Research by a Chulalongkorn University biochemistry expert reveals that more than 30% of randomly tested cannabis flavored drinks contain higher levels of THC than what is allowed. The public is warned to keep their consumption at moderate levels and that children should refrain from drinking this beverage. The government should control its use and warn people about the pros and cons of cannabis.

Following the removal of cannabis and hemp from the list of controlled narcotics paving the way for their commercial and economic benefits, the cannabis flavored beverage market has undergone a rigorous expansion. There are now products such as cannabis tea and cannabis coffee, some of which can be found in vending machines, making them very easily accessible to different groups of consumers.

Information from the ninth academic conference of the Center for Addiction Studies, held recently in February 2022, reveals that cannabis use in Thailand has doubled compared to previous years. Research shows that about 1.89 million Thais over the age of 18, or about 4.3%, use marijuana, compared to about 1 million users in 2020.

The trend has raised some concerns among doctors and addiction researchers who warn that the impact of THC found in cannabis can affect those who consume large amounts of the substance continuously. This could affect brain development while putting them at risk for depression, psychiatric disorders, coronary vessel disorders and testicular cancer, for example.

Chula is at the forefront of research on ∆9-THC levels in cannabis flavored drinks

These concerns led Associate Professor Dr. Kuakarun Krusong from the Department of Biochemistry, Faculty of Science, Chulalongkorn University to conduct a study on ∆9-THC or delta9-tetrahydrocannabinol levels in cannabis flavored drinks to determine if they exceed what has been determined by the Department of Health.

“With marijuana now being freely used as an ingredient in food and drink, this allows easy access to the general public, including children and young people. What we see in the media or advertisements usually only alludes to its benefits like recreational and medicinal use. What one might overlook is that the substance can still be harmful if consumed in excess. Several doctors have warned that children abstain from consuming the substance as it can affect their physical, mental and even emotional development,” explained Associate Professor Dr Kuakarun, how the research project funded by the Center for Addiction Studies began.

This research project is a collaborative effort of a team of experts. For example, the project advisor is Associate Professor Rasmon Kalayasiri, MD from the Department of Psychiatry, Faculty of Medical Sciences, Chulalongkorn University, who is also the Director of the Center for Addiction Studies, Associate Professor Dr. Sornkanok Vimolmangkang from the Department of Pharmacognosy and Pharmaceutical Botany, Faculty of Pharmaceutical Sciences whose research focused on marijuana and its derivatives of natural substances with Prof. Dr. Orawon Chailapakul and Assistant Prof. Dr. Chadin Kulsing from the Department of Chemistry, Faculty of Science, both of whom lend their expertise in substance analysis to study the ∆9-THC levels in samples taken from these drinks.

Random Test Results

The research team collected more than 30 samples of cannabis-flavored drinks currently on sale at various retail outlets in metropolitan Bangkok, sold as teas, coffees and milk drinks. The technique used in the ∆ test9-THC is the GC-MS (gas chromatography-mass spectroscopy) which involves the separation and specification of various substances in the test sample as well as the HPLC (high performance liquid chromatography) which separates the mixture and provides quantitative determination of the target substance through the use of a high pressure pump.

“If you ask why we specifically focus on cannabis-flavored drinks sold in various stores, the explanation is that ready-to-drink drinks require FDA approval with a clear label indicating the content and amount of ∆9-THC per 100 milliliters or per 1 serving. In contrast, drinks sold in cafes are usually concocted in-house and even the same drink can have a different mix, which means that the amount of ∆9-THC can also be different. This is where it can get dangerous.

According to Assoc. Teacher. Dr. Kuakarun, sample test results show that “most drinks tested show a level of 9-THC within the limit required by the Ministry of Health, while approximately 30% contained 9-THC at levels above what is permitted by law which does not exceed 0.015 milligrams per 100 milliliters. Those who consume drinks with THC levels above the limit are exposed to health risks, especially in the case of people allergic to THC. 9-THC

The search cannot, however, reveal the names of drinks or outlets and the quantities of their ∆9-THC, but it is possible to include it in a report to the Center for Addiction Studies, an agency under the Thai Health Foundation, as a basis for future policy implementation.

This year’s (2022) research is coming to an end and Assoc. Professor Dr. Kuakarun believes that in the future more research sampling will take place. This could mean expanding to other regions or sampling foods other than beverages.

Suggestions for Safe Cannabis Use

Assoc. The concern of Prof. Dr. Kuakarun is that so far there is still no recommended level of safe consumption for ∆9-THC per day in Thailand. There should be, for example, a number proportional to 1 kilogram of a person’s weight and how many micrograms should not be exceeded as this could cause side effects. The same could be said for foreign countries where the number is also unclear. Consumption of cannabis-flavored drinks could follow other beverages such as energy drinks with clear and familiar warnings not to exceed more than 2 bottles per day.

“Even stores or commercial operators are probably not yet aware of the maximum level of ∆9-THC per glass and even if they do, there can be no real regulation since there has not been an ongoing inspection. Another thing is that the drinks are all made differently. This wouldn’t matter so much in cases where the leaves are boiled and mixed into a drink since that usually gives a fairly small number of ∆9-THC. If extracted by heat or oil, there is no way to determine the level of ∆9-THC per serving.

For this reason, Assoc. The teacher. Dr. Kuakarun suggests that those wishing to experiment with cannabis or hemp flavored beverages should exercise caution and consume only moderately so as not to expose the body to high levels of ∆9-THC which could cause danger since the long-term risks are not yet known.

Proposed State Regulation of Cannabis-Flavoured Food and Beverage Venues

Food and beverage outlets that contain cannabis or hemp must have clearly posted signs informing customers of the contents of what they are serving. This is to alert customers who wish to avoid this content and parents of children who should not consume these products.

The media should publicize both the beneficial and harmful effects of marijuana

Government promotion of the economic benefits of cannabis and hemp has caused many sectors, including the media, to focus more on their benefits while neglecting to disclose any harmful effects they might cause.

“The media is now focusing more on the benefits of marijuana as a commercial herbal crop. The packaging of these products is designed to be attractive in order to entice customers to buy these seemingly harmless products. Even if someone ‘one talks about the harmful side, it wouldn’t gain much ground since it’s the side that doesn’t generate revenue and is even considered obsolete.” But we can’t deny that there is a harmful side to this substance. There are other elements of cannabis that are harmful to health but the worst is this ∆9-THC that we have discussed, especially in the case of children who may wish to try such products. I hope the campaigns focus on both aspects. One can point out the benefits but one should not forget the potential harm they can do. Assoc. Professor Kuakarun reminded us of this with great concern.

Although cannabis and hemp have been removed from the list of narcotics, this does not mean that they can be used freely. Should the level of ∆9-THC exceeds 0.2% by weight, the Board of Narcotics Control still considers it an addictive substance. The public should therefore be cautious when consuming foods and beverages mixed with cannabis or its extraction to avoid the harmful effects it may cause in the long term.

Researchers uncover secrets of color-changing minerals with potential uses for medicine and space studies

Researchers from the University of Turku, Finland explain why the natural mineral hackmanite can change color when exposed to UV rays. As this process can occur repeatedly and without exhausting the material, hackmanite could form the basis of new LED and UV monitoring techniques.

Image credits Bob Fosbury/Flickr.

Hackmanite has been under study at the University of Turku for almost a decade now. The mineral is easy to synthesize and has excellent durability. Together with its reaction to UV radiation, these properties make it a very attractive material for researchers looking to leverage its use for applications ranging from consumer electronics to medical devices.

What sets it apart is that hackmanite is one of only three known minerals that can change color from white to purple when exposed to UV light: this process is known as photochromism. Unlike the other two, however, the hackmanite change is reversible, relatively durable, and does not wear down the mineral in any way.

The exact reason for this color change and how, however, has so far remained unknown. The new paper worked with the three natural color-changing minerals – hackmanite, tugtupite and scapolite – to find the answer.

Reliable color change

Although the three minerals studied for this article are all naturally occurring inorganic compounds, there are a number of organic compounds that can also change color reversibly when exposed to UV light. These hydrocarbons, however, can only endure the process a few times before their molecular structure undergoes complete degradation. This is because any noticeable change in the color of a substance is created by significant changes in its structure, and repeatedly experiencing these changes damages the hydrocarbon molecule.

“In this research, we discovered for the first time that there is also a structural change involved in the color change process. When the color changes, the sodium atoms in the structure move relatively far from their usual location and then return. This can be called structural breathing and it does not destroy the structure even if it is repeated a large number of times,” explains Professor Mika Lastusaari from the Department of Chemistry at the University of Turku, Finland, co-author of the article.

According to the results, the three inorganic minerals can apparently survive this process indefinitely. Their ability to do so stems from their three-dimensional chemical structure. This is similar to that of zeolites, a class of minerals used to produce detergents, drying agents and air purifiers, as their cage-like structure allows them to capture and release different particles. Zeolite-based detergents, for example, remove magnesium and calcium atoms from water by binding them inside the pores of their cage-like molecules.

“In these color-changing minerals, all of the processes associated with color change occur inside the pores of the zeolite cage where the sodium and chlorine atoms reside. That is, the cage-like structure allows for atomic movement within the cage while keeping the cage itself intact. This is why minerals can change color and return to their original color practically indefinitely”, explains doctoral researcher Sami Vuori, co-author of the article.

Additionally, the team explains that the rate at which these minerals can change color depends on how far the sodium atoms inside their structures have to travel. This information is particularly valuable for medical applications, as we now know how to more precisely control the color-changing properties of a particular structure.

This is the first time we have had a model of how color-changing minerals work, the team explained. The team is currently exploring different applications for hackmanite, such as replacing LEDs and other bulbs or using it for X-ray imaging. Another interesting possibility is the development of radiation detectors and detection tools. measure based on hackmanite; these would be deployed on the International Space Station and other manned space missions to allow crew members to measure the radiation absorption of different materials.

“The color strength of hackmanite depends on the amount of UV radiation it is exposed to, which means that the material can be used, for example, to determine the UV index of solar radiation. The hackmanite that will be tested on the space station will be used in a similar way, but this property can also be used in everyday applications. For example, we have already developed a mobile application for measuring UV radiation that can be used by everyone,” explains Sami Vuori.

The article “Structural origin of effective photochromism in natural minerals” was published in the review PNAS.

Global shortage of contrast media means urgent c

image: CM = contrast agent; CO2 = carbon dioxide; Gd=gadolinium; IVUS = intravascular ultrasound
see After

Credit: Journal of Vascular and Interventional Radiology

Philadelphia, June 22, 2022 – Supply chain disruptions have created critical shortages of Omnipaque (iohexol) and Visipaque (iodixanol), iodinated contrast agents used in imaging studies for the diagnosis and treatment of disease. GE Healthcare, the manufacturer, had to shut down their factory in Shanghai, China due to local COVID policies, disrupting 80% of their production. Writing in the flagship publication of the Society of Interventional Radiology, the Journal of Vascular and Interventional Radiology (JVIR), published by Elsevier, Investigators provide clinicians with guidance on alternative imaging methods for interventional radiology procedures and strategies for maintaining insufficient supply in an emergency.

“As interventionists, coping is central to our specialty, and this situation turned out to be no different,” said lead author Nikki A. Keefe, MD, Department of Radiology, University of North Carolina North in Chapel Hill, North Carolina, USA, and its co-authors. “We developed an initial approach to case prioritization, and we also looked at short-term strategies for managing existing supply to maximize utility and minimize waste.”

In response to this shortage, the American College of Radiology’s (ACR) Committee on Drugs and Contrast Policy issued a guidance statement. Using these guidelines as a basis, Dr. Keefe and his co-authors offer a set of practical solutions to deal with the current situation.

The authors recommend creating a priority matrix covering the following categories: procedures requiring an iodinated contrast product versus procedures that can be postponed; those that can be performed with alternative imaging modalities such as intravascular ultrasound; and those that can be done with an alternative contrast medium. They stress the importance of creating harmonized leadership to oversee the use of contrast media across all departments at the institutional level. This would include both diagnostic and intervention teams, including non-radiological divisions that also use iodinated contrast.

Although case prioritization and the use of other contrast media may stretch the supply, many interventional radiology procedures will continue to require these agents. As part of centralizing the management of contrast media, Dr. Keefe and his co-authors recommend that a central pharmacy and inventory system be used to distribute the agents. At the point of care, multi-use valve equipment and dilution of contrast medium with saline solution may be appropriate and can expand supply and minimize waste.

Alternative contrast agents may be appropriate for some patients. With maximum dose recommendations, gadolinium (Gd) can be used in the vascular system even in patients with renal insufficiency. Carbon dioxide has been used as a safer alternative to iodinated contrast media in patients with renal dysfunction or allergy, although there are some associated risks. To prevent ischemia, doses should be spaced one to two minutes apart. While alternative contrast agents have limitations in defining the anatomy of large diameter vessels such as the aorta, digital image stacking can improve visualization.

For non-vascular gastrointestinal and genitourinary applications, alternatives are available. Gastrografin (diatrizoate meglumine, Bracco Diagnostic Inc.) for oral or rectal administration is a safe alternative for gastrointestinal access and catheter exchange procedures. Cystografin (meglumine diatrizoate, Bracco Diagnostic Inc.) by injection is a viable alternative for genitourinary access and procedures including nephrostomy and nephro-ureteral stent placement/exchange. Intravascular ultrasound has an established role in vascular procedures, and it can avoid the use of contrast media and reduce radiation exposure and procedure times. With proper training, clinicians can apply intravascular ultrasound for procedures such as inferior vena cava filter placement and transvenous biopsy.

GE Healthcare recently announced that it was able to reopen its Shanghai factory, but distribution issues and other supply chain issues may persist. “That being said,” Dr. Keefe and his co-authors warned, “with China’s zero COVID policy, a shutdown can unfortunately happen again, and it would be prudent to have a plan in place if shortages happen again.” They suggest that some of the changes in practice and procedures that are being implemented as a result of this shortage could prove beneficial and permanent, adding that they can serve patients in the long term by minimizing both the burden of contrast medium and radiation exposure. ”

JVIR is built on methodical peer review of research and evidence-based medicine, but to serve our readership in this time of international emergency, rapid publication of practical educational material was warranted,” said Daniel Sze, MD, PhD , editor-in-chief of JVIR.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of press releases posted on EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Global Valve Terminals Market 2022 Key Players and Production Insights Analysis with Forecast 2028 – Instant Interview

Market research on Global Valve Terminal Market from 2022 to 2028 driven by MarketandResearch.biz contains remarkable data along with future forecast and in-depth analysis of the market at international and regional level. The report throws light on various uncertainties such as economic downturn in major economies, negative and positive influencing factors, fluctuation in market value, high industry growth rate, and trend in the global Terminal market. of valves.

The industry is intensely competitive and fragmented due to the presence of several established players participating in various marketing strategies to increase their market share. The vendors available in the market are analyzed based on price, quality, brand, product differentiation, and product portfolio. It assesses the impact of various crucial industry trends as well as recent developments on the overall demand dynamics for the global Valve Terminals market.

Request a sample report: https://www.marketandresearch.biz/sample-request/214115

The market is segmented on the basis of technology, type, application and region. The report also provides information on the risk faced by the new entrants as well as the existing players in the global Valve Terminals market by considering factors such as key trends, technological advancement and also emphasizes on a solution to overcome the risk.

This report segments the market into the following types:

  • Multi-pin interface type
  • Fieldbus type

Based on Application, the market is segmented into:

  • food and drinks
  • Cosmetic Industry
  • Pharmacy
  • Others

Key Region/Countries Covered:

  • North America (United States, Canada and Mexico)
  • Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
  • Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
  • South America (Brazil, Argentina, Colombia and rest of South America)
  • Middle East and Africa (Saudi Arabia, United Arab Emirates, Egypt, South Africa and Rest of Middle East and Africa)

This Global Valve Terminals Market report studies trends in consumer and supply chain dynamics that have proven useful in developing production strategies for the industry. With the meticulous competitor analysis covered in the market analysis report, companies can assess or analyze the strengths and weaknesses of competitors, which helps in developing superior business strategies for their product.

Browse the full report: https://www.marketandresearch.biz/report/214115/global-valve-terminals-market-growth-2021-2027

Key industry players profiled in the report include:

  • party
  • Hafner-Pneumatik
  • Parker Hannifin
  • AirTAC
  • Airtec Pneumatics GmbH
  • Ebora.nl
  • Air Engineering Group
  • Solidotech
  • Zhejiang Yitainuo Pneumatic Technology
  • Wuxi Aixun Automation Technology

Moreover, the study predicts the size and volume of the market in the present and the future. The report offers a comprehensive study of the industry and information on expected future trends that will have a significant impact on the growth of the Global Valve Terminals Market during the period 2022-2028.

Report customization:

This report can be customized to meet customer requirements. Please contact our sales team ([email protected]), which will ensure that you get a report that suits your needs. You can also get in touch with our executives at +1-201-465-4211 to share your research needs.

Contact us
mark the stone
Business Development Manager
Call: +1-201-465-4211
E-mail: [email protected]
The Web: www.marketandresearch.biz

Other related reports:

Global Video Oculography (VOG) Devices Market Competitive Landscape and Analysis by Recent Trends 2022 to 2028

Global Telescopes Market 2022 Key Regions, Comprehensive Analysis, Growth Drivers and Forecast to 2028

Global Air Curtains Market 2022 Key Players Profile, Value Estimation and Analysis by Recent Trends till 2028

Global Blind Spot Detection (BSD) and Adaptive Cruise Control (ACC) System Market 2022 Business Scenario, Company Profiles, Size and Innovation Dynamics by 2028

Segmentation of the global magnesium citrate market development and trends overview from 2022 to 2028

Global Adsorbents for Mercury Removal Market Size Estimation 2022, Trend Analysis and Competitive Landscape Forecast to 2028

Global Breast Imaging Equipment Market 2022 – Global Overview by Industry Size, Future Trends, Growth Factors and Key Players by 2028

Global Collagen Casings Market 2022 Key Players Profile, Value Estimation and Analysis by Recent Trends Till 2028

Global Automotive Valves Market – Research Report Provides In-Depth Trend Insights (2022-2028)

Global Gear Hobbing Machines Market 2022 Business Scenario, Advanced Technology and Analysis by Recent Trends to 2028

8 benefits of hemp oil for the skin

The legalization of cannabis has brought a wave of innovation and a wave of marijuana products. Fast-flowering seeds make growing easier, and products like hemp oil for the skin allow more people to experience the benefits of cannabis.

Keep reading if you’re curious about the benefits of using cannabis topically. Below, you’ll learn all about hemp oil, its benefits, and whether it’s right for you.

What is hemp oil?

Hemp oil is extracted from the seeds of the hemp plant, a variety of cannabis. Once processed, it contains various beneficial ingredients, including CBD and other cannabidiols.

Although the extract may contain traces of THC, the psychoactive component of cannabis, hemp oil applied to the skin is not psychoactive.

Although they are often confused, hemp oil is not the same as CBD oil.

Hemp seed oil is produced only with hemp seeds, while CBD oil uses cannabis plant material. The former is sometimes used as support for the latter, adding to potential confusion.

Benefits of hemp oil for your skin

The benefits of hemp oil for your skin are many and varied, so let’s dive in and find out.


One of the best documented effects of hemp oil is its moisturizing abilities. It’s emollient and non-comedogenic, which means it won’t clog your pores.

It also includes linoleic, gamma-linolenic and alpha-linolenic acid. These fatty acids help your skin retain moisture, improving its firmness and tone. The inclusion of Omega 3 and 6 enhances the effect of hemp oil and combats dry, flaky skin.

Regulates oil production

Dehydrated skin cells overproduce oil, which leads to acne. Hemp oil absorbs quickly into the skin, is relatively non-greasy, and won’t clog pores. Using it on your body helps hydrate cells and prevent excessive sebum production.

Anti-aging properties

The oleic and linoleic acids in hemp oil have been shown to slow the signs of aging. These compounds are not produced in the body and must be applied topically. Regular use of hemp in your skincare routine can help reduce wrinkles, creases, and crow’s feet.

Antioxidant properties

Hemp oil contains significant amounts of vitamins A, C, E and other antioxidant compounds like gamma-linolenic acid. All of this helps protect your skin and give it a warm, healthy glow.

Anti-inflammatory properties

A study published in Pharmacognosy Review in 2014 showed that hemp oil may help treat symptoms of inflammatory skin conditions. While the results are certainly promising, research is still ongoing.

Antibacterial properties

The antimicrobial compounds and antioxidants in hemp oil help fight bacteria, viruses, and fungi. According to the 2014 study, regular use strengthens the skin’s natural barriers, reducing the risk of infection.

UV damage

The linoleic acids in hemp oil can help repair skin damaged by sun exposure. These acids work to slow melanin production, reducing the effects of UV damage and hyperpigmentation.

Skin diseases

The benefits of hemp oil for the skin go beyond cosmetics. Some recent studies show promising results for a range of conditions. Eczema, atopic and seborrheic dermatitis, psoriasis, lichen planus and rosacea all show improvements when using hemp oil.

How to choose and use hemp oil

Now that you know the benefits of hemp oil for your skin, how are you going to use it? We’ll take a look.

Find the right product

The first step is to choose the right hemp oil product for your needs. The first thing to do when browsing these products is to look at the ingredients. Beware of companies that add tiny amounts of extract to capitalize on a trend.

Make sure there is a decent amount of the desired ingredient, then think about why you want to use hemp oil. Looking to treat dry skin? Use an emollient cream rather than a lotion.

You should also choose products with ingredients that complement each other. For example, if you use hemp oil for its anti-aging properties, look for a product that contains other compounds known to have similar effects.

Glycolic acid and retinol combine well with hemp oil to fight the signs of aging. Lanolin and hyaluronic acid are a good match in hemp oil moisturizers. With a little research, finding the best product is easy.

Use hemp oil

Hemp oil for skin is all natural, non-toxic, and has no side effects. However, like all skin care products, you must test it first to avoid any potential reactions.

  • The best time to test is after a morning shower. Once you’ve dried off, apply a small amount of hemp oil product to an area of ​​skin. Choose an area that is neither too sensitive nor insensitive; the inside of your arm works fine.
  • Cover the applied product with a bandage and leave on all day making sure it does not get wet.
  • At the end of the day, remove the bandage and check for any side effects. If you notice any redness or swelling, or if you feel itching or discomfort, stop using the product and consult a doctor. If not, hemp oil is probably compatible with your skin.

Once you’ve determined that hemp oil is right for you, it’s simple to use. Simply apply directly to desired area and gently massage into skin. Those using it to treat acne should apply it to a clean face for two minutes before washing it off with lukewarm water.

Grease your wheels with hemp oil

You’ve learned the benefits of hemp oil for your skin, so give it a try and treat yourself.

If you’re curious about other ways to consume cannabis that aren’t topical or don’t involve smoking, the best way to find out is to do so. Why not grow high quality cannabis seeds, learn how to make cannabis butter and wow your friends with delicious cannabis cooking.

Lab Muffin’s beauty scientist slams viral sunscreen toast test as a complete lie

An Australian scientist has called the viral ‘toast with sunscreen test’ a complete lie and wondered why anyone would want to apply skincare to bread anyway.

The test claims to show how well a particular brand of sunscreen works by spreading it on half a piece of bread before placing it in the toaster.

When it comes out, the side with the sunscreen is still white and cakey, while the side without is golden brown.

But the video is based on a clever lie, Michelle Wong, a trained cosmetics scientist with a doctorate in organic medicinal chemistry, explained in a video about her. Lab Muffin Beauty Science Instagram.

The beauty expert said she's worried brands will continue to put skincare on food

Michelle Wong, a trained cosmetic scientist with a doctorate in organic medicinal chemistry, slammed viral sunscreen in a toast test

The 34-year-old claims the video simply proves that “beauty standards have gotten out of hand”.

“It just shows that water absorbs heat. Browning bread is the Maillard reaction. It uses heat, water is excellent at absorbing heat.

“It would work with moisturizer.”

Michelle posted the short clip on Tuesday with a cheeky question about why we’re “shaming the texture of bread.”

And others agreed that the toast video and cooking videos about skincare in general are “ridiculous”.

“It’s worse than vitamin C serum on apple slices,” one woman said.

“Skincare over food, food as skincare…don’t know where this is all leading,” said another.

Michelle claims the test result was due to a chemical reaction - and moisturizer would have some effect

Michelle claims the test result was due to a chemical reaction – and moisturizer would have some effect

‘This is the dumbest test. Obviously it’s a marketing tactic, but still very dumb. Sunscreen isn’t supposed to work on bread and even if it did, it wouldn’t tell us anything about how it works on the skin,” added a third.

But there were also a disturbing number of people who believed the initial demonstration.

This isn’t the first time the famous beauty science social media star has tackled sunscreen.

She recently revealed why you should never buy aerosol sunscreen – and even the TGA is reviewing them again.

She said each can of aerosol sunscreen contains only enough SPF for two or three full-body applications.

Michelle Wong, a scientist obsessed with beauty products, posted a video on her Instagram Lab Muffin Beauty Science explaining the problem

Michelle Wong, a scientist obsessed with beauty products, posted a video on her Instagram Lab Muffin Beauty Science explaining the problem

“This study found that a standard aerosol sunscreen contains about one-third propellant,” she said, referring to a Queensland University of Technology study.

“But it can be up to 60%,” she added.

She explained that propellants are pressurized gases that help push the sunscreen out of the box.

“SPF testing is done on sunscreen without propellants, so you get about a third less product than it says,” she said.

“Some of the propellant also lands in liquid form on your skin, so it’s hard to tell how much sunscreen you’ve applied.”

Aerosols generally use butane, propane, isobutane and hydrocarbon – which are included on the can label.

“The Australian TGA is currently reassessing aerosol sunscreens because of this study…stay tuned,” she wrote in the caption.

And his video struck a chord with many of his followers.

‘It’s so wild! No wonder I always thought they weren’t effective,” one makeup artist wrote.

Some revealed that they had been burned after using the sunscreen, not knowing it had come out.

Can confirm from personal experience. Which also involved explaining to a fellow burn surgeon why my back was bright red,” one doctor said.

She also explained the common gases used in aerosol sunscreens.

She also explained the common gases used in aerosol sunscreens.

“My poor husband literally just came home from a great day on the golf course…SUNBURNED. When asked if he applied sunscreen, he said yes…and yes, it was a spray. I just showed him this video, and he’s sold. No more spray cans for us. Lotion only…drops,” one woman wrote.

Others were stunned by the results of the study.

‘I never thought of it before. I loved using them because they are faster, but luckily they were out of thruster anthelios so I didn’t get it this year,” one woman wrote.

Michelle said that while they were convenient, she couldn’t get past the volume issue.

‘They are really practical! I think they’re fine if you spray a ton on them, but the 2/3 value is just overwhelming to me.

She added that pump sunscreen has its own set of problems – but is not affected by the problem of aerosols.

Medical University of Maryland Launches Precision Health Study to Create Largest, Most Diverse Research Database in the State

B-roll for journalists with lab footage and expert interviews available here:

Newswise – BALTIMORE, June 21, 2022 – The University of Maryland Medicine, the joint venture of the University of Maryland School of Medicine, the University of Maryland Medical Center and the University of Maryland Medical System , today launched a landmark initiative called My Healthy Maryland Precision Medicine Research. The project aims to enroll 250,000 Maryland residents over the next decade who reflect the state’s diversity and want to play a pivotal role in helping researchers understand how genes and lifestyle affect the health of a individual.

Particular emphasis will be placed on underserved populations who experience significant health disparities, leading to more disease and shorter lifespans. The large-scale effort to collect broad sources of health data, including genetic information, will help researchers better understand human genomic variation and its relationship to disease and treatment.

“My Healthy Maryland is a pioneering initiative that aims to advance discoveries related to health and disease and accelerate the implementation of those discoveries. medical mysteries, generating insights and accelerating discoveries that can improve the health of Marylanders for generations to come,” said the study’s principal investigator, Stephen Davis, MBBS, FRCP, FACE, MACP, Professor Theodore E. Woodward and chair of the Department of Medicine at UMSOM, director of the Institute for Clinical and Translational Research and vice- chair of clinical translational science at the university. of Maryland, Baltimore.

Residents of Maryland reflect a genetically more diverse community compared to the general population of the United States, with nearly one-third of residents identifying as African American, more than 10% identifying as Hispanic or Latino, and 6 % identifying as Asian. Maryland is also home to a large immigrant population: one in seven Marylanders was born in another country, with El Salvador, India, China, and Nigeria among the top nations represented in the state. Additionally, a significant percentage of state residents live in rural communities, and many live in coastal communities with different environmental exposures and dietary habits than the nation as a whole.

“This is an opportunity for Maryland’s diverse community to team up with researchers to better understand how our biology, lifestyle, and local environment affect our health,” said study co-lead Toni Pollin, PhD, associate professor of medicine at UMSOM. “We also hope it will help accelerate our understanding of how individuals and their healthcare providers can use information about genetic variation to predict, prevent, detect and treat disease.”

Study participants will receive periodic overview reports about study progress, especially research results that may lead to better ways to treat or prevent disease. They will also have the opportunity to enroll in new research studies. In the future, the researchers also hope to offer study participants the opportunity to learn about their own genetic variations that may warrant follow-up medical evaluation.

“We want to advance discovery related to health and disease and accelerate the translation of these discoveries into more effective and safer individualized healthcare,” said study co-director Alan Shuldiner, MD, John L. Whitehurst Professor of Medicine and Associate Dean for Personalized Medicine and Genomics at UMSOM. “It will help us maximize the value of health care delivery in Maryland and beyond.

“A big part of the School of Medicine’s mission is to meet the unique health needs of the local Maryland community. Our state has a vibrant and genetically diverse population, and we must work to fully understand how genes interact with our environment, especially for those living in economically disadvantaged communities.“, said E. Albert Reece, MD, PhD, MBA, Executive Vice President for Medical Affairs, UM Baltimore, and John Z. and Akiko K. Bowers Distinguished Professor and Dean, University of Maryland School of Medicine.

Mohan Suntha, MD, MBAPresident and CEO of the University of Maryland Medical System, added: “As physicians, scientists, and researchers, we are incredibly excited about the hope and promise that My Healthy Maryland offers. This is an example of academic medicine at its best, bringing together exploration, research and innovation to benefit the health of tens of thousands of Marylanders.

The University of Maryland Medicine partnered with digital health research company Vibrent Health to host the study on Vibrent Health’s digital health research platform. This technology platform is designed to recruit and engage diverse research participants and collect data from surveys, genomics, biological samples, electronic health records, wearable devices and other sources. The platform allows researchers to get a complete picture of the health of research participants.

“We are thrilled to partner with the University of Maryland Medicine to bring the latest data-driven digital health research technology to My Healthy Maryland,” said Praduman “PJ” Jain, CEO and Founder of Vibrent Health. “We are committed to working with research institutions like UMSOM to make digital health research accessible to people from diverse communities who have historically been underrepresented in biomedical research.”

About University of Maryland Medical School

Now in its third century, the University of Maryland Medical School was incorporated in 1807 as the first public medical school in the United States. It continues today to be one of the world’s fastest growing leading biomedical research enterprises – with 46 academic departments, centers, institutes and programs, and a faculty of more than 3,000 physicians, scientists and allied health professionals, including members of the National Academy of Medicine and the National Academy of Sciences, and a two-time distinguished recipient of the Albert E. Lasker Award in Medical Research. With an operating budget of more than $1.2 billion, the School of Medicine works closely with the University of Maryland Medical Center and Medical System to provide intensive research, academic, and clinical care to nearly 2 million patients each year. The School of Medicine has nearly $600 million in extramural funding, with most of its academic departments ranking highly among all medical schools in the nation for research funding. As one of seven professional schools that make up the University of Maryland, Baltimore campus, the School of Medicine has a total population of nearly 9,000 faculty and staff, including 2,500 students, trainees, residents and fellows. The combined medical school and medical system (“University of Maryland Medicine”) has an annual budget of more than $6 billion and an economic impact of nearly $20 billion on the state and local community. The School of Medicine, which ranks 8th among public medical schools in terms of research productivity (according to the Association of American Medical Colleges profile) is an innovator in translational medicine, with 606 active patents and 52 start-up companies. In the last US news and world report ranking of best medical schools, released in 2021, UM School of Medicine is ranked #9 among 92 public medical schools in the United States and among the top 15% (#27) of 192 public and private medical schools in the United States. The School of Medicine works locally, nationally and globally, with research and treatment facilities in 36 countries around the world. Visit medschool.umaryland.edu

About the University of Maryland Medical System

The University of Maryland Medical System (UMMS) is an academic regional health care system focused on meeting the health care needs of Maryland, bringing innovation, discovery, and research to the care we provide and educating the state’s future physicians and healthcare professionals through our partnership with the University of Maryland School of Medicine and the University of Maryland, Baltimore Vocational Schools (Nursing, Pharmacy, Social Work and dentistry) in Baltimore. As one of the largest private employers in the state, the health system’s more than 29,500 employees and 4,000 affiliated physicians provide primary and specialty care in more than 150 locations, including 12 hospitals and 9 health centers. emergency care from the University of Maryland. UMMS’ flagship college campus, the University of Maryland Medical Center in downtown Baltimore, is recognized regionally and nationally for excellence and innovation in specialty care. Our acute care and specialty rehabilitation hospitals serve urban, suburban and rural communities and are located in 13 counties across the state. For more information, visit www.umms.org.

The FDA is in a hole with a memorandum of understanding on compound drugs – it should stop digging

When FDA lawyers admitted in federal court in February that the agency failed to properly follow congressional instructions for creating a memorandum of understanding (MOU) with states regarding interstate drug distributions compounds, they finally seemed to heed Will Rogers’ advice: “If you find yourself in a hole, stop digging.

For the FDA, that hole is now 25 years deep. Its impetus was a congressional directive in 1997—part of revisions to the Food, Drug, and Cosmetic Act—that the agency execute a memorandum of understanding under which state pharmacy boards would communicate to the FDA certain information about state-licensed compounding pharmacies that distributed a large percentage of their compounded formulas across state lines.

As Congress designed it, the MOU would be voluntary, but the law would impose restrictions on pharmacies that ship compound drugs from states that have chosen not to sign it. Congress wanted it to be a consensus document, created through the formal rulemaking process, with state input and approval. In other words, Congress expected the FDA to draft a memorandum of understanding that states would be willing to sign.

But that’s not what the agency did. Instead, he started digging. After several proposed iterations over 24 years, the FDA finalized a Memorandum of Understanding in 2020 that:

• Has not been subject to the development of formal notice and comment rules.

• Failed to properly assess the economic impact on pharmacies and state pharmacy boards.

• Merging of 2 important definitions of the Pharmacy Act: “distribute” and “dispense”.

This culminated in a lawsuit against the agency by 7 compounding pharmacies, whose arguments partly found resonance with a federal judge and led to the FDA acknowledging its failures in court last February. Certainly, the agency did not entirely abandon its shovel during this court appearance. Instead, he laid out plans to start working on a new hole: come up with another version of the MOU, this time through the prescribed rule-making process he hadn’t gone through before.

But abandoning this MOU is precisely what the FDA should ask permission to do, because the specific problem for which the MOU was designed in 1997 no longer exists.

To understand why the MOU as envisioned by Congress is obsolete, let’s first go back to the previously mentioned definitions. In federal and state pharmacy law, the terms “distribute” and “dispenser” have remarkably consistent definitions.

The “distribution” is patient-specific; it is a drug prepared for an individual patient in accordance with a prescription from a physician or other prescriber. “Distributions”, on the other hand, are not patient-specific; the term applies to batches of compound drugs prepared for clinical or hospital administration by a physician to a patient, and a prescription is not required.

In 1997, when Congress authorized the creation of the MOU, it was to address compounding and distribution by traditional pharmacies of compounding non-patient-specific drugs for administration in the clinic. It was a practice generally allowed by most state laws at the time, but was later banned by Congress when it passed the Drug Quality and Safety Act (DQSA) in 2013.

Under the DQSA, traditional compounders were prohibited from compounding drugs for clinical use without a prescription. Not only that, but a new category of prep operations, called outsourcing facilities, has been created. These establishments would be allowed to distribute compound drugs to hospitals and clinics if they adhered to current good manufacturing practices, just as manufacturers of FDA-approved drugs do.

The DQSA eliminated the need for this 1997 MOU because traditional preparers could no longer do what the MOU was supposed to inform. Still, the requirement for a memorandum of understanding remained in the Food, Drug, and Cosmetic Act, so the FDA decided to dig a little deeper.

The agency re-drafted a memorandum of understanding that applied to both distributions and the distribution of compound drugs, even though Congress had only authorized the memorandum of understanding to cover distributions, and not patient-specific dispensing, which has long been regulated by state pharmacy boards. . This overbreadth led to the aforementioned lawsuit against the agency complicating pharmacies and that court appearance in February where the FDA climbed out of one hole and announced it would start another.

Here’s the thing, pharmacy compounders are not opposed to some level of reporting on compound drug shipments across state lines, even patient-specific compound drug shipments. Because it’s not unusual for the pharmacy that makes this personalized drug for your partner, child, or Aunt Sadie to be in a different state, it’s not unreasonable for state pharmacy boards and the FDA to want to know which pharmacies ship the majority of their compounded preparations out of state.

So, instead of digging a new hole, the FDA should join the compounding profession in changing the law. Eliminate this outdated memorandum of understanding requirement – a memorandum of understanding that several states have already said they can’t sign (due to state law) or won’t sign (due to administrative burden).

In its place, create a statutory regime for reporting shipping information to state pharmacy boards, to be shared with the FDA. Perhaps also create a narrow but permanent lane in statute for compounding pharmacies to alleviate drug supply chain issues by compounding urgent-use drugs in small batches for hospitals and clinics when these medicines are in national or regional shortage.

Stop fumbling with the FDA and let’s start building a new framework that delivers the reporting you want and maintains patient access to safe, life-enhancing compound medicines.

About the Author

Scott Brunner, CAE, is CEO of the Alliance for Pharmacy Compounding.


AGOURA HILLS, Calif., May 11, 2022 (GLOBE NEWSWIRE) — Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTLC, Financial), is pleased to announce the granting of patent application no. 15/753,882 entitled “USE OF VDAS TO IMPROVE IMMUNOMODULATING THERAPIES FOR TUMOR” by the United States Patent Office.

The patent claims relate to a pharmaceutical composition for producing an antitumor effect in a subject suffering from cancer or tumor, comprising a vascular disrupting agent (VDA) comprising a combretastatin agent and one or more antibodies selected from the group consisting of: a CTLA-4 antibody, a PD-i antibody, a PD-Li antibody and a PD-L2 antibody in therefore effective amounts in a pharmaceutical carrier, wherein in the VDA is combretastatin Al diphosphate (CAl P) or combretastatin A4 phosphate (CA4P) or others.

“With the completion of the joint venture with Dragon Overseas Capital Limited for OT-101, we are now able to strengthen Mateon’s legacy assets, including CA4P and Oxi4503,” said Dr. Vuong Trieu, CEO and Chairman. “Given our team’s experience in the VDA space as well as Abraxane and Cynviloq, we believe we can successfully redeploy CA4P and Oxi4503 for the treatment of difficult-to-treat cancers, alone or in combination with Pembrolizumab/Keytruda. .”

About Oncotelic

Oncotelic (f/k/a Mateon Therapeutics, Inc.), was established in New York State in 1988 as OXiGENE, Inc., reincorporated in the State of Delaware in 1992 and changed its name to Mateon Therapeutics, Inc. in 2016, and Oncotelic Therapeutics, Inc. in November 2020. Oncotelic seeks to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival for cancer patients , with a focus on rare pediatric cancers. Oncotelic has a rare pediatric designation for DIPG (OT-101), melanoma (CA4P), and AML (OXi 4503). Oncotelic also acquired PointR Data Inc. in November 2019.

Additionally, Oncotelic acquired AL-101, in Q4 2021, for the intranasal delivery of apomorphine. We intend to develop AL-101 for the treatment of Parkinson’s disease (“PD”). Over 60,000 new patients are diagnosed with PD in the United States and there are currently over one million patients in the United States and are expected to increase to over 1.2 million by 2030. Additionally, approximately 10 million suffer from this disease in the world. https://www.parkinson.org/Understanding-Parkinsons/Statistics. AL-101 is also being developed for erectile dysfunction (“ED”). Erectile dysfunction is the most common male sexual disorder in the world. The percentages of men affected by erectile dysfunction are as follows: 14.3-70% of men aged ≥60, 6.7-48% of men aged ≥70 and 38% of men aged ≥80 years (Geerkens MJM et al. (2019). Eur Urol Focus. pii: S2405-4569(19)30079-3). However, with the increase in administration of PDE5 inhibitors in clinical practice, it has been found that approximately 30-35% of emergency department patients are treatment failures (McMahon CN et al. (2006). BMJ, 332: 589-92). AL-101 is designed to target treatment failure patients who do not respond to PDE5 inhibitors. Through a similar mechanism of action, AL-101 is being developed for female sexual dysfunction (“FSD”). Female sexual dysfunction is a widespread problem, affecting approximately 40% of women, and there are few treatment options. FSD is more typical as women age and is a progressive and widespread condition. (Allahdadi, KJ et al. (2009) Cardiovascular and Hematological Agents in Medicinal Chemistry, 7(4), 260-269). There are no medications available for the treatment of FSD. In June 2019, the United States Food and Drug Administration approved Vyleesi (bremelanotide) to treat acquired generalized hypoactive sexual desire disorder (“HSDD”) in premenopausal women. It is the only drug treatment available. Vyleesi has essentially replaced the only other drug for HSDD – however, it has a long list of drug interactions, including commonly used antidepressants, such as fluoxetine and sertraline. Additionally, it contains a black box warning regarding its use with alcohol, a combination that has been associated with episodes of hypotension and syncope. Therefore, there is an urgent need for an effective therapy for FSD and HSDD.

About CA4P

CA4P causes rapid and generalized necrosis of tumor cells. CA4P increases the immunogenic effect of checkpoint inhibitors when used alone as monotherapy. Counts of white blood cells, T-lymphocytes and tumour-fighting cytotoxic T-lymphocytes compared to immuno-oncology agents alone. Tumor necrosis with the combination of CA4P and immuno-oncology agents is almost double the necrosis with the immuno-oncology agents alone (63.9% vs. 32.8%, control = 25.8%). The aggregate data from all of these studies provide evidence that CA4P can enhance the activity of immuno-oncology agents for the treatment of cancer, including anti-CTLA4 antibodies. The FDA has granted Rare Pediatric Disease Designation to CA4P/fosbretabulin tromethamine for the treatment of stage IIB-IV melanoma due to genetic mutations that disproportionately affect pediatric patients as a drug. For more information, please visit www.oncotelic.com

Oncotelic Caution Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included in this release regarding strategy, future operations, future financial condition, Management’s outlook, plans and objectives are forward-looking statements. Words such as “may”, “expect”, “anticipate”, “hope”, “vision”, “optimism”, “design”, “exciting”, “promising”, “will”, “belief” , “estimate”, “intend”, “believe”, “seek a cure for cancer”, “focus on innovation”, “paradigm shift”, “high scientific merit”, “potential for impact” and similar expressions are intended to identify forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements about future plans relating to the JV’s operations, the JV’s participation in or success of an initial public offering, progress, the timing of clinical development, the scope and success of future clinical trials, the reporting of clinical data for the Company’s product candidates and the potential use of the Company’s product candidates to treat various cancer indications as well as the obtaining the regulatory approval required to conduct clinical trials and upon granting approval by regulatory agencies, the successful commercialization of products. Each of these forward-looking statements involves risks and uncertainties, and actual results may differ materially from these forward-looking statements. Many factors could cause current expectations to differ from actual results, including unexpected safety or efficacy data observed in preclinical or clinical studies, drug site activation or enrollment rates, lower than expected clinical trials, changes in anticipated or existing competition, changes in the regulatory environment, inability of collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes. These risks are not exhaustive, the Company faces known and unknown risks, including the risk factors described in the Company’s Annual Report on Form 10-K filed with the SEC on April 15, 2022 and in other company periodic filings. Forward-looking statements are based on expectations and assumptions as of the date of this press release. Except as required by law, the company undertakes no obligation to update the forward-looking statements contained herein to reflect any change in expectations, whether as a result of new information, future events or otherwise. .

Contact information:
For Oncotelic Therapeutics, Inc.:
Amit Shah
[email protected]


Walking around Surrey’s least deprived area felt a world apart during the cost of living crisis – David Bradshaw

We are all hearing a lot at the moment about petrol costing £2 a litre, energy bills almost doubling for some households and the weekly supermarket costing more than ever – but is the pressure everywhere makes you feel? Surrey has the reputation of being one of the wealthiest regions in the UK. So I decided to go to the statistically least deprived area of ​​the county to see if life was going normally.

Part of the reason for my decision was that earlier in the day I had been to the area at the other end of the spectrum from Surrey – a part of Merstham ranked by the English Deprivation Indexes 2019 as the poorest in the county. During my visit there I had been struck by both the community spirit and the hardship of the people, so I was interested to see and feel the contrast as I headed to Lower Bourne just to the south of Farnham.

Going from one to the other in the space of an hour is really quite shocking and helps to appreciate the disparities in living conditions at contrasting ends of the social spectrum. Almost every building in Merstham was an apartment block, some modern looking while others needed a lick of paint, but all involved people living in small properties and often on top of each other. You won’t find such a sight in Lower Bourne.

READ MORE: Residents of Surrey’s most deprived ward must turn off fridges to save money

With no obvious equivalent to the community center I had just visited in Merstham, I opted instead to wander around Lower Bourne and see who I met. It was a beautifully sunny lunchtime, and on Burnt Hill Road some parents were collecting their babies from a crèche held in a lovely little social club, with its own pristine green bowls in the back.

Elsewhere, I found an exclusive tennis club and passed a few members on their way to a lunch game. A member of staff told me that there had been no obvious drop in membership since the cost of living crisis set in, adding that there was also no clear signs of trouble in shops in Farnham town center which seemed busier than ever.

At the Fox Inn, a quaint pub on Frensham’s main road, the place was empty except for a group of young men enjoying a lunchtime pint in the beer garden. The pub has its own Greek restaurant on site, and I was told the place would be much busier in the evenings as locals were celebrating the start of the weekend.

Lower Bourne (top) and Merstham (bottom) show just how diverse Surrey neighborhoods are

The streets were mostly deserted and many houses were large, isolated and often closed. The little row of shops in the middle of the neighborhood just south of the pub were also mostly empty but I was surprised to see that among them was a Costcutter grocery store. It almost seemed out of place to have a budget food store amongst such obvious wealth, so I walked in and had a chat.

“Prices have definitely gone up recently,” said Andy, who worked the cashier inside. “But we’re still seeing as many people come into the store as ever.” Indeed, there were a few other shoppers browsing the shelves, including a young woman who was fighting an uphill battle to control two young children as she hunted for a bargain.

As I walked back to my car and calculated how much of my savings I had spent on fuel to get here, I was struck by how normal everything was. I don’t know what I honestly expected to find here, but my main thoughts as I left were that everything seemed oddly normal, although it sure wasn’t for everyone. After all, you never know what goes on behind the closed doors of a household.

Yes, Lower Bourne felt immediately different to Merstham, and I’m sure a lot of people here are doing just fine. But there will undoubtedly be some who will be in difficulty, as there are in all the districts of the country. The fact that they’re not as visible in a place like this made me think about the importance of avoiding complacency: it’s not because I couldn’t see any obvious signs of a crisis in this affluent area of ​​Surrey that doesn’t mean they don’t exist.

Read more

Find out how you can get more information about SurreyLive’s cost of living crisis straight to your inbox for free here.

Announcement of New Bengal Pharmacy Manager

POCATELLO, Idaho (KIFI) – Idaho State University has announced that the new Head of Pharmacy in Bengal is Rikki Trussel, a 2012 ISU alumnus of the pharmacy program.

“I just think there are so many opportunities with Bengal Pharmacy,” Trussel said. “I worked in the pharmacy when I was an intern, but the telepharmacy part didn’t exist when I was here. It was exciting to do.

Trussel was previously at Kroger, first as pharmacy manager for Fred Meyer, then as district pharmacy manager for Smith’s Food and Drugs. She said she looked into Bengal Pharmacy and was thrilled to see how it has grown and changed.

Bengal Pharmacy’s mission is to provide high quality care to all of our patients while making healthcare accessible through our knowledgeable staff of pharmacists, residents, technicians and interns.

“The majority of our prescriptions are made in Challis and Arco. Both were community pharmacies with owners who tried to sell them but couldn’t find anyone,” Trussel said. “Bengal Pharmacy took them over and now we are providing access to care for communities that would otherwise have to drive hours to get to a pharmacy.”

Pharmacy is a growing field, especially for pharmacy technicians. Many pharmacists also receive hiring bonuses or other hiring incentives for working in the field.

Idaho is one of the few states with pharmacists who can prescribe medications under certain criteria, and she says Idaho State University’s work with rural medicine and advancing the practice of pharmacy l always interested and excited.

“I always kept Bengal Pharmacy in the back of my mind. I wondered if they had the right leadership to go in the direction I felt I needed to go,” Trussel said. “They have the same vision as me, as to what the pharmacy of tomorrow will look like. We need to change our profession to a service-based profession instead of a product-based profession.

Trussel noted that the pandemic has highlighted the need for pharmacists and pharmacies to change and grow with patient needs.

“I see the pharmacy becoming very similar to the urgent care type model, where someone can come in with a pink eye or a urinary tract infection, where the pharmacist can give them first aid,” Trussel said. “Particularly in rural areas, where there’s a lack of prescribers, that would be an incredible benefit to those small communities.”

She also said telehealth work has helped her realize that a pharmacy can operate with a smaller in-person staff, with many other staff working from home or through other virtual means.

“At the moment, pharmacy is really in a phase of redefinition. You have practitioners who work for Amazon or for mail-order pharmacies, but we also have practitioners who offer interdisciplinary approaches, like working with those who need a little more care. It’s very exciting for pharmacists to have a seat at the table,” said Trussel. “We are now seen as healthcare professionals, and that stems from the pandemic, where we were perhaps the only patient access to healthcare at the time. We are easing the burden of health care.

Trussel says rural medicine is vitally important and pharmacists have a unique opportunity in Idaho to be at the forefront of modern pharmacy practice. She says she also looks forward to working with the students.

“They keep you up to date, because they come in and they ask you questions, and that helps you stay on top of your practice,” she said. “It’s an exciting time to be a pharmacist.

The Bengal Pharmacy in Pocatello is open Monday through Friday from 9 a.m. to 6 p.m. In Challis and Arco, the Bengal pharmacy is open from 10 a.m. to 6 p.m. Monday to Friday.

Governor Newsom Continues to Override COVID-19 Executive Orders

New executive action maintains several provisions to continue state action vaccination and tests efforts, protect the health care delivery system

SACRAMENTO – Continuing California’s progress in responsibly removing executive orders implemented in response to the pandemic, Governor Gavin Newsom today took steps to lift the additional provisions of executive orders related to COVID-19, while maintaining California’s state-of-the-art testing and vaccination programs and protecting hospital capacity — key components of the state’s SMARTER plan to guide California’s response to the pandemic.

“As California navigates the evolving pandemic, the state remains focused on keeping Californians safe while advancing our ongoing recovery,” Governor Newsom said. “We continue to deploy proven strategies and programs that enable us to respond quickly and effectively to changing pandemic conditions, close equity gaps, and enable us to move forward.”

The governor’s action today immediately ends five provisions related to Cal/OSHA’s temporary COVID-19 emergency standards, following updated workplace safety rules that took effect on last month. Fifteen additional provisions are set to expire on June 30, after which only 5% of the provisions of the COVID-19-related executive order issued throughout the pandemic will remain in place.

Important measures still in place to strengthen the state’s COVID response and recovery efforts include provisions that support:

  • COVID test – Provide flexibility to support the state’s testing program, which under the SMARTER plan will continue to be able to process at least 500,000 tests per day. For example, through executive action, the governor waived a provision that would require a medical professional to review every test result before it is released electronically to patients, and expanded the scopes of exercise of pharmacists and pharmacy technicians to perform COVID tests.
  • Vaccinations and boosters – Provide flexibility to advance the state’s vaccination and booster programs, which under the SMARTER plan will continue to be able to distribute at least 200,000 doses per day. This includes temporarily waiving licensing requirements to allow pharmacists and pharmacy technicians to administer COVID vaccines and waiving requirements so the state can offer mobile vaccination clinics.
  • Protecting hospital capacity and vulnerable populations – Provisions to protect both the capacity of our health care delivery system and vulnerable populations, especially during COVID surges. This includes provisions for out-of-state healthcare workers to provide services in California and for the Department of Developmental Services to provide remote and expanded non-residential services to more clients.
  • Protections against excessive prices of infant formula – Provisions that protect consumers from predatory pricing of infant formula in response to the continued supply chain challenges caused by the pandemic and the closure of a manufacturing plant which further impacted supply. To help improve access for parents and caregivers, vendors are generally prohibited from selling formula for more than 10% more than the price they charged on February 17.

A copy of the order rescinding additional executive measures related to COVID-19 can be found here.

Since the start of the pandemic, California has led the national fight against COVID-19 with significant public health efforts that have administered more than 76 million COVID-19 vaccines, helped maintain one of the highest death rates the lowest among major states and made the state a national leader in preventing school closings. Building on lessons learned and the state’s ongoing commitment to equity, Governor Newsom unveiled the SMARTER Plan earlier this year, which outlines the state’s strategic approach to managing the next phase of the pandemic with core pillars and preparedness measures based on proven strategies used to successfully slow the spread of the virus and protect Californians.

# # #

Why Garlic Was Called “Russian Penicillin” During World War II

As reported by the Los Angeles Times, the remarkable health benefits of garlic were noticed “as early as 1500 BC”, when the Egyptians used garlic as a means of alleviating ailments such as heart problems, general weakness , headaches and migraines. During World War II, garlic was actually called “Russian penicillin” for its amazing healing properties – it was used to treat wounds and injuries sustained on the battlefield.

Where does this name come from, you ask me? Western New York Urology Associates explains that “garlic was called Russian penicillin during World War II because, after running out of antibiotics, the Russian government turned to this ancient treatment for its soldiers.” Garlic “poultices” are said to have been used to prevent infection of open wounds or wounds. Additionally, in 1961, the British government “issued a general appeal to the public to supply them with garlic to meet wartime needs”, and that Louis Pasteur’s original experimentation involved the use of garlic as a means of killing bacteria. Additionally, Urology Associates notes that “there is no doubt that raw garlic can kill a wide variety of microorganisms by direct contact, including fungi, bacteria, viruses, and protozoa.” Obviously, garlic is a particularly powerful ingredient, belied by the small size of cloves.

Over 120 attend two-day event designed to promote minority STEM careers – The Oxford Eagle

Chemistry and chemical engineering students from across the Southeast and Southwest recently gathered at the University of Mississippi for a two-day conference designed to promote STEM careers for people of color.

Some 120 students and researchers, including 95 in-person attendees, attended the joint Southeast and Southwest regional conference of the National Organization for the Professional Advancement of Black Chemists and Chemical Engineers, or NOBCChE, on the campus of Ole Miss. Students represented 70% of the total number of participants in the hybrid event.

“The conference showcased the research excellence of black chemists and engineers considered the top experts in their respective fields,” said Murrell Godfrey, professor of chemistry and outgoing president of NOBCChE. “It also provided young researchers with a platform to present original research and receive valuable feedback.”

More than 75 students from underrepresented backgrounds in chemistry, chemical engineering, and related STEM fields took part in networking and professional development opportunities. Milcah Jackson and Joerg Schlatterer, both of the American Chemical Society, presented professional development workshops on creating effective resumes and resumes and making personal connections that matter.

Former NOBCChE Presidents Emanual Waddell and Marquita “Dr. Q” Qualls featured on “Opportunities with the National Science Foundation” and “Building Your Brand,” respectively.

Students also entered oral presentation and poster competitions, with cash prizes up for grabs. First, second and third place winners in each category shared $1,650 in prize money.

Tomayo Berida, research assistant in pharmacognosy at UM, won first place in the poster presentation competition. The original Nigerian’s poster, ‘The New Potent 1,2,4-Triazolyl Pyridine Agent Against Mycobacterium Tuberculosis’ discusses ongoing efforts to develop a new class of potent agents against the organism that causes tuberculosis.

“I was beyond excited (to win),” Berida said. “It was gratifying to note that my poster presentation was well received by students, faculty and judges at the conference.”

Davita Watkins, associate professor of chemistry and biochemistry at UM, was among the keynote speakers. She recently won a prestigious National Science Foundation CAREER Award for her work elucidating the role of sigma-hole interactions in the advanced functional materials she develops in her on-campus labs.

Others who gave keynote addresses included LSU Professor Isaiah Warner and Philip W. West, professor emeritus of analytical and environmental chemistry at LSU; Montray Leavy, deputy chief technology officer at Entegris in Singapore; and LaRico Treadwell, R&D chemist and materials scientist at Sandia National Laboratories.

Students also participated in a graduate expo which allowed undergraduates to learn about top graduate programs and job opportunities. Schools and organizations represented included:

  • Auburn University
  • Texas A&M University
  • LS-PAC MODELS Center
  • Jackson State University
  • Entered
  • the UM departments of biomolecular sciences and chemistry and biochemistry and engineering school
  • Emory University Department of Chemistry
  • Louisiana State University
  • the american chemical society

Ole Miss academic units provided undergraduate students with information on various doctoral programs and tours of their departments. Professionals and students had the opportunity to visit the School of Pharmacy’s marijuana and medicinal plant gardens.

“The conference provided a space for discussion to foster partnerships and collaborations that can lead to new research, innovations and solutions to global challenges,” said Godfrey. “It also allowed NOBCChE student chapter members to give back to the community by performing a chemical magic show for approximately 30 Coffeeville, Mississippi, Upward Bound students in grades 9-12 during the end-of-conference barbecue. »

The National Science Board recently awarded its 2022 Public Service Award to NOBCChE. The award honors exemplary public service in promoting public understanding of science and engineering.

NBRI Lucknow Initiative: Now ‘NITYA’ Herbal Stress Mask to Solve Respiratory Discomforts

Amid a spike in daily Covid-19 cases prompting citizens to be on their guard, the ‘NITYA’ herbal anti-stress face mask developed by NBRI (National Botanical Research Institute) scientists , Lucknow could be helpful in dealing with respiratory discomforts commonly experienced due to long hours of wearing masks.

“NITYA is an innovative herbal “stress-reducing mask” product that reduces respiratory discomforts such as congestion, excessive nostril wetting, and dizziness from long hours of wearing face masks. It has been prepared by blending three traditionally known essential oils and carrier oils,” said Dr. Sharad Srivastava, Senior Principal Scientist and Head of Pharmacognosy Division, NBRI, Lucknow.

“During the first and second waves of Covid, many people complained of respiratory discomfort due to the masks, in particular dizziness. People used camphor and other oils to get rid of the problem, but no definite combination was available. So we took on that challenge and created this herbal anti-stress face mask. It is completely herbal, devoid of any harmful chemicals,” Srivastava informed.

“The user can spray the oil in their mask and inhale deeply to smell it. An advantage is that you can spray it in close proximity, such as a closed room or office environment. It clears the nostrils, making it easier to breathe the person wearing the mask,” he added.

We even distributed the samples to frontline warriors because their jobs require them to wear masks longer, which has proven effective for them, he said.

“The name NITYA is inspired by Padma Shri Nitya Anand, former director of CDRI (Central Drugs Research Institute) and president of the Ranbaxy Science Foundation (RSF). A Gurugram-based “MARC” company received the spray production technologies for its fuller range of market availability,” he said.

CD3 primary candidates weigh in on key issues facing Pueblo

The Congressional District 3 primary has been called one of the highest-profile races in Colorado this election season.

Only candidates from the Democratic and Republican parties appear on the primary ballots, which voters began receiving last week. Candidates tied to neither of the two main parties will not appear on the ballot until November.

Unaffiliated voters who have not chosen which party they will vote for in the primaries are supposed to receive two ballots – one for the Democratic Party and one for the Republican Party – but can only vote for candidates from one single party.

After:Letter to the Leader: The Power of Unaffiliated Voters

Voters have been urged to mail in their ballots by June 21 to ensure their choices are received on Election Day, June 28, and counted.

We asked the five candidates hoping to run for the U.S. House of Representatives seat, currently held by Rep. Lauren Boebert, to tell us what they think are the top three issues facing Pueblo and what they hope to accomplish in their first month in Washington, DC, if elected in November.

Their responses are below, in alphabetical order by last name. The answers may have been cut off for lack of space, but the wording has not been changed.

Representative Lauren Boebert

Rep. Lauren Boebert, Republican. lives in silt

Three main problems facing Pueblo

Unemployment. Totaling 5.8% in April, Pueblo had one of the highest unemployment rates in the entire state. Economic strength and job growth come from policies that free up job creators, enable American ingenuity, and provide certainty. I support reducing job-killing regulations, cutting taxes for the middle class, and keeping small businesses open.

veterans issues. In many cases, veterans do not receive the services they need at the local VA clinic. This is unacceptable and I will continue to push for better services for Hero House and our veterans. In addition, my staff continues to work on important files to help our veterans and ensure that they receive the benefits they have earned.

Evraz. The factory provided jobs for 22,000 workers at its peak and was the region’s largest private employer. Evraz’s operations in Colorado represent approximately 50% of the entire rail market in North America. Recently, Evraz North America has faced bureaucratic challenges due to sanctions against Russia and ownership issues within its parent company.

First month in DC

I will continue to provide excellent service to constituents who need help and to focus on district priorities including jobs, energy legislation that will help lower gas prices and bring the inflation, water issues as the Arkansas Valley leads and to continue solving veterans’ issues. I will continue to offer solutions to get our country back and (sic) track and hold Biden and his bureaucrats accountable for the border crisis, the inflation crisis, the energy crisis, etc. I will continue to be a strong voice and advance legislation that supports and guarantees the rights and freedoms of the American people.

Don Coram

State Senator Don Coram, Republican. Lives in Montrose

Three main problems facing Pueblo

economy is the #1 problem facing Pueblo County. Whether it’s buying groceries, filling up your gas tank, paying rent, etc., it’s a struggle. Fighting out-of-control inflation is the priority. It is critical to ensure that even as some industries downsize, we take full advantage of other Pueblo opportunities, particularly in tourism, to pick up the slack. I look forward to supporting policies that achieve this goal.

Agriculture. During my time at the State House, I was recognized as a strong advocate for agriculture, and I will be in Congress. Unfortunately, staying in this business is becoming much more difficult due to rising costs, increased regulation, water issues, and because our country now imports more than we export.

Finally, I will do my best to close everything Virginia Hospital or VA clinic in Pueblo and the rest of the 3rd CD. As the Home of Hero’s (sic), it’s a shame that closing these facilities is even considered an option. We must serve our Veterans with the best possible care.

First month in DC

I look forward to setting my legislative agenda. The plan will include economic policy, agriculture, trade, health care and energy production. I will also begin to build relationships with other members of both parties to further my agenda for the district. I will establish a strong district office staff to ensure that constituent issues are heard and resolved. Finally, I will begin scheduling town hall meetings throughout the district.

Adam Frisch

Adam Frisch, Democrat. Lives in Aspen

Three main problems facing Pueblo

Inflation. American families are being cheated at the gas pump, at the pharmacy and at the grocery store. These prices are hurting Pueblo families and making Pueblo and communities like it a harder place to live. As a businessman, I know we need to fix our supply chain issues, reduce unnecessary government regulations, and reduce bureaucratic expenses. In Congress, I will fight so that more people can earn a living, afford a home, and put food on the table.

Water rights. Our ranchers and farmers depend on abundant and secure access to water to provide the resources that fuel our country and beyond. We must protect and care for our district’s resources. Natural resources and the beauty of the surroundings become an even more important driver of economic growth in our district.

The current representative in Washington. Lauren Boebert used her office to boost her self-esteem and ignored the pressing needs of the people in her district. Pueblo is worth heading to. I will negotiate and advocate on behalf of the issues and values ​​most important to the people of southern and western Colorado, including protecting women’s right to choose, funding school districts, removing unnecessary government regulations, and the transition to clean, renewable energy while protecting and supporting those living in gas and coal communities.

First month in DC

I will be joining the Problem Solvers Caucus, a group of Republicans and Democrats working together to pass bipartisan legislation. As part of this caucus, I will work to fight inflation, grow our economy, and add financial resources to our classrooms. More importantly, I will restore the dignity of the 3rd congressional district. The people of our district deserve a congressman whose reputation reflects the values ​​of our community, instead of hatred and narcissism.

Sol Sandoval

Sol Sandoval, Democrat. Lives in Pueblo

Three main problems facing Pueblo

Economy. We need to create more job opportunities through apprenticeships, trade schools, well-paying union jobs, and training for people who are already working. By investing in workforce development, apprenticeship training and growing industries like healthcare, technology, manufacturing and renewable energy, we can open the door to career advancement and better opportunities for Pueblo families and businesses.

Education. Our schools are underfunded and understaffed. I will support federal education funding programs and support expanding student loan forgiveness for teachers. For higher education, I will work to increase the availability of the TRIO program, which helps low-income, disabled, and entry-level students.

Veterans. We need to expand the availability of mental health services in Pueblo, just as the VA Hospital in Grand Junction has done. And we must pass the PACT Act to ensure veterans injured by exposure to toxic chemicals are eligible for VA health benefits. They fought for my freedom, I will fight for our veterans in Congress.

First month in DC

In my first month in DC, my top priority will be to ensure funding and bills for infrastructure and budget bills are prioritized in a way that benefits CD3 – from water conservation to I-70 improvements to training for renewable energy jobs. My other top priority will be ensuring the affordability of health care, including maximizing funding for rural community health centres. We need to fully support women’s access to reproductive health care, cap insulin prices, allow Medicare to negotiate drug prices, and expand coverage for things like hearing aids.

Alex Walker

Alex Walker, Democrat. Lives in Avon

Three main problems facing Pueblo

Lodging. Our families struggle to find housing, let alone afford it. It is a representative’s responsibility to lobby for federal funds to ease the burden of inflation on our working and middle class families.

Economy. Pueblo’s economy is tied to dying industries. We need to start attracting clean, well-paying jobs so families can put more food on the table and maintain quality health coverage.

Education. Children are falling behind as teacher shortages rage, with parents bearing the brunt. We need to start paying teachers a fair wage and covering Pueblo (and CD3) with broadband to expand access to remote learning opportunities.

First month in DC

I would push for immediate action on gun reform, including closing the Charleston loophole, mandating background checks, and passing red flag laws; bill allocating federal funds to boost infrastructure and clean energy jobs in CD3; and support legislation for new housing infrastructure in Pueblo and the rest of CD3.

Karin Zeitvogel has left the Chieftain but welcomes messages from readers at [email protected]

Stop the sticker clash at the pharmacy counter – The Hamburg Reporter

Chuck Grassely

Q: What are Pharmacy Benefit Managers (PBMs) and why are you working to reform how they work?

A: So far this year, I have held 61 county meetings statewide. I hear from Iowans that it’s harder than ever to make ends meet. Paying for gas and groceries takes up more of their wallet. And that makes it even more difficult to pay for soaring prescription drug prices. The shock of the stickers at the pharmacy counter is more painful than ever.

For several years, I led the effort in Congress to push for a bipartisan consensus on reforms that would reduce costs for consumers without undermining the medical breakthroughs on which generations of Americans depend to live more healthier, longer and more productive.

When I chaired the Senate Finance Committee, I led a two-year investigation into insulin drug prices and called on big pharma and insurance executives to testify on Capitol Hill. , as well as Pharmacy Benefit Managers (PBMs) who serve as intermediaries in the complex. prescription drug supply chain.

Through my investigative work, policy review, and Iowans feedback, it is clear that the drug pricing structure needs transparency to root out unfair and deceptive practices that allow drug prices on order to soar.

Sunlight will help curb predatory pricing schemes and hold drug prices paid by taxpayers, patients and employers accountable. I worked with Senator Pat Leahy of Vermont to stop the anti-competitive schemes used by Big Pharma that are delaying the arrival of more affordable generic drugs on pharmacy shelves. Our CREATES Act was signed into law in 2019 and will save consumers and taxpayers billions of dollars over the next decade.

My bipartisan Right to Reimbursement Act was also signed into law during the Trump administration and closes a loophole that Big Pharma has exploited to misclassify drugs in the Medicaid Drug Reimbursement Program and defraud the taxpayer out of billions every year.

More recently, I introduced a bipartisan bill with Senator Maria Cantwell of Washington that would require the Federal Trade Commission (FTC) to crack down on abusive PBM practices and review pricing structures, such as the pricing of deviations. This practice occurs when the PBM pays a price to the pharmacy but charges the patient’s health plan a higher rate to pocket the difference.

Our Pharmacy Benefit Manager Transparency Act would help eliminate misleading pricing systems; prohibit PBMs from collecting payments from pharmacies; and requiring PBMs to report to the FTC how much money they make from split pricing and pharmacy fees. Nonpartisan budget markers from the Congressional Budget Office estimate that ending differential pricing in Medicaid would save taxpayers about $900 million over the next decade.

Q: Should the federal government negotiate drug prices for the Medicare program?

A: First of all, let’s be perfectly clear on what it means to “negotiate”. This means the government would dictate drug prices, there would be no bargaining. It puts government bureaucrats between Americans and what’s in their medicine cabinets. Fixing the prices pharmaceutical companies can recoup for research and development would dry up innovation, cede our American ingenuity and leadership to China, deprive the consumer of choice, and ration access to drugs, therapies and cures that save lives.

When I chaired the Senate Finance Committee in 2003, I authored the most comprehensive modernization of Medicare since its enactment more than five decades ago.

My bill created voluntary Part D prescription drug coverage. Today, 49 million seniors have drug coverage.

At that point, I stopped the progressive push to give the federal government responsibility for a single drug pricing regime. Instead, my bill promoted competition to keep costs low, expand patient choice, and encourage innovation for better medicine for Americans.

Analyzes from the Congressional Budget Office, the Council of Economic Advisers and the University of Chicago all estimate that fewer drugs and treatments would be invented in the next generation if the federal government dictated drug prices.

Countries with socialized medicine may be willing to accept fewer treatments, but I think we should encourage more innovation and treatments while reducing costs for patients and taxpayers. And yet, the Biden administration and others want the federal government to dictate drug prices.

The Build Back Better agenda has included it among its Big Government plans. Americans can breathe a sigh of relief, these socialist price controls were stopped in the US Senate thanks to longstanding rules that force collaboration and consensus, commonly referred to as filibuster. In the meantime, I haven’t given up my job to

In the meantime, I haven’t given up my job to push through my bipartisan prescription drug price reduction legislation. Instead of harmful socialized price controls, my bill would not stop new drugs from coming to market.

It would cut costs for seniors by $72 billion, save taxpayers $95 billion, cap out-of-pocket spending at $3,100, and cap Medicare year-over-year drug prices at inflation price index. It would also reduce the costs of diabetes drugs that could save lives.

In a nutshell, it would end unlimited taxpayer-funded subsidies to Big Pharma, an approach supported by the CATO Free Market Institute. My bill can cross the threshold of 60 votes in the United States Senate if the majority leader puts it to a vote.

Partisan ideas got us nowhere and the Americans paid the price. Legislators must come to the table and do what is right for patients and taxpayers.

Notes from a Comrade Buckeye – Office of the President

The following message was sent to all Ohio State students on Tuesday, June 14, 2022. Click here to view the message to faculty and staff.

Dear Buckeyes,

I hope you are enjoying the summer and finding the opportunity to relax, start a new adventure, or just indulge in a good book. Our campuses have been quiet, which is nice, but I can’t wait for crowds of Buckeyes to return in the fall with excitement and enthusiasm.

Wherever you are, I hope you take the time to celebrate Pride Month and observe June 16 next week. One thing the pandemic has reminded us of is the need to support and care for each other.

Pride Month is a time to recognize our LGBTQ+ colleagues, friends, and neighbors, and to honor their many contributions to the State of Ohio, our communities, and Ohio. Thanks to the tireless efforts of so many members of the LGBTQ+ community, we have made great strides towards equality for all. This journey continues, here and around the world. I encourage everyone in the University community to explore the many resources available on our campuses to support and celebrate the LGBTQ+ community, this month and always.

We are also delighted to celebrate Juneteenth. The holiday has grown in size over the years and is now widely celebrated across the country, including on our campuses and more broadly across Ohio. These celebrations exemplify a commitment to celebrate Black people’s right to live as free human beings and allow us all to reflect on the resilience of our ancestors. We are proud as a university to offer celebrations to commemorate Juneteenth 2022. And on June 18, the Wexner Center for the Arts will host “All Day Blackness,” a celebration of Juneteenth and the Black community in Columbus with a series of free one-day programs, events and conversation.

June marks the 50th anniversary of Title IX, the groundbreaking civil rights law that requires all federally funded educational institutions to prohibit discrimination based on sex. As many of you know, I played field hockey at Stanford and founded a women’s lacrosse team there, so this law is very close to my heart. I was honored in 2012 on the 40th anniversary of Title IX to be named by ESPNW as one of “40 Women Who Made an Impact.” And now I’m so grateful to be President of the State of Ohio, which serves as an outstanding example to the nation at the intersection of athletics and inclusiveness.

This month is also the 50th anniversary of the Pell Grant a critically important source of funding that has opened doors for many Buckeyes and young people nationwide. College affordability is one of my top priorities, and one of the ways to achieve that goal is the Scarlet & Gray Advantage program. As the program expands over the next decade, it will provide pathways for our undergraduates to graduate, debt-free. Currently, just under half of our graduates leave Ohio State with student debt, averaging around $27,000. We know that debt can influence the decisions students make about college and after graduation.

We pride ourselves on our focus on affordability. We’re enrolling more Pell-eligible students approximately 12,350 in 2021 than the whole Ivy League put together. At Ohio State, we focus on creating opportunity instead of focusing privilege.

I am also proud that Ohio State remains affordable relative to our peers, nationally and within the state. Our undergraduate resident student tuition and fees are the second most affordable among Ohio’s selective admission public universities and seventh most affordable among Big Ten public schools.

Celebrate Success

Congratulations to Rakesh Murugesan, a senior student and biomedical science major who received a 2022 award from the Astronaut Scholarship Foundation. The scholarships are awarded to juniors and seniors studying science, technology, engineering or mathematics with the aim of pursuing research or advancing their field upon completion of their final degree.

Astronaut scholars are some of the best and brightest minds in STEM who demonstrate initiative, creativity, and excellence in their chosen field, and Rakesh certainly deserves this honor.

As always, go Buckeyes!


Kristina M. Johnson, Ph.D.

Wellness Resources

The following message was sent to all Ohio State faculty and staff on Tuesday, June 14, 2022. Click here to view the message to students.

Ohio State graduates make OHIO during a graduation ceremony

Dear colleagues,

I hope you are enjoying the summer and finding the opportunity to relax, start a new adventure, or just indulge in a good book. Our campuses have been quiet, which is nice, but I can’t wait for crowds of Buckeyes to return in the fall with excitement and enthusiasm.

Wherever you are, I hope you take the time to celebrate Pride Month and observe June 16 next week. One thing the pandemic has reminded us of is the need to support and care for each other.

Pride Month is a time to recognize our LGBTQ+ colleagues, friends, and neighbors, and to honor their many contributions to the State of Ohio, our communities, and Ohio. Thanks to the tireless efforts of so many members of the LGBTQ+ community, we have made great strides towards equality for all. This journey continues, here and around the world. I encourage everyone in the University community to explore the many resources available on our campuses to support and celebrate the LGBTQ+ community, this month and always.

We are also delighted to celebrate Juneteenth. The holiday has grown in size over the years and is now widely celebrated across the country, including on our campuses and more broadly across Ohio. These celebrations exemplify a commitment to celebrate Black people’s right to live as free human beings and allow us all to reflect on the resilience of our ancestors. We are proud as a university to offer celebrations to commemorate June 19, 2022.

On June 17, Wexner Medical Center will host an in-person event from noon to 1:30 p.m. in the auditorium at Ross Heart Hospital with food, music, speakers and more to commemorate the end of the slavery and celebrating African American culture. (A live stream option is available using this link with access code 524231.) And on June 18, the Wexner Center for the Arts will host “All Day Blackness,“a celebration of Juneteenth and the black community of Columbus with a series of free day-long shows, events and conversations.

June marks the 50th anniversary of Title IX, the groundbreaking civil rights law that requires all federally funded educational institutions to prohibit discrimination based on sex. As many of you know, I played field hockey at Stanford and founded a women’s lacrosse team there, so this law is very close to my heart. I was honored in 2012 on the 40th anniversary of Title IX to be named by ESPNW as one of “40 Women Who Made an Impact.” And now I’m so grateful to be President of the State of Ohio, which serves as an outstanding example to the nation at the intersection of athletics and inclusiveness.

This month also marks the 50th anniversary of the Pell Grant – a critically important source of funding that has opened doors for many Buckeyes and young people nationwide. College affordability is one of my top priorities, and one of the ways to achieve that goal is the Scarlet & Gray Advantage program. As the program expands over the next decade, it will provide pathways for our undergraduates to graduate, debt-free. Currently, just under half of our graduates leave Ohio State with student debt, averaging around $27,000. We know that debt can influence the decisions students make about college and after graduation.

We pride ourselves on our focus on affordability. We enroll more Pell-eligible students – approximately 12,350 in 2021 – than the entire Ivy League combined. At Ohio State, we focus on creating opportunity instead of focusing privilege.

I am also proud that Ohio State remains affordable relative to our peers, nationally and within the state. Our undergraduate resident student tuition and fees are the second most affordable among Ohio’s selective admission public universities and seventh most affordable among Big Ten public schools.

Celebrate Success

Congratulations to Dr. William S. Marras, Honda Chair in the Department of Integrated Systems Engineering, and Dr. A. Douglas Kinghorn, Professor and Jack L. Beal Chair in the Department of Medicinal Chemistry and Pharmacognosy, who have been selected to receive the Distinguished 2022 University Professor Award. It is the highest honor we bestow on faculty members – those who have truly outstanding records in teaching, research, and scholarly service.

Dr. Maria M. Mihaylova, Assistant Professor of Biological Chemistry and Pharmacology, was selected as the 2022 Pew Scholar by the National Advisory Committee for the Pew Scholars Program in Biomedical Sciences.

Dr. Betty Lise Anderson, professor of electrical and computer engineering, won the National Science Board’s 2022 Public Service Award. The award honors individuals and groups who have made substantial contributions to improving the public understanding of science and engineering in the United States.

As always, go Buckeyes!


Kristina M. Johnson, Ph.D.

Wellness Resources

Molecule that combines three distinct technologies

image: Nanostructured lipid carriers containing docetaxel and functionalized with bevacizumab magnified 100,000 times
see After

Credit: Leonardo Di Filippo/UNESP

A drug carrier capable of reaching the brain, attaching to an aggressive type of tumor called glioblastoma multiforme and releasing a chemotherapeutic agent has been tested for the first time by Brazilian researchers. According to an article published in the International Journal of Pharmacythe potential treatment has been shown to be effective in isolated cells and animal models through a combination of nanotechnology, chemotherapy and a monoclonal antibody.

Glioblastoma multiforme accounts for 60% of all brain tumors in adults and is also the most aggressive type of brain cancer. Even after surgery, radiotherapy and conventional chemotherapy, patient survival averages about 14 months. One of the reasons is angiogenesis, a process by which the tumor rapidly creates its own blood vessels in order to grow.

“Another difficulty is the blood-brain barrier, which prevents drugs from reaching the tumor,” said Leonardo DiFilippoPhD student and researcher at the School of Pharmaceutical Sciences of the State University of São Paulo in Araraquara (FCFAr-UNESP).

To address these challenges, Di Filippo worked with fellow researchers from UNESP and two other Brazilian institutions, the University of Campinas (UNICAMP) and the University of São Paulo (USP) in Ribeirão Preto, to combine docetaxel , a potent chemotherapeutic agent, with a nanostructured lipid carrier designed to cross the blood-brain barrier. “We developed a formulation in which the substances were stably combined,” he said.

The researchers also paired the transporter with bevacizumab, a monoclonal antibody developed against vascular endothelial growth factor (VEGF) and approved for other uses. “VEGF is the cancer protein that stimulates angiogenesis and tends to be overexpressed in glioblastoma multiforme,” Di Filippo explained. The goal was to create a formulation capable of entering the brain and releasing a chemotherapy drug to destroy the tumor.

“Developing this system with this app is an innovation,” said Marlus Choriliprofessor at UNESP and principal researcher of the project, who was supported by FAPESP.

Quality testing

After creating the nanostructured lipid carrier with docetaxel and bevacizumab, the researchers set out to ensure that it met certain basic criteria. Laboratory tests showed its size to be 128 nanometers, small enough to cross the blood-brain barrier. In addition, the entrapment of docetaxel was 90% and the coupling efficiency of bevacizumab was 62%. “These are positive numbers, sufficient to ensure adequate therapeutic concentrations,” Di Filippo said.

The next step was to evaluate the effects of the compound on two glioblastoma cell lines and healthy cells. The nanocarrier eliminated five times more cancer cells than docetaxel alone without affecting healthy cells. It was particularly effective against U87MG, a glioblastoma cell that overexpresses VEGF, but less so against A172, which expresses relatively little VEGF. “These results show that our nanocarrier selectively attacks cells that express a lot of VEGF,” Di Filippo said.

The researchers also found that the potential drug was able to enter cancer cells and release docetaxel continuously for around 84 hours, suggesting prolonged availability of the chemotherapy drug in the body.

Good results in animals

Using techniques developed by the UNICAMP team, rats were inoculated with glioma cells (glioma is a type of cancer similar to glioblastoma). Five days later, they were divided into six groups: treatment with placebo; docetaxel alone; nanocarrier alone, without bevacizumab or docetaxel; nanocarrier and bevacizumab, without docetaxel; nanocarrier and docetaxel, without bevacizumab; nanocarrier with docetaxel and bevacizumab.

After 15 days, the first four groups turned out not to have benefited from the treatment. In the fifth group (nanocarrier with docetaxel) and the sixth group (nanocarrier with docetaxel and bevacizumab), the tumor volume was reduced by 40% and 70% respectively. “These are significant numbers for trials of this type,” Chorilli said.

The researchers also found that the formulation did not cause any deterioration in levels of biomarkers such as albumin and creatinine compared to using docetaxel alone. “It shows that the toxicity has not been intensified,” Di Filippo explained.

Next steps

According to Chorilli, the results were positive but these were the first experiences with the nanostructured lipid carrier for this specific application. “We need to do more studies in isolated cells and animals. If the results against glioblastoma multiforme remain good, we could try to find partners for clinical trials with human volunteers,” he said.

The study reported in the article highlighted the potential of lipid nanocarriers in the treatment of brain cancer, he added: “We can use different combinations with other monoclonal antibodies and chemotherapy drugs against other types of cancer. Many years will undoubtedly be needed to complete this research.

Chorilli is studying similar methods for treating infections, such as gastritis and other illnesses caused by the bacteria Helicobacter pylorialso looking for supported by FAPESP.


About the São Paulo Research Foundation (FAPESP)

The São Paulo Research Foundation (FAPESP) is a public institution whose mission is to support scientific research in all areas of knowledge by granting scholarships, fellowships and grants to researchers linked to educational institutions University and Research from the State of São Paulo, Brazil. FAPESP is aware that the best research can only be done by working with the best researchers at the international level. Therefore, it has established partnerships with funding agencies, higher education institutions, private companies and research organizations in other countries known for the quality of their research and has encouraged scientists funded by its grants to further develop their international collaboration. You can find out more about FAPESP at www.fapesp.br/en and visit the FAPESP press agency at www.agencia.fapesp.br/en to keep abreast of the latest scientific advances that FAPESP helps to achieve through its many programs, prizes and research centers. You can also subscribe to the FAPESP press agency on http://agencia.fapesp.br/subscribe.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of press releases posted on EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Bar coded medication administration can be used to help minimize medication errors

In an interview with Pharmacy hours® at the American Society of Health-System Pharmacists Summer Meetings and Expos, Kayla Cierniak, PharmD, MS, BCPS, FISMP, Oncology Medication Safety Lead at Seidman Cancer Center, discusses medication administration by barcode and some of the challenges the initiative has faced.

Q: What is Barcode Medication Delivery?

Kayla Cierniak: BCMA is a technology used by nurses at the bedside when preparing a medication to be administered. This is an important medication safety technology that was actually invented by a nurse. In the 90s, she was living in Topeka, Kansas, she was very innovative, and she was on vacation and rented a car. When she was done with her vacation, she returned the car to the car rental company and noticed that they opened the door and scanned a barcode on the inside of the door to verify that it was the right car, coming to the right place, at the right time.

She thought, wait a minute, this reminds me a lot of administering beds or medication at the bedside, and she thought, why can’t we apply this to improve patient safety? Can you put a barcode on the patient’s wristband, a barcode on the medication, scan both, and have the computer verify that you have the correct product in your hand?

So here we are decades later. We have widely implemented it in many of our hospital facilities in all organizations across the United States.

Q: What was this year-long process like in a multi-site hospital?

Kayla Cierniak: As I mentioned, BCMA is widely implemented in hospital settings for most large organizations, and the same is true for our main campus. Our inpatient compliance rate is well above our target goal of 95%, which means that out of 100 medications administered, you have scanned 95 and verified via the EMR, or electronic medical record, that it is good medicine.

However, as a cancer center we also have a strong presence in the community. We have outpatient infusion centers located throughout northeast Ohio. The objective of this project was to examine compliance in 10 of these outpatient remote sites and where we know they have an operational setup to perform BCMA, but their compliance is low compared to inpatients. 75% was our compliance rate on outpatient sites at the start of this project, and it was a one-year process improvement project.

We didn’t know it at the time, but this project fits really well with the new ISMP 16 best practice, which encourages health systems to expand BCMA beyond inpatient units and into limited-stay areas or short-term patients.

Q: How has this affected the hospital multi-site oncology infusion service?

Kayla Cierniak: In order to have an effect on infusion centres, we needed a certain methodology. The drug safety office has leveraged some low-cost and simple interventions. These had worked for us on the inpatient side and luckily for us we had the support of our leaders. We have a head nurse who is really supportive of medication safety. We created a cheat sheet that explained how to do the bedside scan, how to troubleshoot it, if you are a frontline nurse. We have ensured that nursing managers have access to these unit-specific reports as this is what is most useful to them when coaching their staff.

We also held training courses, even had one-on-one peer-to-peer conversations with nurse managers, and also reported our trends at monthly safety committees involving nursing. We really invited them to participate, which made it a truly interdisciplinary effort. After one year, our average compliance rate increased from 78% to 96%. We landed right on target at the end of our project.

Q: What were the challenges faced by the initiative?

Kayla Cierniak: Of course, we had challenges along the way. Luckily, many of our nurse managers had walked inpatient spaces before, where, as I said, our compliance was really good. They had seen a lot of best practices. We just needed to educate to make it known to the community.

We had challenges where nurse managers were leaving for a new position. What would the transfer between leaving the nurse manager and integrating the nurse manager look like to transfer these reports? In particular for oncology infusion we had 1 site that had very low compliance, they were around 52% at the start, and we went there to observe what was happening and understand why we are only scanning half medication ?

Turns out they thought only the chemo should be scanned, but with the chemo comes the premeds. You need hydration, perhaps normal saline infusions or other supportive care. They didn’t document any of this. We needed to re-educate that BCMA is not only important for medical safety, but helps us with billing. This helps us track medication usage and ultimately improves the safety of our patients.

Q: What should pharmacists know about this initiative and how should they apply it to their pharmacy to reduce medication errors?

Kayla Cierniak: Pharmacists, know that you can use the new good practice ISMP 16 to give you firepower. If you find management support lacking, or if you have struggled in the past, engage management by moving BCMA only inpatient units to all other areas of patient care. Vanderbilt’s tragic mistake and the unjust prosecution of this nurse. This happened in a CT imaging room, which is a limited patient care area in the state that did not have BCMA technology available to the nurse and could have caught this error.

The remaining spots we need to expand BCMA are a bit notoriously difficult and have held up in the past. They include radiology, emergency services, operating rooms, PACU, dialysis. To start nibbling, find perhaps the one area of ​​your organization that might be the low-hanging fruit where you might have the most stakeholder buy-in initially to try and move this practice forward.

We hope that as these regions continue to embrace BCMA and recognize the value of this technology and improve patient safety, perhaps they will all fall in line like a cascade of dominoes. The reality is that it’s going to take a lot more time and effort on the part of those advocating for drug safety.

NSF Funds Undergraduate Research Experiments

Her REU is at the University of North Carolina at Chapel Hill, and she was accepted into five of the eight REUs she applied for, giving her the choice of where to go.

“I was shaking every time I got an acceptance email,” Clark said. “The teachers at UNG have been amazing at seeing what I’m capable of, even when I can’t see it. They’ve been phenomenal.”

Ramiro Ferreyra, a senior from Washington, Georgia pursuing a degree in physics and cybersecurity, is grateful for the opportunity to conduct experimental nuclear physics research in his REU at Notre Dame University with Dr. Tan Ahn . He said his time at Notre Dame should help shape his career path further.

“I want to take this opportunity and learn as much as possible,” Ferreyra said. “It will help me get more ideas for my future research.”

Other UNG students participating in research experiments are:

  • Anna Cronan, biology, University of Michigan
  • Destiney Dempsey, Psychology, West Virginia University
  • Annaleena Hansen, Chemistry, Mississippi State University
  • Fernando Linares, biology, Emory University
  • Haley Menees, biology, University of Minnesota
  • Kate Monheim, Chemistry, Georgia State University
  • James Pearce, Chemistry, Mississippi State University
  • Kyala Shabani, Chemistry, Georgia Southern University
  • Andy Sunshine, Chemistry, Georgia State University

Students interested in applying for REUs or scholarships can contact the National Competitive Scholarships (NCS) office at [email protected] or Dr. David Patterson, Associate Professor of Biology and NCS Faculty Member for STEM Scholarships, at [email protected] .

WVU Releases Graduate List for Spring 2022 | New

MORGANTOWN — West Virginia University has released its Spring 2022 Dean’s and President’s lists, as well as the full list of graduates for the spring semester.

A total of 6,007 students earned honors during the spring semester.

A total of 3,403 students were named to the Dean’s List, having achieved grade point averages of 3.5 or higher.

The university president’s list includes 2,604 students who achieved 4.0 GPA.

Thousands of graduates participated in 16 launch ceremonies at the Coliseum and the Canady Creative Arts Center from May 13-15.

The final total number of graduates for the Spring 2022 semester was 3,888.

The complete list of graduates is available at lists.wvu.edu.

I’m going

Graduate students in The Register-Herald coverage area:

Beckley’s Corey Acord, Sports Management

Anna Ahern of Lewisburg, marketing

Tyler Aliff of Mount Hope, Business Administration

Fahad Almuammar de Beckley, finance

Niki Amick de Nettie, Multidisciplinary Studies

Beckley’s Shaylan Anderson, Energy Environments

Rebecca Arthur de Hinton, professional pharmacist

Dalton Ash from Princeton, economics, international studies

Caleb Bailes of Fayetteville, General Affairs

Sydney Ballard of Peterstown, Health Administration

Eva Barber from Lookout, criminology

Amelia Bard of Richwood, Wildlife and Fish Resources

Brandon Barnes of Ronceverte, Neuroscience

Amanda Barrett from Athens, physiotherapy

Machiah Baxter of Lewisburg, Finance

Summersville Lacey Beam, Communication Science and Disorders

Sarah Benfield of Crab Orchard, clinical rehabilitation and mental health counseling

Faith Bigelow of Oak Hill, landscape architecture

Hannah Blankenship of Beckley, Criminology

Madilyn Bodkin of Fayetteville, nurse

Emily Bollinger of Summersville, nurse

Madison Bolt of Lewisburg, criminology, psychology

Emily Boyd of Mount Hope, Human Performance and Health

Haley Butcher from Brenton, social work

Madison Campbell of Craigsville, Occupational Therapy

Channing Carr from Greenville, Multidisciplinary Studies/BMdS

Rachel Carrico from Shady Spring, Occupational Therapy

Charleigh Carter of White Sulfur Springs, IT

Emily Carter of Cool Ridge, Exercise Physiology

Halie Casto de Nallen, primary education

John Casto of Lewisburg, aerospace engineering, mechanical engineering

Terri Childress of Daniels, Psychology

Marcus Christian de Beckley, conductor

Carrie Clemons of Lewisburg, Occupational Therapy

Madeline Cochran of Lewisburg, Exercise Physiology

Emily Compton de Montcalm, advertising and public relations

Algie Cook from Oceana, Professional Pharmacy

Andrew Cook of Summersville, biochemistry

Jacob Coots de Beckley, public administration

Kenneth Corhn of Bluefield, Chemical Engineering

Caraline Coughlin de Rupert, nurse

Jenny Culicerto of Princeton, Occupational Therapy

Brooke Daniels of Beckley, nurse

Amanda Davis of Oak Hill, Legal Studies

Beckley’s Konner Davis, sports management

Carson Dewese from Beckley, Exercise Physiology

Matthew Dillon of Beaver, accounting

Stephanie Dillon of Princeton, Management Information Systems

Michaela Donovan of Lewisburg, Speech Pathology

Jacie Dotson from Ghent, Industrial Engineering

Taylor Duncan of Daniels, Biology

Jason Edwards of Bluefield, Bachelor of Arts Regents

Kali Ellison of Pineville, Public Health

Benjamin Evans of Peterstown, public administration

Demitria Evans of Mount Hope, Arts Education

Baylee Fitzwater of Beaver, Dental Hygiene

Matthew Fleshman of Wayside, Exercise Physiology

Marissa Fletcher of Craigsville, dentistry

Logan Foley de Rupert, Animal and Nutritional Sciences

Trevor Ford of Meadow Bridge, Physics, Chemistry

Morgan Francis of Summersville, Literacy

Toby Francis de Rainelle, theater design and technology

Logan Garris of Sophia, Education/Social Services

Cody Gillespie of Scarbro, aerospace engineering, mechanical engineering

Kristie Gillilan of Lewisburg, Integrated Studies

Colson Glover of Lewisburg, neuroscience

Amanda Gottshall from Caldwell, social work

Aliyah Gwinn of Shady Spring, Nurse

Devin Hamrick of Summersville, Global Supply Chain Management

Madison Handy of White Oak, nurse

Kelsea Harler of Fayetteville, Animal and Nutritional Sciences

Emily Harrah de Beckley, nurse

Sierra Harris of Beckley, Psychology

Sarah Harvey de Beckley, physiotherapy

Vincent Harvey de Beckley, physical education and kinesiology

Julia Hays of Hinton, medical assistant

Beckley’s Kira Henson, Psychology

Drew Hicks of Canvas, Professional Pharmacy

James Higgins of Beaver, Computer Engineering, Electrical Engineering

Abigail Hill of Daniels, nurse

Courtney Holbrook of Oak Hill, Animal and Nutritional Sciences

Mackayla Holdren of Fenwick, Elementary Education

Allison Houchins of Shady Spring, Health Informatics and Information Management

Emily Hyler-Both of Clintonville, physical therapy

Luke Jarrell de Beckley, Immunology and Medical Microbiology

James Jarrett of Whitesville, Psychology

Jerreyanne Jeffries of Charlton Heights, Regents Bachelor of Arts

Rachel Johnson of Princeton, advertising and public relations

Hannah Kania of Oak Hill, nurse

Madison Kelbaugh of Summersville, advertising and public relations

Bradshaw’s Logan Kennedy, story

Savannah Kincaid of Fayetteville, Exercise Physiology

Summer Kuhn of Shady Spring, Sociology

Jacob Lambert de Ronceverte, medicine

Beckley’s Ashlee Lane, nurse

Jessica Lawson from Corinne, nurse

Lauren Lane from Peterstown, Psychology

Abby Lester of Princeton, advertising and public relations

Madison Lilly of Shady Spring, nurse

Aron Ludwinski de Welch, IT

Amy Lusk from Bud, Professional Pharmacy

Makenzie Lusk of Pineville, nurse

Beckley’s Destiny Lylyk, Criminology

Jessica Mason de Lester, nursing

Andrea Masters of Caldwell, Animal and Nutritional Sciences

Mattie McArthur of Beckley, Psychology

Samantha McManus de Beckley, sociology

Felicity McSweeney de Hico, nurse

Madison Mills of White Sulfur Springs, interactive design for media

Fayth Mitchell of Mount Hope, Nursing

Alexis Moss of Mount Hope, Animal and Nutritional Sciences

Phyllis Murray of Bluefield, Nursing

Nettie’s River Myers, Nursing

Josiah Nieto of Princeton, Medicine

Mike O’Brien of Ronceverte, Finance

Erika Osborne of Rockview, Civil Engineering

Nayreshca Pacheco Sanchez de Fayetteville, Women’s and Gender Studies

Leslie Payne of Oak Hill, Psychology

Madeline Peck of MacArthur, Biology

Trent Pendleton of Princeton, Psychology

Dalton Perdue of Oak Hill Health and Wellness

Hunter Peyatt of Richwood, Electrical Engineering

Miranda Plumley de Beckley, nurse

Kandice Pruitt of Bradshaw, Dental Hygiene

Jonathan Pullens of Fayetteville, nurse

Beckley’s Zainab Rana, health policy

Bailey Ratliff of Daniels, General Affairs

Joshua Rhudy from Ghent, medicine

Union’s Margaret Rice, Exercise Physiology

Nathan Richmond of Jumping Branch, Medicine

Kelsy Robbins de Rainelle, Women’s and Gender Studies

Tyler Robinette of White Sulfur Springs, international studies, history

Kathryn Robinson of Renick, Medicine

Carly Rojas de Daniels, dentistry

Giulia Romani de Beckley, exercise physiology

Rachel Rowe of Mount Hope, nurse

Matthew Ryan of Hinton, Multidisciplinary Studies/BMdS

Sofia Salon de Daniels, Exercise Physiology

Frank Sammons of Oceana, Professional Pharmacy

Zoe Sampson of Lewisburg, Councilor

Caleb Schoolcraft of Castor, International Studies

Cosmo Scott of Lookout, Wildlife and Fish Resources

Taylor Scott of Hinton, Advisor

Felicia Seabolt of Summersville, nurse

Meagan Seaton of Mullens, Occupational Therapy

Elizabeth Sheets of Renick, Animal and Nutritional Sciences

Emily Simmons of Maben, Regents Bachelor of Arts

Madison Simms of Summersville, Marketing

Amber Skaggs of Fayetteville, nurse

Shelby Smith of Hinton, Occupational Therapy

Jessica Spearing of Beckley, nurse

Raven Spencer of Peterstown, Medicine

Robert Stclair of Cool Ridge, nurse

Sherrell Taylor of Craigsville, Health Informatics and Information Management

Cydney Thomas of Oak Hill, painting

Jacob Toney of Crab Orchard, biomedical laboratory diagnostics

Katy Trent of Scarbro, anthropology

Jason Truman of Mount Nebo, Assistant Physician

Tyler Trump of Glen Daniel, Electrical Engineering

Karen Truong of Summersville, Management Information Systems

Lainey Vargo of Oak Hill, Professional Pharmacy

Tanner Veneri of Princeton, Industrial Engineering, Mechanical Engineering

Christopher VonScio de Beckley, Business Administration

Madison Walker of Beckley, Psychology

Sierra de Cool Ridge Ward, Biochemistry

Lauren Weatherford of Fayetteville, Community Development Policy and Practice

James Weiss of Jumping Branch, social work

Shae West of Lewisburg, Public Administration

Hannah White de Beckley, nurse

Madison Wiley of Lerona, nurse

Brandon Williams of Mount Hope, director

Leann Williams de Beckley, public administration, social work

Leslie Williams of Shady Spring, Nursing

Catherine Williamson of Summersville, nurse

Brianna Wingrove of Glen Jean, Health Informatics and Information Management

Makayla Wooten of Dixie, Multidisciplinary Studies/BMdS

Natalie Workman of Daniels, nurse

Lily Wright of Bluefield, English, French

Amy Yeung of Daniels, Professional Pharmacy

Norman Yeung of Daniels, IT

Jacob Young de Beckley, landscape architecture

Tyler Zimm of Fayetteville, Professional Pharmacy

Short-term stake in NLS Pharmaceutics AG (NASDAQ:NLSPW) increases by 400.0%

NLS Pharmaceuticals SA (NASDAQ: NLSPWGet a rating) benefited from significant growth in short-term interest during the month of May. As of May 31, there were short interests totaling 11,000 shares, a growth of 400.0% from the May 15 total of 2,200 shares. Based on an average daily volume of 5,300 shares, the day-to-cover ratio is currently 2.1 days.

Shares of NLSPW Inventory opened at $0.27 on Friday. NLS Pharmaceuticals has a 12 month minimum of $0.06 and a 12 month maximum of $1.20.

An institutional investor recently bought a new position in the shares of NLS Pharmaceuticals. Empery Asset Management LP acquired a new position in NLS Pharmaceuticals AG (NASDAQ: NLSPWGet a rating) during Q1, according to its most recent filing with the Securities & Exchange Commission. The fund bought 150,000 shares of the company, valued at around $38,000.

See also

Get news and reviews for NLS Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for NLS Pharmaceutics and related companies with MarketBeat.com’s FREE daily newsletter.

A new molecule kills a wide range of hard-to-treat cancers

A new molecule synthesized by a University of Texas at Dallas researcher kills a wide range of hard-to-treat cancers, including triple-negative breast cancer, by exploiting a weakness in cells that were not previously targeted by d other drugs.

A study describing the research -; which has been carried out in isolated cells, in human cancerous tissues and in human cancers cultured in mice -; was published online June 2 in the journal nature cancer.

Dr. Jung-Mo Ahn, co-corresponding author of the study and associate professor of chemistry and biochemistry at UT Dallas in the School of Natural Sciences and Mathematics, is passionate about his work designing small molecules that have been targeting protein-protein interactions in cells for over a decade. Using an approach called structure-based rational drug design, he has previously developed potential therapeutic candidate compounds for treatment-resistant breast cancer and for prostate cancer.

In current work, Ahn and his colleagues tested a new compound he synthesized called ERX-41 for its effects against breast cancer cells, both those that contain estrogen receptors (ER) and those that do not contain it. Although there are effective treatments for patients with ER-positive breast cancer, there are few treatment options for patients with triple-negative breast cancer (TNBC), which lacks receptors for estrogen, progesterone, and human epidermal growth factor 2. TNBC typically affects women under 40 and has poorer outcomes than other types of breast cancer.

“The ERX-41 compound didn’t kill healthy cells, but it killed tumor cells, whether or not the cancer cells had estrogen receptors,” Ahn said. “It actually killed triple-negative breast cancer cells better than ER-positive cells.

“It baffled us at the time. We knew it must be targeting something other than estrogen receptors in TNBC cells, but we didn’t know what it was.”

To study the ERX-41 molecule, Ahn worked with collaborators including co-corresponding authors Dr. Ganesh Raj, professor of urology and pharmacology at UT Southwestern Medical Center’s Harold C. Simmons Comprehensive Cancer Center, as well as Dr. Ratna Vadlamudi, professor of obstetrics and gynecology at UT Health San Antonio. Dr. Tae-Kyung Lee, a former UTD researcher at Ahn’s Bio-Organic/Medicinal Chemistry Laboratory, was involved in synthesizing the compound.

The researchers found that ERX-41 binds to a cellular protein called lysosomal acid lipase A (LIPA). LIPA is found in a cellular structure called the endoplasmic reticulum, an organelle that processes and folds proteins.

For a tumor cell to grow rapidly, it must produce a lot of protein, which puts stress on the endoplasmic reticulum. Cancer cells significantly overproduce LIPA, much more than healthy cells. By binding to LIPA, ERX-41 blocks protein processing in the endoplasmic reticulum, which becomes swollen, leading to cell death.”

Dr. Jung-Mo Ahn, study co-corresponding author and associate professor of chemistry and biochemistry at UT Dallas

The research team also tested the compound on healthy mice and found no adverse effects.

“It took us several years to research exactly which protein was affected by ERX-41. That was the hardest part. We chased many dead ends, but we didn’t give up,” Ahn said.

“Triple negative breast cancer is particularly insidious; it targets younger women; he is aggressive; and it is resistant to treatment. I am really happy that we have discovered something that has the potential to make a significant difference for these patients.

The researchers gave the compound to mice with human forms of cancerous tumors, and the tumors grew smaller. The molecule has also been shown to be effective in killing cancer cells in human tissue taken from patients whose tumors have been removed.

They also found that ERX-41 is effective against other types of cancer with high endoplasmic reticulum stress, including difficult-to-treat pancreatic and ovarian cancers and glioblastoma, the most common primary brain cancer. aggressive and deadliest.

“As a chemist, I’m somewhat isolated from patients, so this success is an opportunity for me to feel like what I’m doing can be useful to society,” Ahn said.

Ahn is co-holder of issued and pending patents on ERX-41 and related compounds, which have been licensed to Dallas-based startup EtiraRX, a company co-founded in 2018 by Ahn, Raj and Vadlamudi. The company recently announced that it plans to begin clinical trials of ERX-41 as early as the first quarter of 2023.

Ahn’s research on this project is supported by the National Cancer Institute, part of the National Institutes of Health (1R01CA223828); the Texas Institute for Cancer Prevention and Research; and the Welch Foundation.

In addition to the researchers from UT Southwestern and UT Health San Antonio, other study authors from the Janelia Research Campus of the Howard Hughes Medical Institute, Northwest A&F University in China, and College Medical from Xiamen University in China contributed.


Journal reference:

Liu, X. et al. (2022) Targeting LIPA independent of its lipase activity is a therapeutic strategy in solid tumors via the induction of endoplasmic reticulum stress. NatureCancer. doi.org/10.1038/s43018-022-00389-8.

Two UBC students complete a month-long internship at QU-CPH

Under a student exchange program between Qatar University College of Pharmacy (QU-CPH) and the University of British Columbia (UBC) in Canada, Doctor of Pharmacy (PharmD) students from UBC, Andrew Overend and John Anthony, recently visited QU-CPH for a month-long internship focusing on academic pharmacy.

PharmD students participated in a variety of activities during the four-week rotation.
During the first two weeks, they had meetings with college deans, department chairs and faculty members with administrative portfolios to learn about their roles and activities.

A group photo of students

In addition, they visited the Department of Pharmacy and Drug Control of the Ministry of Public Health to learn more about the registration of new drugs in Qatar.
For teaching-related experience, they contributed to the Professional Skills Lab, Integrated Case-Based Learning (ICBL), Structured Multi-Skills Assessment (SMSA), and Objective Clinical Examination structured (OSCE).
In addition, they contributed to other activities such as the validation of the comprehensive oral exam for the PharmD program and the participation in an awareness event on the coronavirus (Covid-19).
Finally, to learn more about patient care in Qatar, they visited four Hamad Medical Corporation (HMC) hospitals/centers (Al Khor, Al Wakra, Hamad General Hospital and Women’s Wellness and Research Centre), Sidra Medicine and Pharmacy Wellcare community to observe the activities of health professionals.
These were in addition to having the opportunity to interact with QU-CPH pharmacy students.
Acting Dean of QU-CPH, Dr. Feras Alali, said, “CPH is keen to provide international students with the opportunity to experience Qatar and its clinical and educational system.
Dr. Hazem Elewa, Head of Clinical Education at QU-CPH, one of the student preceptors during their international rotation, said, “It was a pleasure to host the pharmacy students from Colombia University British, as it provided a platform to learn about the progress of pharmaceutical practice between Qatar and Canada.
“It was great to learn about the similarities between pharmacy in Qatar and pharmacy in Canada, especially in terms of how community and hospital pharmacies work,” Overend said.
“Everyone I met in Qatar was incredibly friendly and ready to help with anything and everything,” he said. “It was very interesting to learn about the different career paths that a Pharmacy Doctorate can take you, as well as being part of the academic component of the program for my rotation.”
“I am incredibly grateful that I was able to do my internship at Qatar University,” Overrend added. “It was a once in a lifetime experience and I couldn’t have asked for a better way to complete my program.”
“Qatar University and CPH taught me so many different facets of pharmacy that I might never have learned,” Anthony said.

NLS Pharmaceuticals Announces Receipt of NASDAQ Minimum Bid Price Notice

Receive instant alerts when news is published about your stocks. Claim your one week free trial for StreetInsider Premium here.

ZURICH, SWITZERLAND / ACCESSWIRE / June 10, 2022 / NLS Pharmaceuticals Ltd. (NASDAQ: NLSP),(NASDAQ: NLSPW) (“NLS” or the “Company”), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that it has received written notice (l “Notice”) of Nasdaq Stock Market LLC that the Company is in non-compliance with the minimum offer price requirement for continued listing set forth in Listing Rule 5550(a)(2 ), which requires listed securities to maintain a minimum offering price of $1.00 per share. Under Nasdaq listing rule 5810(c)(3)(A), the Company has been granted allow 180 calendar days to restore compliance with the minimum bid price requirement. The notice does not have an immediate effect on the company’s Nasdaq listing or trading in its common stock, and during the grace period, which may be extended, the common shares of NLS will continue to trade s on the Nasdaq Capital Market under the symbol “NLSP”.

According to the Notice, the Company has until December 5, 2022 to again comply with the minimum offering price requirement. The Company may revert to compliance if, at any time during such 180-day period, the closing bid price for its common shares is at least $1.00 for at least ten consecutive business days, in which case the Company will receive written confirmation of compliance and this matter will be closed. In the event that NLS does not regain compliance after the initial 180 day period, the Company may then be eligible for an additional 180 day compliance period if it meets the continued listing requirement for the market value of the publicly held shares and all other initial listings. standards applicable to the Nasdaq Capital Market, except for the minimum offer price requirement. In this case, NLS will be required to provide written notice of its intent to remedy the deficiency during the second compliance period.

If the Company cannot demonstrate compliance within the specified compliance timeframe, Nasdaq staff will notify the Company that its common stock is subject to debarment.

About NLS Pharmaceuticals Ltd.

NLS Pharmaceuticals Ltd. is a clinical-stage Swiss biopharmaceutical company led by an experienced management team with a proven track record in the development and reuse of product candidates to treat rare and complex central nervous system disorders. The Company’s lead product candidate, Quilience®, is a proprietary extended-release formulation of Mazindol (Mazindol ER) and is being developed for the treatment of narcolepsy and potentially other sleep and wakefulness disorders such as than idiopathic hypersomnia (IH). Mazindol is a triple monoamine reuptake inhibitor and partial orexin-2 receptor agonist that has been used for many years to treat patients with narcolepsy in compassionate use programs. A Phase 2a clinical trial evaluating Quiilience® in adult subjects with narcolepsy is currently underway in the United States. Previously, NLS successfully completed a Phase 2 study in the United States evaluating Nolazol® (Mazindol Controlled-Release) in adult subjects with ADHD. The study met all primary and secondary endpoints and Nolazol® was well tolerated. Quilience® has received orphan drug designation in the United States and Europe for the treatment of narcolepsy. Up to 1/3 of narcoleptic patients are also diagnosed with ADHD. NLS announced plans to allow patients diagnosed with IH to access treatment with Quiilience® through an Early Access Program (EAP). EAPs have great potential to benefit all stakeholders involved, from the patient who receives the drug as soon as possible to the pharmaceutical company who supplies it. While EAPs can be big business, companies that invest in them can reap significant benefits in terms of launch readiness, relationship building, and market penetration.

Safe Harbor Statement

This press release contains express or implied forward-looking statements pursuant to United States federal securities laws. For example, NLS uses forward-looking statements when discussing the return to compliance with Nasdaq’s continuing listing requirements, and the timing and effect thereof. These forward-looking statements and their implications are based on the current expectations of NLS management only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; NLS may encounter delays or obstacles in initiating and/or completing its clinical trials; NLS products may not be approved by regulatory agencies, NLS technology may not be validated as it advances, and its methods may not be accepted by the scientific community; NLS may not be able to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with the NLS process; NLS products may turn out to be more expensive than expected; laboratory results may not translate to as good results under real clinical conditions; results of preclinical studies may not correlate with results of human clinical trials; NLS patents may not be enough; NLS products may harm recipients; changes in legislation may have a negative impact on the NLS; failure to develop and introduce new technologies, products and applications on a timely basis; loss of market share and pricing pressure resulting from competition, which could cause NLS’s actual results or performance to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, NLS undertakes no obligation to issue revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unforeseen events. More detailed information about the risks and uncertainties affecting NLS can be found under the heading “Risk Factors” in NLS’s Annual Report on Form 20-F for the fiscal year ended December 31, 2021 filed with the Securities and Exchange Commission (SEC ), which is available on the SEC’s website, www.sec.gov, and in NLS’s subsequent filings with the SEC.

Corporate contact details
Alex Zwyer, CEO: +41 44 512 21 50

Investor Relations
Cindy Rizzo: +1 908-229-7050

Media Contact
Pascal Nigen: +1 917-385-2160
Alpha Bronze, LLC

THE SOURCE: NLS Pharmaceuticals SA

See the source version on accesswire.com:

Virginia: Approved Budget Recriminalizes Public Marijuana Possession of More Than Four Ounces of Marijuana

Today, the Virginia General Assembly voted to approve the budget bill that contains language to recriminalize personal possession of more than four ounces of marijuana in public. The language, which creates two new offenses, will take effect immediately after Republican Gov. Glenn Youngkin signs the budget.

Currently, personal possession in public of more than one ounce and up to one pound of marijuana by adults 21 and older is punishable by a civil fine of up to $25. Upon the Governor’s signature, personal possession in public of more than four ounces and less than one pound of cannabis will be a Class 3 misdemeanor, making it subject to a $500 fine. Second or subsequent offenses will be class 2 misdemeanors punishable by up to 6 months in jail and/or a $1,000 fine.

“Rather than create additional avenues to criminalize Virginians for personal possession of cannabis, the Virginia General Assembly would better serve voters by establishing a legal market for adult-use marijuana and ensuring that all of cannabis sold in the Commonwealth are accurately labeled and regulated for consumer safety,” said JM Pedini, NORML Director of Development and Virginia NORML Executive Director.

“Virginia has, through legislation through the budget, legalized the retail sale of marijuana, we’ll just call it ‘hemp,'” said delegate Dawn Adams, who spoke against the budget wording, to Virginia NORML. “All tetrahydrocannabinols – not just delta-9 THC, but delta-8 THC and other synthetics – with Governor Youngkin’s stroke of the pen will be legal in Virginia as long as they are labeled ‘hemp,'” added Dr. Adams, a nurse. practitioner with substantial expertise in cannabis medicine.

During the April veto session, Governor Youngkin attempted to recriminalize activities involving the possession of two ounces of marijuana by adults through the enactment of an amendment to SB 591. This effort failed with the denial of the Virginia Senate to advance the amendment.

During the 2022 Virginia General Assembly, Republican members of the House General Laws Subcommittee halted any further progress on Senate-backed legislation, SB 391, which sought to initiate the retail sale of marijuana to adults starting in September.

“There appears to have been a fundamental lack of understanding by budget delegates of existing marijuana laws. If their intent was to prevent public possession of greater amounts of cannabis in public in order to reduce illicit transactions, then they should have known that the distribution and possession with intent to distribute of marijuana in any quantity is already prohibited by several articles of the Code. The General Assembly adopted new sanctions for actions for which sanctions already exist,” Pedini noted. “Also, the 4-ounce possession limit is for ‘marijuana‘, the definition of which includes cannabis flower, seeds, concentrates and edibles. Until the Cannabis Authority Board of Directors is able to enact equivalent possession amounts for edibles and other extraction-based formulations, Virginians can quickly break this new law.

Virginia NORML successfully advocated for language included in the budget to clarify that possession of cannabis in one’s residence for personal use is not punishable and to eliminate several Class 6 crimes related to personal cultivation – do not label plants, shield them from public view, or prevent access by persons under 21 years of age. When the new law comes into effect, these minor personal cultivation offenses will not be subject to a civil fine of more than $25.

Additional budget language will also prohibit the retail sale of any THC-containing product that is ingestible “by mouth or inhalation” to those under 21 and will ban packaging products from resembling other famous brands.

“Approved consumer safety language requires only the most basic level of testing and consumer information for otherwise unregulated products flooding the market. It also maintains existing loopholes for synthetic marijuana and high-THC products for sale at retail and wholesale outside of the strict regulatory oversight currently required for legal cannabis products produced in Virginia,” Pedini added.

Legislation signed earlier this year by Governor Youngkin, HB 933 and SB 671, to eliminate the requirement for patients to register with the Board of Pharmacy after receiving written certification from a licensed practitioner takes effect on July 1, 2022. At this time, patients only need their written certification to shop at one of the state’s ten operational dispensaries. Patients must still see a registered practitioner to obtain this certification and registered agents will still need to register. Patients who wish to receive a physical card will still have the option of requesting one by registering with the Pharmacy Board.

“These legislative improvements will bring great relief to the thousands of Virginians waiting to access the medical cannabis program,” Pedini said. “We hear from dozens of Virginians every week who struggle with the registration process and are frustrated with the 60-day wait to receive their approval from the Board of Pharmacy,” Pedini added.

There are currently over 50,000 enrolled in the program. At the time of the passage, there were approximately 8,000 applicants awaiting approval.

For more Miami news, visit www.communitynewsapers.com

Connect with your customers and grow your business

Click here

Discover the many benefits of Ashwagandha

Any rational consumer or trustworthy nutrition expert should know that there is no type of food or supplement that can magically cure physical ailments or change your physique, but given the number of benefits for health and performance it’s been linked to, we’re beginning to think ashwagandha extract deserves to be considered as close to “magic” as we’ve seen.

The ashwagandha shrub with its small yellow flowers grows natively throughout Indian country, as well as parts of the African continent. It’s been used in natural medicine for ages, and modern medical professionals are beginning to recognize its health (and even psychological) benefits. These benefits range from managing stress and improving and supporting cognitive function, to increasing testosterone levels and building muscle, especially in those who exercise regularly with endurance efforts and bodybuilding.

Here’s what science knows so far about the effects of the ashwagandha plant when taken internally as a nutritional supplement, and how it can help you achieve optimal health and well-being.

What is Ashwagandha and how can it improve your health?

The herb we commonly know as ashwagandha actually goes by several names, depending on the region. Some call it Indian ginseng, while others know it as poison gooseberry (even though it really isn’t poisonous at all). It is also known as winter cherry and its scientific name is Withania somnifera in some parts of the world. The term “ashwagandha” in the ancient Indian language of Sanskrit means “like a horse”. This is due to the potent and somewhat unpleasant smell of the ashwagandha plant as well as the herb’s stimulating properties. However, don’t let the horsey aroma completely deter you from taking ashwagandha supplements, as they won’t smell like stables (or your breath) at all. The strong smell is mostly extracted from the herb when it is made into a supplement form.

Due to its adaptogen status, ashwagandha is believed to aid the body’s ability to deal with the damaging effects of stress. Research suggests that ashwagandha may influence the hypothalamic-pituitary-adrenal (HPA) axis. The specific mechanism by which ashwagandha exerts its effects is not fully understood at present.

Let’s put this situation into perspective for a second.

The hypothalamus region of the brain controls the body’s homeostasis process by regulating temperature, thirst, appetite, and other physiological functions that keep the body in a balanced state. In addition to this, it has a role in regulating sleep patterns as well as day-to-day emotional responses to restlessness and stress. Beneath the brain is an organ known as the pituitary gland, which is responsible for making hormones that regulate body functions. After that, it has an effect on the production of cortisol, which is a hormone generated by the adrenal glands in response to stressful situations and conditions, as well as when there is a lack of sugar in the blood.

The HPA axis is a group of systems that work together to control how your body physically responds to different types of stressful circumstances. Scientists believe that ashwagandha may help moderate the body’s response to stress by having an effect on the HPA axis. This will relieve the strain on your system and allow it to work more efficiently in a number of ways.

The Many Health Benefits of Ashwagandha

Using ashwagandha can have a wide variety of beneficial effects, including reducing mental stress and improving cognitive function in the brain, as well as improving physical performance in the gym or during sports. .

Ashwagandha can help people struggling with stress

According to a study published in 2019, ashwagandha supplementation helped both men and women lower cortisol levels and improve sleep quality. effects. Subjects in the study who took the highest doses of ashwagandha supplements experienced the largest drop in overall cortisol levels, which was around 30% on average. They also reported the most positive changes in how they felt about their overall emotional states and sense of well-being.

According to the findings of an Indian study, consuming ashwagandha not only improved a person’s ability to cope with stress, but it was also associated with self-reported improvements in the overall quality of their life. These results support the hypothesis that lower cortisol levels are associated with more positive feelings. High levels of cortisol are thought to lead to increased weight gain, especially fatty deposits around the waist and belly, which in turn is believed to have a direct link to heart and cardiovascular disease. Thus, the reduction in cortisol from the daily intake of ashwagandha supplements can have significant health benefits for people prone to weight gain and subsequent heart problems.

Ashwagandha provides mental state protection and a healthy brain

Ashwagandha has been shown to help people feel more focused when working. A study conducted on healthy men and published in Pharmacognosy Research found that healthy men who took ashwagandha herb performed better on cognitive and psychomotor tests.

Ashwagandha may be able to help older people who fear experiencing “senior moments” to maintain focus. According to a 2017 study of older adults with mild cognitive impairment, after eight weeks of treatment, participants’ memory improved to the point that they were able to recognize faces in family photos. They were also able to grasp intellectual material better, perform more tasks at once without difficulty, and it also helped them stay focused with attention directed to a single task for longer and with more concentration without effort or particular constraint.

Ashwagandha helps increase endurance as well as muscle strength

You’ve definitely heard of whey protein and creatine if you’re trying to improve your body, but after reading this you might want to consider adding ashwagandha to your workout supplement regimen.

In a study published in the Journal of the International Society of Sports Nutrition, strength training was supplemented with ashwagandha for an eight-week period for male participants between the ages of 18 and 50. As they developed more chest and arm muscles, they saw an increase in their maximums for bench press and leg extension exercise tolerance. Simultaneously, body fat levels decreased more than twice as much as in the placebo group, while testosterone levels increased.

Another study done a few years ago indicated that ashwagandha helped people improve their strength while reducing the amount of total body fat they had. Total cholesterol levels as well as LDL cholesterol values ​​both decreased.

Ashwagandha seems to benefit everyone, not just people who lift weights. In fact, an in-depth analysis of nine separate ashwagandha studies that was published in the journal Nutrients in 2020 indicated that the supplement helped athletes and non-athletes increase their VO2 max. The term “VO2 max” refers to the maximum volume of oxygen that can be used by a body during intense physical exercise. It can also be called “oxygen uptake peak”. This is something that will be of interest to anyone engaging in marathon endurance training. According to a study published in the International Journal of Ayurveda Research, ashwagandha resulted in clear improvements in speed, power, and VO2 max in young men and women.

Also shown in a study published in Ayu, ashwagandha improves athletic cardiorespiratory endurance as well as an athlete’s overall quality of life. This was determined using a detailed questionnaire that measured the athlete’s physical and psychological well-being as well as their social connections and relationship status.

What would be considered an appropriate Ashwagandha dosage?

There is a range of healthy doses for ashwagandha supplementation, and the amount varies depending on the reason for taking; nevertheless, research indicates that it is safe to take up to 1,250 mg at a time, usually in capsule or gum form. In excessive doses or in people with sensitive stomachs, ashwagandha can cause digestive issues, including diarrhea and nausea. therefore, you should consult your physician before adding it to your routine, particularly if you are already taking prescription medications or other herbal supplements which may be contraindicated.

Whether you’re looking to boost your physical stamina, reduce body fat, increase your cognitive function, or simply better manage stress, ashwagandha may be the perfect ancient remedy that should make its way back into your daily supplement routine. With a fairly low price, a good margin of safety and accessibility, as well as documented effectiveness for a wide variety of issues, most consumers looking for an all-purpose supplement will greatly benefit from taking this humble little herb that contains a wealth of value.


Affiliate Disclosure:

Links in this product review may result in a small commission if you choose to purchase the recommended product at no additional cost to you. This serves to support our research and writing team. Know that we only recommend high quality products.


Please understand that any advice or guidance revealed here does not even remotely replace sound medical or financial advice from a licensed healthcare provider or certified financial advisor. Be sure to consult a professional doctor or financial advisor before making any purchasing decisions if you are using any medications or have any concerns from the review details shared above. Individual results may vary and are not guaranteed as statements regarding these products have not been evaluated by the Food and Drug Administration or Health Canada. The effectiveness of these products has not been confirmed by the FDA or Health Canada approved research. These products are not intended to diagnose, treat, cure or prevent any disease and do not provide any type of enrichment program. Reviewer is not responsible for pricing inaccuracies. See the product sales page for final prices.

The news and editorial team at Sound Publishing, Inc. played no role in the preparation of this post. The views and opinions expressed in this sponsored post are those of the advertiser and do not reflect those of Sound Publishing, Inc.

Sound Publishing, Inc. accepts no responsibility for any loss or damage caused by the use of any product, and we do not endorse any product displayed on our Marketplace.

2022-06-09 | NEO:FH | Press release

Drug discovery collaboration will leverage both companies’ botanical drug development expertise

VANCOUVER, BC, June 9, 2022 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) and Jaguar Health, Inc. (NASDAQ: JAGX) today announced that the companies have signed a letter of intent to enter into an agreement to collaborate to develop drugs prescription botanicals for specific indications of psychoactive targets in United States. The objective of the collaboration is to extend the botanical drug development capabilities of both companies to develop standardized pharmaceutical-grade drug candidates and to partner with a potential future licensee regarding the development and commercialization of these new herbal medicines for indications such as attention deficit/hyperactivity disorder (ADHD) and social anxiety disorder.

“We are excited about this collaboration with Filament Health, a company focused on the discovery, development and standardization of botanical medicines as well as delivery to patients with mental health issues,” said Steven King, PhD, Jaguar’s Head of Sustainable Sourcing, Head of Ethnobotanical Research and Intellectual Property, and Head of the Company’s Entheogen Therapeutics (ETI) Initiative. Jaguar’s ETI aims to discover and develop breakthrough, innovative and natural medicines derived from psychedelic and psychoactive plants for the treatment of mood disorders, neurodegenerative diseases, addiction and mental health disorders. “Jaguar and Filament are identifying plant candidates that may prove beneficial in treating indications such as ADHD and social anxiety disorder, for which we plan to work collaboratively to develop botanical medicines.”

“Filament is a leader in the development of botanical medicines, and we are committed to supporting the treatment of mental health conditions through our expertise and technology,” said Benjamin Lightburn, CEO of Filament Health. “We have developed new manufacturing and standardization techniques which we have applied to psilocybin, psilocin and ayahuasca. We are delighted to partner with Jaguar and look forward to working with their team to identify and standardize new entheogens.

Under the partnership, Jaguar will be responsible for the identification of plants that may offer novel mechanisms of action, as well as the development of botanical drugs and the raw material supply chain. Filament will be responsible for developing the manufacturing techniques needed to produce standardized pharmaceutical-grade drug candidates. The two companies will then jointly seek a partnership with a potential licensee for the full development and commercialization of new drug candidates, with proceeds from the relationship split equally between Jaguar and Filament.

“We very much look forward to working with Filament on this initiative,” said Lisa Conte, Chairman, CEO and Founder of Jaguar. “Jaguar’s core team began focusing more than 30 years ago on the development and commercialization of herbal prescription medicines, and our Mytesi® (crofelemer), approved by the US FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy, is the only oral herbal prescription drug approved by the FDA Botanical Guidance. Filament’s expertise in natural product chemistry and drug development leverages a key asset we’ve generated over 30 years – a library of 2,300 medicinal plants and 3,500 plant extracts, all derived from a survey first-hand ethnobotany by Jaguar and our ETI Science Strategy Team (SST).”

The ETI SST will support this collaboration and is composed of world-renowned ethnobotanists, physicians and pharmacologists, as well as experts in the fields of natural product chemistry and neuropharmacology:

  • Michael J. Balickdoctorate: Considered one of the greatest ethnobotanists and economic botanists in the world; specialist in medicinal plants and poisonous plants and their use by indigenous peoples; research associate of the Brain Chemistry Labs of the Institute of Ethnomedicine; member of the original science strategy team that helped develop Jaguar’s plant library.
  • Thomas CarlsonMD, MS: Ethnobotanist, botanist, physician; professor of integrative biology at University of California, Berkeley; member of the original science strategy team that helped develop the Jaguar Plant Library; key architect of the ethnomedical field research process conducted by ethnobotanist/physician teams from Jaguar’s predecessor company, Shaman Pharmaceuticals.
  • Pravin Chaturvedidoctorate: Pharmacologist with specialty in neuropharmacology; Chairman of the Scientific Advisory Board of Napo Pharmaceuticals (Napo), a wholly owned subsidiary of Jaguar, and Chief Scientific Officer of Jaguar; Over 25-year career, led discovery and/or development activities for several new chemical entities, including the development of Napo’s FDA-approved drug, Mytesi® (crofelemer), the only oral herbal medicine approved by the FDA Botanical Guidance.
  • Julie Anne Chinnock, ND, MPH, ARNP/CRNA: ethnobotanist; doctor of naturopathic medicine; owner and manager of Ketamine Clinic; member of the original Shaman Pharmaceuticals field research teams; public health specialist.
  • Stephen DahmerMD: Researcher in ethnomedicine and practicing integrative physician; endocannabinoid expert who has conducted ethnomedical field research in tropical regions.
  • Wade Davisdoctorate: Ethnobotanist, anthropologist, writer and professor of anthropology at University of British Columbia; extensive international ethnobotanical field research.
  • Elaine Elisabetsky, Ph.D.: Among the best ethnopharmacologists in the world; professor in the departments of pharmacology and biochemistry of the Universidade Federal do Rio Grande do Sul in Brazil; member of the original science strategy team that helped develop Jaguar’s plant library.
  • Nigel GerickeMBBCh. : Physician, ethnobotanist and ethnopharmacologist; former member of the United States Pharmacopoeia Advisory Board; long-time member of the World Wide Fund for Nature’s Medicinal Plants Specialist Group; founding member of the Association for African Standards of Medicinal Plants.
  • Maurice Iwudoctorate: Chairman of the Bioresources Development Group and founder of the International Center for Ethnomedicine and Drug Development (InterCEDD) in Nigeria; member of the original science strategy team that helped develop Jaguar’s plant library.
  • Steven R. Kingdoctorate: ethnobotanist; Napo Sustainable Sourcing and Ethnobotanical Research Manager; managed Napo’s original science strategy team and its results; associate researcher at the Brain Chemistry Labs of the Institute of Ethnomedecine.
  • Charles LimbachMD: Ethnomedical specialist and family physician; member of the original science strategy team that helped develop Jaguar’s plant library.
  • David Sesindoctorate: Natural products chemist; manufacturing director of Jaguar; created an insulation and manufacturing process for Mytesi (crofelemer).

About Filament Health(OTCQB: FLHLF) (NEO: FH) (FSE: 7QS)

Filament Health is a clinical-stage natural psychedelic drug development company. Filament believes that safe, standardized, naturally derived botanical medicines can improve the lives of many people, with a mission to get them into the hands of everyone who needs them as soon as possible. Filament’s proprietary intellectual property platform enables the discovery, development and delivery of natural medicines, including psychedelic drugs, for clinical development. The filament is leading the way with the very first natural psychedelic drug candidates.

Learn more about www.filament.health and on Twitter, instagram and LinkedIn

About Jaguar Health, Jaguar Animal Health, Napo Pharmaceuticals and Napo Therapeutics

Jaguar Health, Inc. is a commercial-stage pharmaceutical company focused on developing novel herbal, non-opioid, and sustainably-derived prescription medicines for people and animals with gastrointestinal disorders, including chronic and debilitating diarrhea. Jaguar Animal Health is a trading name of Jaguar Health. Jaguar Health’s wholly-owned subsidiary, Napo Pharmaceuticals, Inc., is focused on the development and commercialization of proprietary human plant-based pharmaceutical products from plants responsibly harvested from rainforest areas. Our drug candidate crofelemer is the subject of on target study, an ongoing pivotal Phase 3 clinical trial for the prophylaxis of diarrhea in adult cancer patients receiving targeted therapy. Jaguar Health is the majority shareholder of Napo Therapeutics SpA (f/k/a Napo EU SpA), an Italian company created by Jaguar Health in Milan, Italy in 2021 which focuses on expanding access to crofelemer in Europe.

For more information about Jaguar Health, visit https://jaguar.health. For more information about Napo Pharmaceuticals, visit www.napopharma.com.

Forward-looking statements

Certain statements contained in this press release constitute “forward-looking statements”. These include statements regarding the expectation that the collaboration between Jaguar and Filament will identify candidate herbs that may prove beneficial in treating indications such as ADHD and social anxiety disorder, and the expectation that this collaboration identify and standardize new entheogens. In some cases, you can identify forward-looking statements by words such as “may”, “will”, “should”, “expect”, “plan”, “aim”, “anticipate”, ” could”, “intend”, “target”, “project”, “consider”, “believe”, “estimate”, “predict”, “potential”, or “continue” or the negative form of these terms or other similar expressions. The forward-looking statements contained in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections regarding future events. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control.Except as required by applicable law, Jaguar does not does not intend to publicly update or revise the statements forward-looking statements contained herein, whether as a result of new information, future events, changed circumstances or otherwise.

SOURCE Filament Health Corp.

Quote Show original content to download multimedia: http://www.newswire.ca/en/releases/archive/June2022/09/c5814.html

Governor Hochul Announces Groundbreaking for $41 Million Affordable Housing Development Project in Oneida County

Governor Kathy Hochul today announced that construction has begun on the $41 million Colonial II Apartments rehabilitation and upgrade in the City of Rome, Oneida County. The project will preserve affordability for 74 seniors and the highly energy efficient new design is expected to achieve net zero carbon emissions and help reduce overall utility costs for residents.

“As we strive to make New York more equitable, it’s critical that we provide vulnerable and older New Yorkers with access to affordable housing that allows them to live with the safety and security they deserve,” said he added. Governor Hochul said. “This affordable housing development project will provide older people and people with disabilities in Rome with a modern, highly energy-efficient building that will improve their quality of life, strengthen the community they call home and help achieve climate goals in New York’s long term.”

Colonial II apartments are part of Governor Hochul’s statewide plan to make housing more affordable, equitable and stable. In the recently enacted State Budget, the Governor successfully secured a comprehensive new five-year, $25 billion housing plan that will increase housing supply by creating or preserving 100,000 affordable homes in New York City, including 10,000 with support services for vulnerable populations, plus the electrification of 50,000 additional homes.

Colonial II apartments are located at 310 Cottage Street in Rome and are owned and operated by the Rome Housing Authority. The complex is accessible by public transport and located near a grocery store, pharmacy, medical facilities and public parks.

The seven-storey building opened in 1972 as a school and dormitory and was converted into social housing in 1984. The building was never upgraded before this critical rehabilitation and has become functionally obsolete.

The renovations will reconfigure the size of the apartments, which are currently too small to remain viable. When completed, the building will offer 74 one-bedroom apartments for seniors and people with disabilities, with amenities such as common areas, laundry facilities and an outdoor courtyard for recreation. RHA will employ a full-time maintenance superintendent on site.

The building will be redesigned to achieve net zero carbon emissions using heating and cooling service from on-site geothermal wells connected to individual geothermal heat pumps, individual energy recovery ventilators to provide heat fresh air and exhaust stale air, central heat pump water heaters with a recirculation loop and an extensive photovoltaic solar array to cover 98% of the building’s annual electricity production. The rehabilitation of this project includes the replacement of the exterior walls of the existing building with a highly efficient and cost effective system of exterior windows and wall panels. These new panels will provide a stronger and more durable exterior that will help reduce energy costs.

The developers are Beacon Communities Development LLC and the Rome Housing Authority (RHA).

Homes and Community Renewal Commissioner RuthAnne Visnauskas said: “The Colonial II Apartment Rehabilitation is another example of Governor Hochul’s commitment to preserving New York’s essential public housing stock. We are excited to create a healthy and comfortable environment for 74 seniors and people with disabilities, as well as to invest in a development that will lead to a greener New York State As the first public housing authority in New York to achieve net zero carbon emissions, Colonial II Apartments will serve as a model for our future housing rehabilitation projects and will help us meet the ambitious carbon reduction target set by the state’s Climate Leadership and Community Protection Act. Thanks to Beacon Communities Development and the Rome Housing Authority for partnering on this project. avant-garde and energy efficient.

Doreen M. Harris, President and CEO of the New York State Energy Research and Development Authority, said: “NYSERDA is proud to see the Colonial II Project kick off and begin construction that will expand access to comfortable, energy-efficient affordable housing for seniors and vulnerable Oneida County residents using innovative technology at the indoors and out. Most notably, this premier buildings project is powered primarily by clean, renewable solar energy and is representative of the health and environmental benefits that green building can bring to our underserved communities. as part of Governor Hochul’s goal of reaching 2 million climate-friendly homes by 2030.”

Funding for Colonial II apartments includes $2 million in permanent tax-exempt bonds, federal low-income housing tax credits that will generate $16.6 million in equity and $12.5 million in grant from New York State Homes and Community Renewal. The project also received $1 million in the second round of NYSERDA’s Buildings of Excellence competition and $296,000 through NYSERDA’s New Construction – Housing Program. Additional funding is provided by the Rome Housing Authority and deferred developer fees.

Renovations of the Colonial I apartments, also funded by UNHCR, were completed in 2019. Colonial I offers 83 affordable housing units for seniors and people with disabilities.

Senator Charles Schumer said: “Every resident of Oneida County deserves access to safe, affordable, and energy-efficient housing, and I’m proud that the Federal Low-Income Housing Tax Credit that I fought so hard for has provided the millions of dollars of investment needed to breathe new life into these apartments for the elderly and disabled in Rome. I applaud Governor Hochul for this essential push for affordable housing, and I will continue to fight for getting every dollar of federal support needed to help lay the foundation for a brighter, greener future for all of Central New York.”

Senator Kirsten Gillibrand said: “All New Yorkers should have a safe and affordable place to live. This critical project will help ensure that older adults in Oneida County have access to affordable housing options and that community needs are met. Access to affordable housing is essential now more than ever, and I will always fight to ensure our communities have the resources they need.”

State Senator Joseph A. Griffo said: “As our neighborhoods and communities continue to grow, it is important that we provide safe and affordable housing options for all segments of the population. This project will provide older people and people with disabilities with access to modern, energy-efficient housing while rehabilitating and preserving an existing building in Rome.”

Assembly Member Marianne Buttenschon said: “I want to thank the Governor and NYSERDA for their support of this great project. Colonial Apartments are home to many people, and the rehabilitation and preservation of their homes is much needed and will provide years of safe and comfortable living in the future.”

Oneida County Executive Anthony J. Picente Jr. said: “The Colonial II apartments upgrade will preserve and improve much-needed social housing for older and disabled people in Rome. This zero-carbon project, the first of its kind, will be a model of energy efficiency. I commend the Rome Housing Authority for its vision and thank New York State for the funding to make it happen.”

Beacon Communities CEO Dara Kovel said: “This innovative project illustrates how sustainability and the development and redevelopment of affordable housing can and should go hand in hand. With the support of our public and private sector partners, Beacon will be able to both contribute to the ambitious goals of the “state on climate change and dramatically improve the quality of life for Colonial II residents while boosting the local economy. It’s a win-win for all and establishes a plan that should be replicated at scale.” of State.

Annual general meeting of Gerresheimer AG approves dividend of EUR 1.25 per share after successful financial year

DUESSELDORF, Germany, June 8, 2022 /PRNewswire/ — The annual general meeting of Gerresheimer AG approved the payment of a dividend of €1.25 per share for fiscal year 2021. This represents a payout ratio of 30%. “2021 has been a banner year for us. Our strategic Formula G process and investments in transforming our Gerresheimer into a growth company, innovation leader, solutions provider and systems integrator are paying off. “, said Dietmar Siemssen, CEO of Gerresheimer, at the Annual General Meeting. “We continue to invest in sustainable and profitable growth while paying an attractive dividend,” he added.

The dividend of €1.25 per share represents a payout ratio of 30% of the company’s adjusted net earnings. This is at the upper end of the 20-30% range defined in its dividend policy. The dividend will be paid on June 13, 2022.

The General Meeting approved the concept of a progressive renewal of the Supervisory Board. It elected the six candidates proposed by the Nominations Committee. Teacher. Dr. Annette G. Köhler, university professor and holder of the chair of accounting, auditing and controlling at the University of Duisburg-Essen, will join the board of directors for the first time. The long and commendable presence of his predecessor on the Supervisory Board, Theodore Stuthended at the end of the General Assembly.

Members of the Supervisory Board Udo Vetterdr. Karin Louise Dorrepaal and Dr. Peter Noé were re-elected for a two-year term. dr. Axel HerbergTeacher. Dr. Annette G. Köhler and Andrea Abt were elected for four years each.

At the next meeting of the Supervisory Board, Dr. Axel Herberg was re-elected Chairman of the Supervisory Board. Teacher. Dr. Annette G. Köhler took over as chairman of the audit committee.

The acts of the Management Board and the Supervisory Board for the 2021 financial year were approved by a large majority. The annual general meeting elected Deloitte GmbH Wirtschaftsprüfungsgesellschaft, Dusseldorfas Statutory Auditors for the 2022 financial year.

In total, 80.93% of the share capital was represented at today’s Annual General Meeting. The detailed results of the votes for all the items on the agenda of the General Assembly are available on:


The CEO’s speech and the presentation of the General Assembly are available on:


The annual report is available at:


Contact Gerresheimer AG

Contact Hurry
Ueli Utzinger
Group Senior Director Marketing & Communication
T +49 211 6181-250
[email protected]

Contact Investor Relations

caroline nadilo
Senior Director of Investor Relations
T +49 211 6181-220
[email protected]

About Gerresheim

Gerresheimer is the global partner for pharma, biotech, healthcare and cosmetics with a very wide range of products for pharmaceutical and cosmetic packaging solutions and drug delivery systems. The company is a provider of innovative solutions, from concept to delivery of the final product. Gerresheimer achieves its ambitious goals through a high level of innovative strength, industrial competence and focus on quality and customer orientation. To develop innovative and sustainable solutions, Gerresheimer relies on an extensive international network with numerous innovation and production centers in EuropeAmerica and Asia. Gerresheimer produces close to its customers worldwide with approximately 10,000 employees and generated annual revenues in 2021 of approximately 1.5 billion euros. With its products and solutions, Gerresheimer plays an essential role in people’s health and well-being.

SOURCEGerresheimer AG

Build a culture of mentorship in your pharmacy

Although related to coaching, mentoring is a unique topic that deserves its own attention. Mentors are unique because they choose to invest in another person’s growth by sharing their knowledge while offering support and guidance.

Although we’ve all had managers or supervisors, not everyone has had the opportunity to experience true mentorship. Coaches and managers push us to perform in order to achieve a set goal, but a relationship with a mentor is different because it is transformational and aims at the development of the individual. The relationship is based on trust, support and feedback. Pharmacy mentorship is particularly important as it can contribute to the development of competent, competent and motivated pharmacists to lead the profession and continue to advance the field.

A recent study of pharmacist mentors and mentees was conducted to assess the lived experiences that contribute to these relationships and gain insight into best practices for developing new relationships and mentoring programs.1 The results of the study revealed that mentorship provided a sense of pride, as pharmacists felt they were giving back to the profession and that the relationship could be lifelong in successful cases. Mentees reflected favorably on the experience of being mentored, the flexibility of their mentoring partner, and the program.1

Notably, a lack of engagement and commitment from one party led to frustration from the perspective of both mentors and mentees.1 These results highlight the reciprocal and symbiotic nature of the bond between mentor and mentee and can form the foundation of a successful relationship.

Mentoring is the provision of advice, guidance and direction to a novice with the goal of refining and developing their skills and knowledge base and to help advance the personal and professional growth of the mentee. Identifying a worthy mentee who demonstrates an inherent motivation for personal and professional development is key to forming the relationship, as it can require a great deal of time and energy from both parties. While the time commitment can be viewed as a downside and may deter some people from participating in mentoring, it is also important to realize the benefits. The relationship is often rewarding for both parties, as the mentor may experience intrinsic satisfaction from contributing to the lives of others and observing their advancement, while the mentee may experience improved self-esteem, confidence and professional identity.1

For mentoring relationships to be successful, trust must be built through clear and open communication about expectations. Additionally, mentors and mentees need to consider whether their values ​​align with each other.1 Pharmacy managers acting as mentors should go beyond coaching. While coaching has some benefits, as it offers enhanced consultation and guidance, mentoring involves a more intimate and learned approach.1 Ultimately, mentoring can be more effective for knowledge transfer, employee development, motivation, and engagement.1

Importantly, the study recognizes a lack of mentoring culture within pharmacy, as opposed to medicine and nursing, where extensive literature exists on the human needs of mentors and mentees involved in a mentoring relationship.1 Pharmacy managers need to recognize the need to establish a culture of mentorship within pharmacy where collaboration, knowledge sharing and engagement are encouraged. Creating a culture of mentoring means supporting employees by generating opportunities to build deeper relationships, providing an individualized and personalized approach to development, and identifying strong role models to serve as mentors.

Organizations can value mentorship programs by investing in mentors and providing training and rewards for their commitment to the program, to encourage participation and ensure program sustainability. Even in the absence of a formal mentorship program, the pharmacy manager should communicate the importance and value placed on informal mentorship, encouraging all employees to learn from and protect each other. .

More information on manage people can be found in Pharmacy Management: Essentials for All Practice Settings, Grade 5.


Valerie Wasem is a PharmD candidate at the University of Touro in California.

Shane P. Desselle, RPh, PhD, FAPhA, is a professor of social and behavioral pharmacy at the University of Touro in California.


1. Mantzourani E, Chang H, Desselle S, Canedo J, Fleming G. Reflections of mentors and mentees on a national mentorship program for pharmacists: an examination of relationships, personal and professional development. Res Soc Admin Pharm. 2022;18(3):2495-2504.

Apply for Assistant Professor Vacancies at GIPS Tezpur

Applications are invited for various teaching positions at Girijananda Chowdhury Institute of Pharmaceutical Science (GIPS) Tezpur.

The Girijananda Chowdhury Institute of Pharmaceutical Sciences (GIPS) Tezpur is inviting applications from eligible candidates for the post of Assistant Professor.

Job name : Assistant professor

Number of positions : 5

Eligibility criteria : Applicant must be M.Pharm in Pharmacy/Pharm. Chemistry/Pharma. Analysis / Pharmacology from AICTE and PCI recognized institution. PhD and GPAT applicants will be preferred.

Selection procedure : A walk-in interview will be held on June 13, 2022 from 10:30 a.m. at GIPS- Tezpur Campus, Kunderbari, Dekargaon, Sonitpur, Tezpur, Pin- 784501.

How to register : Applicants may come to the interview with biographical data, original and self-attested copies of all required testimonials.

For more information please contact: Phone Number – 9854046526 or Email: [email protected]

Also Read: Assam Career: Apply for Accounting Vacancies at GIMT Tezpur

Northeast Now is a multi-app based hyper-regional bilingual news portal. Email us at: [email protected] More by NE NOW NEWS

Lexaria grants license to AnodGen Bioceuticals

(via TheNewswire)

  • DehydraTECH pharmaceutical license issued for Europe, Australia and New Zealand markets

  • Lexaria receive royalties from sales of DehydraTECH products

Kelowna, British ColumbiaTheNewswire –June 8, 2022Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the award of a non-exclusive DehydraTECH license five-year term (the “License”) of its wholly-owned subsidiary, Lexaria Pharmaceutical Corp. to AnodGen Bioceuticals (“AnodGen”) of Ireland.

The license granted is valid for the manufacture and distribution of DehydraTECH processed cannabinoid active pharmaceutical ingredient (“API”) powders within Europe including the UK, Australia and New Zealand; including pharmaceutical and medical product applications for psychoactive cannabinoids and medical product applications for non-psychoactive cannabinoids. Anodgen will pay royalties to Lexaria for all API powders sold that use DehydraTECH technology. Anodgen has the right to manufacture and sell these API powders to third party companies for their own products which are designated by a national regulatory body as a medical product, drug, nutraceutical, pharmaceutical or biopharmaceutical, as applicable, under its cannabinoid product license fees.

“This strategic alliance with Lexaria Bioscience Corp. underscores Anodgen’s goal of “bringing science to life”, in addition to our research and APIs,” said Dr. Slimane Aboulkacem, President and Founding Member of Anodgen Bioceuticals.

Doctor Jeffrey Pruskichief medical officer and founding member of Anogen, mentioned that “the partnership with Lexaria will help bring research-based APIs and technologies to businesses and people with superior bioavailability and improved absorption. This alliance will bring changes that we will yet see in pharmacokinetics and formulation. »

Consumer products purchased without consulting a physician or healthcare professional are not permitted under the terms of this license. AnodGen should have its new installation at Ireland fully operational later in 2022 and Lexaria recognizes the long-term growth potential of using DehydraTECH in these pharmaceutical market opportunities.

About AndoGen Bioceuticals.

Anodgen Bioceuticals is a new companycontract manufacturing organizationcompany that is goingmanufacture and distribute active pharmaceutical ingredients for the pharmaceutical industryfocusing on world-class research onpharmacognosy (herbal medicine). Anodgen Bioceuticals’ mission is to “bring science to life” by developing a global, science-driven company specializing inpharmacognosy,active nutrition, health and sustainable lifestyle. Anodgen Bioceuticals has global expertise and innovation to add value to the science around plant-derived medicine. Most importantly, Anodgen specializes in sourcing andCustom compound APIs of cannabinoids and other custom blends. The Company recently signed two research memorandums of understanding with WE universities to collaborate on research.

About Lexaria Bioscience Corp.

Lexaria Bioscience Corp.’s patented drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting more efficient oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bioabsorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also demonstrated the ability to deliver certain drugs more efficiently across the blood-brain barrier. Lexaria operates an in-house licensed research laboratory and holds a strong intellectual property portfolio with 25 issued patents and over 50 patents pending worldwide. For more information, please visitwww.lexariabioscience.com.


This press release contains forward-looking statements. Statements as that term is defined under applicable securities laws. These statements can be identified by words such as “anticipate”, “if”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, ” could”, “should”, “will” and other similar expressions. These forward-looking statements in this press release include, but are not limited to, statements by the Company regarding the Company’s ability to conduct research initiatives, receive regulatory approvals or grants, or experience positive or the results of any research or study. These forward-looking statements are estimates reflecting the best judgment of the Company based on current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions or expectations disclosed in these statements. prospective. statements. As such, you should not place undue reliance on these forward-looking statements. Factors that could cause actual results to differ materially from those estimated by the Company include, but are not limited to, governmental regulation and regulatory approvals, managing and sustaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, patent application and approval process, potential adverse effects arising from the testing or use of products using DehydraTECH technology, the Company’s ability to maintain existing collaborations and derive benefits from them, planned R&D delays or cancellations that may occur due to pandemics or other reasons, and other factors that may be identified from time to time in public announcements of the Company and periodic filings with the US Securities and Exchange Commission on EDGAR. There can be no assurance that any of the uses, benefits, or benefits Lexaria postulates for the patented and patent-pending technology will actually be realized in any way or in any part. No statement herein has been evaluated by the Food and drug administration (FDA). Products associated with Lexaria are not intended to diagnose, treat, cure, or prevent any disease. All forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements contained in this release, whether as a result of new information, future events, changes in circumstances or otherwise. , unless otherwise provided by law.


Georges Jurcic – Head of Investor Relations

[email protected]

Telephone: 250-765-6424 ext. 202

Copyright (c) 2022 TheNewswire – All Rights Reserved.

Copyright (c) 2022 TheNewswire – All rights reserved., source Press Releases

Expert discusses impact of pharmacist intervention on clinical trial enrollment

In an interview with Pharmacy hours at the 2022 American Society of Clinical Oncology, Beth Koselke, PharmD, BCOP, discussed the impact of pharmacist involvement in clinical trial recruitment, particularly in the MYLUNG Consortium.

Q: Can you explain to us what the MYLUNG Consortium is?

Beth Koselke: The MYLUNG Consortium brings together providers and researchers from the US Oncology Network and US Oncology Research, as well as partners from life sciences and patient advocacy groups. Their goal is to promote advanced non-small cell lung cancer research for patients in the community setting, specifically looking at molecular testing for barriers.

Q: What is the role of pharmacists in the recruitment of clinical trials in general?

Beth Koselke: I think that’s actually a very underutilized part of what pharmacists do. Typically, pharmacists have always been in the investigational drug business where we make sure patients get the right investigational drug once patients are enrolled in studies, but I think pharmacists can really be in the business of selecting patients for trials because we are already looking for patients for appropriate drugs and disease status. We may include inclusion and exclusion criteria in this to screen patients for upstream trials. Maybe when doctors are too overwhelmed and don’t really think about enrolling patients in clinical trials, we’re like another pair of eyes that can help with that.

Q: Can you discuss your study design and objectives?

Beth Koselke: We were integrated into phase 2 of the my lung protocol, there are 3 distinct protocols, and we are in the second protocol. This is an observational study, where we examine the operational feasibility of biomarker testing before patients start treatment. There are 11 open trial sites and pharmacist intervention was conducted at 6 of these sites. We looked at before and after the pharmacist’s intervention, which included a selection of the pharmacist patients, both through a weekly report, as well as through the normal review of chemotherapy orders and then messaging providers and clinical trial staff. We hoped to see an improvement in the number of registrations once the pharmacist’s intervention was completed.

Q: What did you find about the impact of pharmacists?

Beth Koselke: We found that we had nearly doubled enrollment rates at the 6 practice sites we were involved with. We therefore went from an average of 3.4 patients registered per month to 6.6 patients registered per month. In every practice site we touched, we saw an improvement. So I think that’s pretty exciting and shows that a pharmacist can be integrated remotely into community oncology and into the whole network.

Q: How could this information be used in the future, both in the MYLUNG consortium and in other clinical trial programs?

Beth Koselke: I think, as I mentioned earlier, that pharmacists involved in a multidisciplinary research team can really benefit the whole team by looking at patients upfront and earlier. Then, when patients are on second and subsequent lines of treatment, it’s really difficult to catch those patients for clinical trials. Thus, a pharmacist would be an excellent second pair of eyes for this as well as for genomic screening of patients. So we see patients presenting with a mutation and we know we have an open trial there. We would be a very good person to stop before the patient gets a prescription and say they would qualify for an open study there.

In-Depth Research Study on Batch Management Software Market, Regional Growth, Company Major Key Players Analysis – mbu timeline

The global Batch Management Software market report emphasizes on detailed understanding of some decisive factors such as size, share, sales, forecasted trends, supply, production, demand, l industry and CAGR to provide a comprehensive perspective of the global market. In addition, the report also highlights challenges hindering market growth and expansion strategies employed by leading companies in the “Batch Management Software Market”.

Global Batch Management Software Market research report analyzes major players in key regions like North America, South America, Middle East & Africa, Asia & Pacific region. It provides insights and expert analysis on key market trends and consumer behaviors, in addition to an overview of market data and key brands. It also provides all data with easily digestible information to guide every businessman’s future innovation and drive business forward.

Global Batch Management Software Market Segmentation Analysis:

Leading players in the Batch Management Software Market are:

Emerson Electric Co.
General Electricity Company.
Siemens AG
Invensys plc.
ABB Ltd.
Yokogawa Electric Corp.
Honeywell International Inc.
Aspen Technology Inc.
Werum Software and Systems AG.

Majority of Batch Management Software Product Type covered in this report are:


Most widely used downstream areas of Batch Management Software Market covered in this report are:

petroleum gas
Food and drink
Pulp and paper

Click the link for a free sample report @ https://crediblemarkets.com/sample-request/batch-management-software-market-294365?utm_source=Kaustubh&utm_medium=SatPR

Batch Management Software Market, By Geography:

The regional analysis of Batch Management Software Market is studied for regions such as Asia-Pacific, North America, Europe and Rest of the World. North America is one of the major regions in the market owing to numerous cross-industry collaborations between automotive original equipment manufacturers and mobile network operators (MNOs) for seamless internet connectivity inside a car to improve the user experience of connected life. , while driving. The Asia-Pacific region is one of the major players in the market as large enterprises and SMEs in the region are increasingly adopting batch management software solutions.

A few points from the table of contents

Global Batch Management Software Market 2022 by Company, Regions, Type and Application, Forecast to 2030

1 Batch Management Software Introduction and Market Overview

2 Industry Chain Analysis

3 Global Batch Management Software Market, by Type

4 Batch Management Software Market, by Application

5 Global Workflow Management Software Consumption, Revenue ($) by Region (2018-2022)

6 Global Workflow Management Software Production by Major Regions (2018-2022)

7 Global Workflow Management Software Consumption by Regions (2018-2022)

8 Competitive Landscape

9 Global Workflow Management Software Market Analysis and Forecast by Type and Application

10 Supply and Demand Forecast of Asset Management Software Market by Regions

11 New Project Feasibility Analysis

12 Expert interview file

13 Research finding and conclusion

14 Appendix

Directly Buy This Market Research Report Now @ https://crediblemarkets.com/reports/purchase/batch-management-software-market-294365?license_type=single_user;utm_source=Kaustubh&utm_medium=SatPR

Reasons to buy this report

  • Qualitative and quantitative market analysis based on segmentation involving both economic and non-economic factors
  • Providing market value data (USD Billion) for each segment and sub-segment
  • Indicates the region and segment expected to grow the fastest and dominate the market
  • Geographical analysis highlighting the consumption of the product/service in the region and indicating the factors affecting the market in each region
  • Competitive landscape that incorporates the market ranking of major players, along with new service/product launches, partnerships, business expansions, and acquisitions over the past five years of profiled companies
  • Comprehensive company profiles including company overview, company information, product benchmarking and SWOT analysis for key market players
  • Current and future industry market outlook with respect to recent developments that involve opportunities and growth drivers along with challenges and restraints of emerging and developed regions
  • Includes in-depth market analysis from various perspectives through Porter’s Five Forces Analysis
  • Provides market insight through the value chain
  • Market dynamics scenario, along with market growth opportunities in the coming years

About Us

Credible Markets is a new era market research company with a firm grip on the pulse of global markets. Credible Markets has become a trusted source for business market research needs in a short period of time. We’ve partnered with leading market intelligence publishers and our report pool coverage spans all key industry verticals and thousands of micro-markets. The massive repository allows our clients to choose from recently released reports from a range of publishers who also provide in-depth analysis by region and country. Moreover, pre-booked research reports are among our best offers.

The collection of market intelligence reports is regularly updated to provide visitors with quick access to the latest market information. We provide round-the-clock support to help you reuse search parameters and benefit from a full range of reserved reports. After all, it’s about helping you make an informed strategic decision on purchasing the right report that meets all your market research demands.

Contact us

Credible market analyzes

99 Wall Street 2124 New York, NY 10005

E-mail: [email protected]

We use green chemistry to protect the environment: Top scientist from CDRI

“The field of ‘green chemistry’, or the development of chemical products and processes that reduce or eliminate the production of hazardous substances, has advanced rapidly in recent decades, and pharmaceuticals have played an important role”

The Central Drug Research Institute (CDRI), Lucknow, is doing its part to protect the environment through its “green chemistry” approach to drug discovery and development by avoiding excessive use of harmful chemicals .

Dr. Atul Kumar, CDRI’s Chief Scientist and Head of Medicinal Processes (Chemistry Division) made the statement on World Environment Day on Sunday. He also explained the “green chemistry” approach.

“CSIR-CDRI Lucknow is committed to protecting the environment through its ‘green chemistry’ approach to drug discovery and development. We try to avoid excessive use of harmful chemicals and multi-step reactions. It is a drug manufacturing process that is less toxic, cost effective and generates zero waste and therefore poses no threat to the environment,” Kumar said.

“The pharmaceutical industry produces significant amounts of waste and pollutants that harm the environment and health. The field of ‘green chemistry’, or the development of chemical products and processes that reduce or eliminate the production of hazardous substances, has advanced rapidly over the past decades, and pharmaceuticals have played an important role,” he said. -he adds.

He mentioned some of the achievements of the CSIR-CDRI in this direction and cited the synthesis of Arteether used for the treatment of malaria and the “smart drug” Modafinil (used in the treatment of excessive sleepiness caused by sleep apnea). sleep, narcolepsy).

He said the concept of “green chemistry” emerged in the 1990s, after which the institute launched a program to develop new green and sustainable processes to create new active pharmaceutical ingredients (APIs) and new drugs. .

Close story

Less time to read?

Try Quickreads

  • The shadow shrunk even as the sun blazed and the youngsters screamed in excitement when the moment came.  (Samir Jana/HT Photo) (File Photo)

    Kolkata is witnessing a zero shadow moment

    Explaining the phenomenon, astrophysicist Debiprosad Duari said: “People and any object, anywhere in the world, sojourning between the Tropic of Cancer and the Tropic of Capricorn lose their shadows, albeit momentarily, twice a year. These two moments are called moments of zero shadow.” This occurs when the sun is directly overhead.

  • The KK playback singer was 53 at the time of his death.

    ‘It happens at rallies too’: TMC MP amid alleged crowd mismanagement at KK concert

    The Bengali actor-turned-TMC MP Dev’s statement comes after Kolkata Police Chief Vineet Goyal said on Friday that there was no situation at the KK concert where attendees were running out of space. He added, however, that the police were introducing measures to prevent overcrowding and to provide emergency medical aid if needed. Goyal also said that at no time had KK been mobbed, with a police arrangement under an assistant commissioner in place long before the singer arrived in Nazrul Mancha.

  • HD Kumaraswamy, Former Chief Minister of Karnataka and Leader of JD(S).  (AP)

  • The accused sexually assaulted and killed the nine-year-old minor 11 months after he was released from prison for another assault case.  (REPRESENTATIVE IMAGE)

    Bombay: a man sentenced to death for sexually assaulting and killing a minor in 2019

    When delivering the verdict, the POCSO Special Court said the defendant could not be allowed to remain in society because, once released, he risked repeating the same offence. The court also refused to grant clemency to the defendant, saying such a man who abused underage girls one after another did not deserve the same.

  • The murder of Vijay Kumar Beniwal came amid a series of terrorist attacks against non-locals in Jammu and Kashmir.  (ANI)

    ‘Not his wedding album yet’: Bank manager killed at J&K married 3 months ago

    Vijay Kumar Beniwal’s father, Om Prakash Beniwal, who is a public school teacher in Nohar tehsil of Hanumangarh, said: “I spoke to him last night. Today at 11 a.m. while I was eating someone called me and told me that there was news on TV that Vijay Kumar had been shot dead. I immediately turned on the TV and saw the same thing.

Recognizing the importance of early referral to palliative care is critical to patient care

In an interview with Pharmacy hours at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, Ajeet Gajra, MD, MBBS, FACP, discussed research that found that using an augmented intelligence-based system can improve the timeliness of referrals to palliative care and palliative care services in community oncology environments.

Can you discuss the importance of timely referrals to hospice and palliative care services?

Ajeet Gajra, MD, MBBS, FACP: Timely referral to palliative care and palliative care approaching end of life is considered a benchmark of quality in oncology. So our own company, ASCO, through its QOPI program, has established that there are ASCO guidelines, NCCN guidelines, on integrating palliative care from the start of treatment patients battling cancer. And what that leads to is a better expectation of, you know, a set of better patient and family expectation levels, number 1. Number 2, it repeatedly avoids traumatic near-end-of-life treatments.

So what we do know is that if patients with advanced cancer receive chemotherapy, radiation therapy, if they have repeat ER visits, hospital admissions, ICU admissions, these are all bad results. These results actually indicate a poor quality of oncology care delivery, and therefore must be avoided at all costs and prevented. Thus, the way to avoid and prevent them is to integrate palliative care from the beginning of the course. And when the time comes, this palliative care can then be transformed into palliative care, if necessary. And I think that’s an essential element. And unfortunately, there’s still, you know, sometimes confusion about equating palliative care with palliative care. And again, I’ll point out that palliative care is just a small segment of palliative care, which is a much broader term in something that has a much longer continuum, and towards the end of that, you know, we use palliative care.

What obstacles stand in the way of such timely referrals for patients with advanced cancer?

Ajeet Gajra, MD, MBBS, FACP: So, I would smash those hurdles into really 3 buckets. So there are obstacles or barriers from the perspective of a patient or, you know, a caregiver. There are barriers from the perspective of the provider or clinician. And then there are barriers that are, you know, system-imposed barriers. So if we’re talking about patients and caregivers first, there’s always this worry that if palliative care isn’t mentioned in the proper context, or how it’s conveyed to them, there’s a fear that my doctor cowardly. So, you know, unfortunately it’s still a widespread thought process. I think through our awareness and patient-centered education, we need to eliminate that and reduce that kind of mentality. I think we need to make it very clear to patients and families that if their clinical team is recommending palliative care, alongside other therapies they’re receiving, the goal is to really help them manage symptoms more effectively and, in fact, to improve the quality of worrying about. And that doesn’t mean that, you know, their cancer care is off.

So I think there is the other side of the coin. So I said, you know, there’s also the clinician or provider aspect. Thus, providers must also believe that palliative care is an essential component of the cancer control continuum. And when integrated early on, we have many studies, you know, the pioneering work came first, in patients with advanced lung cancer, and now it’s been 10 years. And since then, we have many more studies to demonstrate that early integration of palliative care improves outcomes, both in terms of quality of life and perhaps also survival for these patients. So I think we have to do it.

In other work Cardinal Health has done with community oncology clinicians, there is still a deficit where people don’t integrate palliative care early on. They wait, you know, for very late stages and near the end of life before starting such care. And so it’s still clinicians and providers, perhaps specialized in a community setting. And, you know, the United States is a big country and there are many practices, and especially in rural areas where they are busy practices and these clinicians are busy taking care of all kinds of cancer patients and so maybe it’s not great spirit for them. Education therefore seems essential.

And the third, as I said, is a systemic problem. Do we have enough palliative care providers? You know, it doesn’t have to be doctors, it can be advanced practice providers. It can be a team, you know, that includes an APP and the social worker and other components. But it must be recognized that it is an essential part of patient care.

JSMU Institute of Pharmaceutical Sciences Launches Herbal Projects Exhibition

Institute of Pharmaceutical Sciences – Jinnah Sindh Medical University (JSMU) launched a display project for herbal products aimed at infusing the benefits of ancient medicine with modern methods. The project exhibition was organized by third-year pharmacy students from the Pharmacognosy Laboratory.

JSMU Vice Chancellor, Prof. Amjad Siraj Memon appreciated the entrepreneurial efforts of pharmacy students and said that herbal medicine can be a game-changer for healthcare in Pakistan when backed by evidence, the sustainability and innovation.
Senior Professor Huma Ali of IPS-JSMU informed the Communications Office that pharmacy students presented sixteen herbal projects, based on herbal orientation to therapeutics, cosmeceuticals and nutraceuticals. She further added that the pharmaceutical industry has conducted a lot of research on the important compounds of traditional medicines and herbal medicines.

The Vice-Principal and Head of the Department of Pharmacognosy, Professor Dr Huma Shareef – who recently returned from the UK after completing a postdoctoral program – imparted her knowledge and experience in the field of pharmacy to the students and led the Herbal Project Exhibition, with Assistant Professor and Course Leader Sumaira Ishaque and Lecturer Kaneez Fatima.

The second group earned the top position out of sixteen groups for their herbal product, Rapid Relief Castor for Leaf Paste and Patches. Group eleven won the second position for the formulation of aromatherapy for stress relief and organic toothpaste, while the fourth group won the third position for their Neem balm for eczema and aloe vera for the Sun burn. Other groups have won special awards for their herbal products. The project has received much appreciation and recognition from the entire faculty and staff of JSMU.

Related: Religious and Motivational Session Held at JSMU

Bluefield University slashes programs to deal with impact of pandemic | New

BLUEFIELD, Va. — In a plan to manage the impact of the pandemic, Bluefield University has initiated several measures, including eliminating some academic programs.

President David Olive said in an announcement that the changes result from the university’s spring board meeting.

Board members established a $19.5 million operating budget for 2022-23 and also approved a new tuition plan for Virginia students, several faculty promotions and appointed a task force to review programs and University operations.

On May 26, the board approved the closure of low-enrolment, low-graduation programs to prospective students. Current students in these programs will be taught until graduation by full-time or part-time faculty with degrees in the discipline.

“Our university’s budget depends on several variables,” Olive said. “This year, the work of drawing up a budget has been more difficult. This is because some variables are influenced by things like the wider effects of the COVID pandemic. It’s no secret that the university, along with businesses across the county, have had to work very hard to maintain balanced budgets and pivot to meet market demands during this time.

Closed programs include the Art, Art Business, History, Mathematics, and Mathematics majors as well as the Department of Modern Languages, the General Music major with an Applied Voice concentration, Theater as a major, and the Health/Physical Education major.

However, Olive said that as required by the university’s accreditation through the Southern Association of Colleges and Schools Commission on Colleges (SACSCOC), current students currently enrolled in closed programs will continue their program at Bluefield University until graduation in what is commonly referred to as. as a “teaching”.

While some majors will be closed, the institution will offer prospective students the opportunity to engage in similar and/or revamped degree programs created by the university’s faculty, he said. This transition will also better position the institution with future resources for new study programs.

Olive also said the theater program will continue to operate as an “extracurricular activity including the Bluefield Youth Theater.”

“Although these decisions were difficult to make, let me be clear,” Olive said. “The institution is not in danger of closure, as has been falsely rumored during this process. On the contrary, the institution is taking steps to adjust its operations and continue the development of highly sought after and ready degree programs. Career Through our collaborative partnerships with VCOM (Virginia College of Osteopathic Medicine) and the Appalachian College of Pharmacy, we have a bright future as we enter the next 100 years of Christian higher education.

A Commonwealth Connection Tuition Plan was also created at the spring board meeting.

Intended as an extension of the institution’s Pathways tuition program for students from the local community, students will now have the option of paying a fixed tuition rate, Olive said. Students eligible for the Pathways tuition rate receive a flat rate of $13,600. Students must have a 3.0 GPA to qualify and reside in one of the following counties: Bland, Buchanan, Carroll, Floyd, Giles, Grayson, Montgomery, Pulaski, Russell, Smyth, Tazewell, Washington, and Wythe Virginia; and McDowell, Mercer, Monroe, Raleigh, Summers and Wyoming in West Virginia.

Students eligible for the Commonwealth Connection tuition fee receive a flat fee of $15,000, must have a GPA of 3.0 and reside in Virginia. Most, if not all, of each tuition rate may be covered by the Virginia Tuition Assistance Grant (VTAG), Pell Grant funding, outside scholarship aid, and other identified sources of funding. Students eligible for the Pathways program are also eligible for reduced room and board rates.

“We realize the affordability of higher education continues to be a kitchen table conversation for many families,” Olive said. “We designed our two best tuition models to serve those we were founded to serve 100 years ago, here in our local area of ​​Southwest Virginia and Southern West Virginia, sides of the Commonwealth of Virginia.”

Olive said that in budget presentations, university officials cited the multi-year effects created by periods of declining enrollment in online and on-campus programs during the pandemic now reaching its full impact.

The initial deficits were mitigated by the assistance of federal funds through programs such as the CARES Act and the Employee Retention Credit, he said, and “those effects materialize through the enrollment cycle traditional four-year term, as larger classes of students graduate and natural attrition takes place from year to year, leaving behind smaller classes of retained enrolled students.

However, projections have shown a positive note with enrollment of new students on campus returning to pre-pandemic levels for the 2022-2023 academic year, he said, and work will continue to further improve enrollment. online programs through curriculum review.

The board appointed the task force “to provide a holistic review of the university’s programs and operations to ensure the institution is well positioned for the future.”

— Contact Charles Boothe at [email protected]

Inventiva announces the presentation of a scientific study

Daix (France), Long Island City (New York, United States), June 3, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases with significant medical needs not satisfied, today announced that the abstract “Pan-PPAR agonist lanifibranor improves non-alcoholic steatohepatitis (NASH) and glycemic control” has been selected for poster presentation at the 82n/a Scientific Sessions June 3-7, 2022 New Orleans, USA.

PPAR signaling is implicated in disease pathways common to NASH and type 2 diabetes (T2D) and this summary focuses on improved glycemic control and NASH markers in patients treated with lanifibranor versus placebo. In Inventiva’s “NATIVE” Phase IIb clinical trial, lanifibranor, compared to placebo, demonstrated beneficial effects on liver histology, resolution of NASH and regression of fibrosis in patients with of non-cirrhotic NASH.

Based on the NATIVE data, the authors of the abstract show that glycemic control is correlated with the severity of NASH measured by liver biopsy. Additionally, improved glycemic control in patients who received lanifibranor was correlated with improved metabolic-immune markers of NASH insulin resistance, lipid metabolism, inflammation, liver enzymes and hepatic steatosis, measured by the continuous attenuation parameter (CAP).

The details of the presentation are as follows:

Date: June 5, 2022
Poster session schedule: 1:00-2:00 PM EST
Poster ID: 830-P
Title of abstract: “The Pan-PPAR agonist lanifibranor improves non-alcoholic steatohepatitis (NASH) and glycemic control”
Author: Dr. Michael P. Cooreman, Chief Medical Officer of Inventiva

About Inventiva

Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of NASH and other diseases with significant unmet medical need. The Company benefits from strong expertise and experience in the field of compounds targeting nuclear receptors, transcription factors and epigenetic modulation. Inventiva’s lead product candidate, lanifibranor, is currently in a pivotal Phase III clinical trial, NATiV3, for the treatment of adult patients with NASH, a common and progressive chronic liver disease for which there is no currently no approved treatment.

The Company has established a strategic collaboration with AbbVie in the area of ​​autoimmune diseases which resulted in the discovery of the drug candidate cedirogant (ABBV-157), an oral RORγ inverse agonist which is being evaluated in a trial Phase IIb clinical trial, conducted by AbbVie, in adult patients with moderate to severe chronic plaque psoriasis. Inventiva’s pipeline also includes odiparcil, a drug candidate for the treatment of adult patients with mucopolysaccharidosis (MPS) VI. As part of Inventiva’s decision to focus its clinical efforts on the development of lanifibranor, Inventiva has suspended clinical efforts with odiparcil and is reviewing available options regarding its possible further development. Inventiva is in the process of selecting an oncology development candidate for its Hippo signaling pathway program.

The Company has a scientific team of approximately 80 people with in-depth expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, and clinical development. It has an extensive library of approximately 240,000 pharmacologically relevant molecules, of which approximately 60% are proprietary, as well as a wholly owned research and development center.

Inventiva is a public limited company listed on compartment C of the regulated market of Euronext Paris (ticker: IVA – ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). www.inventivapharma.com.


Important Notice

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included in this press release are forward-looking statements. These statements include, but are not limited toforecasts and estimates regarding Inventiva’s preclinical programs and clinical trials, including recruitment for such trials, publications of clinical trial data, including for part 1 of the Phase III clinical trial of lanifibranor in patients with NASH and two Phase II trials in patients with NAFLD and type 2 diabetes, and in combination with empagliflozin, preclinical and clinical development pipeline and plans, milestone payments, royalties and product sales, future business, Inventiva’s expectations, plans, growth and prospects and sufficiency of cash resources and Inventiva’s cash trail. Some of these statements, forecasts and estimates can be recognized by the use of words such as, but not limited to, “believes”, “anticipates”, “expects”, “intends”, ” plans”, “seeks”, “estimates”, “may”, “will”, “would”, “could”, “could”, “should”, “plan”, and “continue” and similar expressions. These statements are not historical facts, but rather statements of future expectations and other forward-looking statements based on the beliefs of management. These statements reflect opinions and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance or events to differ materially from those expressed or implied by these statements. Future events are difficult to predict and may depend on factors beyond Inventiva’s control. There can be no assurance with respect to pipeline product candidates that clinical trial results will be available within the expected timeframes, that future clinical trials will be initiated as planned, that the product candidates will receive the necessary regulatory approvals, or that any of the Inventiva’s or its partners’ milestones will be met on schedule, if at all. Actual results may differ materially from any anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates, due to a number of factors, including the fact that Inventiva is a clinical phase with no approved products and no historical product revenue, Inventiva has suffered significant losses since its inception, Inventiva has a limited operating history and has never generated revenue from product sales, Inventiva will need additional capital to fund its operations, Inventiva’s future success depends on successful clinical development, regulatory approval and subsequent commercialization of current and future product candidates, preclinical studies or prior clinical trials are not necessarily predictive of future results and the results of Inventiva’s clinical trials may not support the he claims of Inventiva’s product candidates, Inventiva may encounter significant delays in its clinical trials or Inventiva may not demonstrate safety and efficacy to the satisfaction of the relevant regulatory authorities, the recruitment and retention of patients in the trials clinical trials is an expensive and time-consuming process and could be made more difficult or impossible by multiple factors beyond Inventiva’s control, Inventiva’s product candidates may cause adverse drug reactions or have other properties that could delay or prevent their regulatory approval, or limit their commercial potential, Inventiva faces significant competition and Inventiva’s business, preclinical study and clinical development programs and schedules, its financial condition and its operating results could be materially and adversely affected by the current COVID-19 pandemic and geopolitical events, such as the conflict between Russia and Ukraine and the related and potential impacts on the timely initiation, recruitment and completion of Inventiva’s clinical trials . Given these risks and uncertainties, no representation is made as to the accuracy or correctness of such forward-looking statements, forecasts and estimates. Further, forward-looking statements, forecasts and estimates speak only as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements.

Please refer to the Universal Registration Document for the financial year ended December 31, 2021 filed with the Autorité des marchés financiers on March 11, 2022 and the Annual Report on Form 20-F for the financial year ended December 31, 2021 filed with the Securities and Exchange Commission on March 11, 2022 for additional information regarding such factors, risks and uncertainties.

All information contained in this press release speaks as of the date of the release. Except as required by law, Inventiva does not intend and has no obligation to update or revise the forward-looking statements mentioned above.

  • Inventiva – PR – ADA – PR – 03062022

Elevar Therapeutics adds Drs. Honghui Zhou and David Lilienfeld as Vice Presidents

News and research before you hear about it on CNBC and others. Claim your one week free trial for StreetInsider Premium here.

Biopharmaceutical company promotes Jennifer Lee to senior vice president of clinical operations, data management and biostatistics

SALT LAKE CITY, June 02, 2022 (GLOBE NEWSWIRE) — Elevar Therapeutics, Inc., a fully integrated biopharmaceutical company dedicated to improving treatment experiences and outcomes for patients who have limited or inadequate treatment options, announced today the hiring of Dr. David E. Lilienfeld as Vice President of Safety and Pharmacovigilance and Dr. Honghui Zhou as Vice President of Pharmacology.

Jennifer Lee, who joined Elevar in 2021 as Vice President of Clinical Operations and Data Management, has been promoted to Senior Vice President of Clinical Operations, Data Management and Biostatistics.

“We are fortunate to have someone of Dr. Lilienfeld’s stature to lead our drug safety operation, as he has worked for biotech companies at every stage of development and in a myriad of therapeutic areas, including oncology,” said Dr. Saeho Chong, Managing Director. from Elevar. “Dr. Zhou’s track record of providing end-to-end clinical pharmacology support for a long list of approved drugs will serve Elevar well as we work to bring our products to market.”

Lilienfeld comes to Elevar from Recursion Pharmaceuticals, where he was senior director of safety, pharmacovigilance and epidemiology. Recursion is a public biotechnology company that uses machine learning for the optimization of drug candidates. For more than a decade, he was also a principal at Write for the Pharm, LLC, a biotechnology/pharmaceutical/medical device consulting firm.

Author or co-author of more than 100 articles or book chapters, Lilienfeld is a member of the American College of Epidemiology, the American Heart Association and the International Society for Pharmacoepidemiology (of which he was one of three co-founders in 1985), and has an active medical license in California. He earned a Master of Business Administration, Master of Science in Engineering (Statistical Computing), and Bachelor of Arts (Public Health Opinion) from Johns Hopkins University, as well as a Master of Public Health in Epidemiology from Johns Hopkins University. ‘University of Minnesota. and an MD from the University of Maryland.

Zhou, a seasoned clinical pharmacologist and pharmacometrician, joins Elevar after more than 18 years in increasing leadership roles in clinical pharmacology, pharmacometrics, and pharmacological and translational modeling at Johnson & Johnson (Janssen). As US Head of Pharmacometrics at Janssen since 2018, Zhou has overseen more than 20 pharmacometricians who have supported Janssen’s portfolio across multiple therapeutic areas including Oncology/Hematology, Immunology, and Cardiovascular/Metabolic Diseases.

Zhou is board certified by the American Board of Clinical Pharmacology and was elected a Fellow of the American Association of Pharmaceutical Scientists (FAAPS) and a Fellow of Clinical Pharmacology (FCP) by the American College of Clinical Pharmacology (ACCP). Recently, he received the 2022 Nathaniel T. Kwit Memorial Distinguished Service Award from CACP. He obtained a doctorate. in Pharmacy from the University of Iowa and a B.Pharm in Pharmacology from China Pharmaceutical University.

Lee, who joined Elevar in September from Radius Health, Inc., is responsible for providing operational expertise on the strategy, design, execution, and data interpretation of late-stage solid tumor clinical programs. ‘Elevate. She has over 25 years of life science experience in developing clinical strategies in new products, initiating new drug applications, launching new products and leading phase I-IV clinical operations. for small molecules, biologics, and cell and gene therapy for multiple therapeutic areas. . Lee has accelerated numerous therapies, resulting in the approval of seven new treatments and has been instrumental in advancing product candidates through labeling changes, licensing agreements and market applications.

“Jennifer has already made an immeasurable contribution to Elevar’s clinical development program in her short time with the company,” said Chong. “We are excited to expand his role in advancing our therapies, bringing us closer to fulfilling our promise to address the unmet needs of cancer patients.”

Lee received a Master of Science in Clinical Research and Regulatory Administration from Northwestern University and a Bachelor of Science in Biochemistry from the University of Illinois at Chicago.

About Elevar Therapeutics

Elevar Therapeutics is a rapidly growing, fully integrated biopharmaceutical company built on the promise of improving treatment experiences and outcomes for patients who have limited or inadequate treatment options. Elevar’s lead proprietary drug candidates include rivoceranib (apatinib) and Apealea® (micellar paclitaxel). Rivoceranib is the first small molecule tyrosine kinase inhibitor (TKI) to be approved for gastric cancer (China, December 2014). It has received orphan drug designation in the United States, Europe and South Korea and has been clinically tested on over 1,000 patients worldwide in numerous cancer indications. Apealea® (micellar paclitaxel) is a non-Cremophor EL formulation of paclitaxel which received marketing authorization from the European Commission in November 2018, making it the first European non-Cremophor EL formulation of paclitaxel approved for use in ovarian cancer. Elevar Therapeutics has offices in Utah, California, and South Korea, and additional information is available at www.elevartherapeutics.com.

Photos accompanying this ad are available athttps://www.globenewswire.com/NewsRoom/AttachmentNg/4507003a-fa15-4739-9280-8948f1d05ef5https://www.globenewswire.com/NewsRoom/AttachmentNg/045cbe00-d17e-4005-9dec-690c01645294https://www.globenewswire.com/NewsRoom/AttachmentNg/e7f88b88-293b-4b1f-a301-2ddd4a165262


Jennifer Leckstrom
(215) 681-0770
[email protected]

main logo

Honghui Zhou

Elevar Therapeutics adds Dr. Honghui Zhou as Vice President.

David Lilienfeld

Elevar Therapeutics adds Dr. David Lilienfeld as Vice President.

Jennifer Lee

Jennifer Lee, who joined Elevar in 2021 as Vice President of Clinical Operations and Data Management, has been promoted to Senior Vice President of Clinical Operations, Data Management and Biostatistics.

Source: Elevar Therapeutics

NLA 2022 will feature new statin intolerance guidelines, award-winning abstracts, and more.



Healio Interviews

Disclosures: Saseen does not report any relevant financial information.

We have not been able to process your request. Please try again later. If you continue to have this problem, please contact [email protected]

The National Lipid Association Science Sessions will be held today through Saturday and will highlight statements on muscle symptoms associated with statins, sessions focused on translational and implementation science, and more.

Healio spoke with the president of the National Lipid Association (NLA) Joseph Saseen, PharmDAssociate Dean for Clinical Affairs, Professor in the Department of Clinical Pharmacy and Department of Family Medicine at Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, on some of this year’s featured topics and what attendees can hope to harvest sessions.

microphone in meeting

Source: Adobe Stock

“It is the right time [for NLA]. Even if we remain on our guard and [COVID-19] precautions in place, like requiring vaccinations, we are all thrilled and excited to have an annual face-to-face live meeting again,” Saseen told Healio. “Our desire with our scientific sessions to have content that applies to our diverse population of members, which includes clinical pharmacists, dietitians, nurses, physicians, physician assistants and clinical scientists…and many of our sessions convey this broad perspective.

Joseph Saeen

“Our opening session will focus on assessing the evidence supporting non-statin treatment in patients with statin-associated muscle symptoms,” said Saseen. “We’re going to use a fun approach where we have four people presenting evidence with four different treatment options and then we’re going to discuss a case presentation broadly and use audience polls and panel discussions to spice it all up.”

The NLA’s keynote session, “Expert Analysis: Evidence Supporting Non-Statin Therapies in a Patient with Statin-Associated Muscle Symptoms (SAMS),” will take place today at 4:00 p.m. MST.

“Another thing that you might not see in many sessions is this session on translating evidence into practice or translational or implementation science on Friday morning,” Saseen told Healio. “It reviews things like effective communication strategies, optimizing your electronic health record, and using new approaches to improve care, not just of an individual patient, but of your patient population. .

On Saturday, three last-minute clinical trials will be presented:

  • Apolipoprotein B and lipoprotein (a) in atherosclerotic cardiovascular disease risk categories in Hispanic/Latino people residing in the United States: results from the Hispanic Community Health Study/Latino Study (HCHS/SOL) – presented by Parag H. Joshi, MD, MHS;
  • Obicetrapib lowers LDL-C in patients taking high-intensity statins – Results from the ROSE clinical trial – presented by Michael H. Davidson, MD, FACC, FNLA; and
  • Reduction of ischemic events, including cardiovascular mortality, with icosapent ethyl in patients with a history of myocardial infarction: REDUCE-IT PRIOR MI – presented by Prakriti Gaba, MD.

“We also have our science abstracts where we hope to present cutting-edge science, but we have a lot of our other sessions,” Saseen told Healio. “We have sessions aimed at clinicians, such as different perspectives on treatment options; session on drug-related misadventures; we have a Diversity, Equity and Inclusion (DEI) session to give our audience members tips on how to improve their DEI efforts, whether it’s a training program or providing more IED-focused wellness care.

Among nearly 40 scientific abstracts that will be presented during NLA, the following four will be oral presentations:

  • Universal screening for familial hypercholesterolemia in two populations – presented by Urh Groselj, MD;
  • A Novel ABCG8 Variant and Apo(A) Short Isoform Associated with Premature Atherosclerosis and Familial Hypercholesterolemia Phenocopy – presented by Loba Alam, MD;
  • An unresolved case: HF or sitosterolemia? – presented by Juliette Logan, MD, the first Young Investigator Award winner and first oral presenter; and
  • Gender Disparities in Familial Hypercholesterolemia Treatment and Outcomes – presented by Amanda Guerin, BScDonald Hunninghake, MD, Familial Hypercholesterolemia Award Winner

“Maybe the icing on the cake is that we’re going to have a session called science statements, and we’re going to release our science statement on statin intolerance, which we’re really excited about. Journal of Clinical Pathology that morning,” Saseen told Healio.

The statement on statin intolerance will be presented by Kevin C. Maki, PhD, CLS, FNLA, the new president of the ALN, Saturday at 9 a.m. MST.

Also presented will be a scientific statement titled “Non-Alcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement from the American Heart Association”. This statement will be presented by P. Barton Duell, MD, FNLA, Saturdays at 9:30 a.m. MST.

Healio is a media partner of the NLA Scientific Sessions. The Healio team will provide coverage of the meeting, including reports on the above sessions and more. Follow this link and on Twitter at @CardiologyToday. For more information about the NLA, visit www.lipid.org/meetings/sessions/home.

the new wonder drug against lung cancer?

Researchers have found that berberine, a natural compound, effectively fights cancer cells in in vitro tests.

As lung cancer is widely recognized As the leading cause of cancer death in both men and women, the global scientific community continues to exert tremendous efforts to find ways to treat the disease.

Scientists have found a sign of hope, however. A study of berberine, a natural compound found in plants such as barberry and goldenseal, concludes that this herbal treatment may have a suppressive effect on lung cancer.

The study finds that in in vitro trials, berberine “suppress the proliferation of lung cancer cells in the laboratory, new research suggests. It also reduces airway inflammation and damage to healthy lung cells exposed to chemicals in cigarette smoke,” a statement Press Remarks.

In 2020, an estimated 1,796,144 people died worldwide from lung cancer, according

“Berberine has shown therapeutic benefits for diabetes and cardiovascular disease. We wanted to explore its potential to suppress lung cancer and reduce inflammation,” says lead researcher Dr. Kamal Dua, senior lecturer in pharmacy at the University of Technology Sydney (UTS) in Australia.

The study exploring the effect of berberine on non-small cell lung cancer was published in the journal Pharmacy. Dua and colleagues found that “berberine exhibits potent anti-cancer activity, suppressing the growth of cancer cells in vitro“, explains the press release.

How berberine works to fight cancer was determined by measuring mRNA levels of tumor-associated genes and protein expression levels. The study found that the natural compound stimulates tumor suppressor genes and reduces proteins involved in cancer cell migration and proliferation.

Dua had published in April 2022 another research study in Antioxidants. The researchers of this earlier study write: “In our study, we explored whether treatment with liquid crystalline nanoparticles loaded with berberine (an alkaloid) (berberine-LCN) on human bronchoepithelial cells and macrophages inhibits stress. oxidative, inflammation and senescence. induced by cigarette smoke extract.

Researchers conducting the April 2022 study found that “may inhibit oxidative stress and reduce cigarette smoke extract-induced inflammation and cellular senescence in laboratory-cultured healthy human lung cells,” notes the Press release.

WebMD, berberine is good for a number of conditions, including diabetes, high cholesterol, and high blood pressure. Berberine has also been used for centuries in traditional Chinese and Ayurvedic medicine.

Yet the plant extract is limited in its therapeutic benefits because it is not water soluble and is not easily absorbed in the gut. It is also toxic in high doses and not recommended for infants and pregnant women.

Due to these drawbacks, Dua has developed a different delivery system for berberine that relies on liquid crystalline nanoparticles, an advanced method that encapsulates berberine in tiny soluble and biodegradable polymer beads, improving safety and efficiency.

“Cigarettes can damage lung tissue, impairing its ability to function properly, and may increase the risk of diseases such as emphysema, lung cancer and chronic obstructive pulmonary disease (COPD)”, Explain the United States Food and Drug Administration (FDA).

According to the press release, researchers found that “berberine suppressed the generation of inflammatory chemicals, called reactive oxygen species, which cause damaging effects on cells. It also modulated genes involved in inflammation. , oxidative stress and reduction of premature cells. senescence.”

Researchers are now trying to translate the results of this study into something that will benefit as many patients as possible. They are working to find the best formulation and delivery system for these nanoparticles so that pharmaceutical companies can offer berberine in a potent yet non-toxic form to the public.

Source: TRTWorld and agencies

A multidisciplinary approach is essential for the implementation and optimization of biosimilars

Healthcare systems need to implement a flexible workflow to enable the use of non-preferred agents to meet payer demands and reduce financial toxicity.

Competition from biosimilars in the US market has led to a significant reduction in healthcare spending. Biosimilars are assigned unique HCPCS (Healthcare Common Procedure Coding System) codes by the Centers for Medicare and Medicaid Services (CMS) and there are currently few AB-rated interchangeable products on the market.

These factors create logistical barriers to how to successfully integrate biosimilars into health system practice.

Additionally, due to variable coverage and payer demands, healthcare systems must have a flexible workflow to enable the use of non-preferred agents to meet payer demands and reduce financial toxicity for the health system and patients.


Formation of multidisciplinary teams and buy-in from stakeholders

Creating and maintaining a multidisciplinary team that understands the biosimilar strategy and is invested in the success of the project is critical. At Mayo Clinic, our multidisciplinary group for biosimilars implementation includes supply chain management, pharmaceutical contracts and formulary, revenue cycle prior authorization (PA), pharmaceutical operations, pharmaceutical informatics and practice, pharmacy and nursing leadership.

Our biosimilars implementation project focused on 5 biologic categories, including bevacizumab (Avastin), epoetin alfa (Epogen, Procrit), filgrastim (Neupogen), rituximab (Rituxan), and trastuzumab (Herceptin). First, we educated vendors on the FDA biosimilar regulatory approval pathway and achieved consensus that the biosimilars were just as safe and effective as the reference products.

Second, we described the financial implications with an emphasis on reduced healthcare costs, CMS reimbursement of biosimilars, and financial benefits for 340B sites. Third, we got feedback from AP teams to understand what our major commercial payers required.

Our AP team confirmed that many commercial payers require the use of biosimilars but do not require the use of a specific biosimilar. The multidisciplinary team, with agreement from key stakeholders, agreed on a biosimilar-first strategy with a collective goal of reducing the overall cost of care for drug classes with biosimilar competition.

We then leveraged the agreement of equivalent safety and efficacy between biosimilars and reference products, while understanding that our major commercial payers required biosimilars, but not specific biosimilars, to complete a comprehensive offering in the 5 categories of organic products with an emphasis on the product with the lowest net cost. and advantageous contractual conditions.

Once the contract was concluded, we selected the preferred biosimilars from the formulary in each pharmaceutical category. In line with our goal of reducing the overall cost of healthcare and putting the needs of the patient first, discount purchase contracts were used, from which the savings were passed on to payers and patients.


Our next step was to determine how to operationalize the use of biosimilars and develop a flexible workflow to replace biosimilars. Because there were no interchangeable FDA-approved biosimilars in the 5 biologic categories we targeted, we checked the state board of pharmacy rules for each state in which the Mayo Clinic operates and decided that therapeutic substitution would be an appropriate strategy for effective implementation of biosimilars.

We then established a workflow between the pharmacy and PA teams to facilitate biosimilar therapeutic exchange while responding to payer requests (Figure 1).

In collaboration with colleagues from pharmaceutical informatics, we have optimized the EHR control pathways. As part of the hematology-oncology ordering pathway, we had the ability to default our preferred biosimilars to the form and use advanced control panels to access non-preferred biosimilars and reference products.

The ability to default to accelerated use of biosimilars in hematology and oncology settings and reduce workload. As part of the inpatient and outpatient infusion ordering pathways, we did not have the ability to default formulary preferred biosimilars, so we sequenced preferred agents first with “Preferred” notation and non-preferred agents thereafter with “restricted” notation.

Regardless of the order route, the ability to switch to a non-preferred alternative product by leveraging pharmacist-driven therapeutic exchange was relevant to meeting payer demand and reducing financial risk for healthcare facilities. health and patients. Once the implementation was planned, providers were asked to introduce new patients to biosimilars.

For patients currently on a reference biologic, they were asked to consider switching these patients to a biosimilar upon PA renewal.

Success Monitoring

We tracked drug units and pharmaceutical expenditures for reference and biosimilars in each therapeutic class at baseline before EHR implementation and every 3 months after EHR implementation using historical information purchases from our main wholesaler. For the trastuzumab category, we had to use a conversion factor because reference trastuzumab is supplied in 150 mg single dose vials and biosimilars are supplied in 150 mg single dose or 420 mg multidose vials.

If there was an issue, we used EHR reporting tools to determine root causes. We then made additional changes to EHR optimization, communicated directly to specific practices for proactive order conversion, and leveraged frontline pharmacy staff to optimize conversion, especially for practice sites. 340B.


Comparing the quarterly average market share from baseline to the final post-implementation measurement period, the absolute percentage increase in the use of preferred biosimilars in the formulary was 69% for bevacizumab, 63% for epoetin alfa, 80% for filgrastim, 79% for rituximab, and 72% for trastuzumab.

The corresponding reduction in spending in each category comparing the baseline at 12 months post-implementation was $3.175 million for bevacizumab, $323,269 million for epoetin alfa, $1.158 million for filgrastim, $12.993 million for rituximab and $5.444 million for trastuzumab (Table 1).

In the 12 months following the implementation of the biosimilars first strategy at Mayo Clinic, savings of $23.1 million on pharmaceutical items were achieved, representing a reduction in expenses of 24.3% .


Creating a multidisciplinary group, optimizing the EHR, and a flexible workflow using pharmacist-driven therapeutic exchange is an effective strategy to accelerate the use of biosimilars within a healthcare facility and achieve significant savings on pharmaceutical items.


Jensen Chelsee J, Tichy Eric M, Lempke Mary B, Ewald Adam M, Erickson Sara J, Holm Michelle R, Soefje Scott A. Implementing and optimizing the use of biosimilars at Mayo Clinic. Mayo Clinic Proceedings, 2022, ISSN 0025-6196, https://doi.org/10.1016/j.mayocp.2022.02.015

JPS Health Network moves forward with $1.2 billion modernization and expansion plan in Tarrant County

JPS Health Network serves all of Tarrant County, but its main campus is located at 1500 S. Main St. in Fort Worth. (Courtesy of JPS Health Network)

JPS Health Network is accepting bids from an at-risk construction manager for a new psychiatric emergency center in Fort Worth.

The project is funded under the Tarrant County Hospital District’s $800 million bond program that was approved by voters in 2018. JPS Health Network plans to invest an additional $400 million in its operations for a combined $1.2 billion modernization and expansion plan.

“When it comes to bond work, there continues to be a lot of work going on,” Dr. Karen Duncan, president and CEO of JPS Health Network, told Tarrant County Commissioners in May. . “There have been a lot of calls for tenders [requests for proposals] and tenders [requests for qualifications] who came out. We had a great response.

The master plan calls for four phases of improvements to the hospital’s main campus at 1500 S. Main St. in Fort Worth. Plans include eight new buildings or parking structures as well as the expansion of two existing buildings and additional parking lots, according to the plans. There will also be four medical homes, or clinics, funded through the planned expansion.

The new building that will temporarily house the Psychiatric Emergency Center will be located on the hospital’s main campus. The center is being built to add more space and meet a “short-term critical need”, according to hospital officials. The center will then be integrated into a new behavioral health inpatient hospital that will be constructed in Phase 4. The new center building will then be redeveloped.

The first project to be funded by the bond program will be one of four planned medical homes. These clinics offer multiple services, including primary care, radiology, laboratory, pharmacy, dental and behavioral health, in one building.

The hospital network’s newest clinic, Medical Home Northeast Tarrant in Euless, opened in October 2018.

The next new medical home will be in the far southwest of Fort Worth. Duncan told the commissioners that contract terms for the property were being finalized before the location was announced.

The locations of the other three new medical homes will be determined based on need, hospital officials said.

JPS Health Network operates the only Level I trauma center in Tarrant County and the only psychiatric emergency center in the county. The Hospital District receives nearly 40% of its operating revenue from property taxes collected throughout Tarrant County, according to its fiscal year 2021-22 budget. His tax rate last year was $0.224429 per $100 of assessment.

As part of its broader bond program, JPS Health Network is conducting an online survey of Tarrant County residents. The 20-question survey solicits “feedback and ideas on how they use area medical facilities and provides feedback on how JPS can provide health facilities and resources that meet their needs,” according to a press release.

Residents who wish to complete the survey can visit www.yestojps.org/engagement to do so.

Dicot AB begins research collaboration with Uppsala University and the W. Szafer Institute of Botany

Press release: Uppsala, May 31, 2022. Dicot AB is developing the drug candidate LIB-01, which will be a powerful agent to better treat erectile dysfunction and premature ejaculation. Dicot announces today that the company has entered into a research collaboration with Uppsala University and the W. Szafer Institute of Botany of the polish academy of sciences (PAS) to study a new technology to manufacture starting material for the production of the drug substance.

Dicot is developing a powerful new drug intended to be the first choice for the treatment of erectile dysfunction and premature ejaculation. The drug candidate LIB-01 contains an active substance of natural origin. As part of the preparation for the future commercialization of LIB-01 in the global market, the company has now entered into a research collaboration with Uppsala University and the W. Szafer Institute of Botany PAS.

The collaboration aims to determine if the starting material for the drug substance in LIB-01 can be obtained using plant cells cultured in cultures. It is a proven technology for the sustainable large-scale commercial supply of medicines from nature.

Teacher Ulf Goransson, Uppsala Universityand Dr. Błażej Ślązak from W. Szafer Institute of Botany PAS currently working in Uppsala, both experts in the field of pharmacognosy, will lead the research project. The founder of Dicot, Professor Jarl Wikbergis also involved in the collaboration.

The collaboration aims to demonstrate proof of concept and is a year-long research project to test the technology with Dicot’s plant material at laboratory scale. If this is successful, it will be followed by further evaluations. The project will be executed in parallel with the current manufacturing process already established where the plant material, seeds, is used to extract the starting material for the production of the drug substance.

“- It is important to prepare and prepare the ground for a future successful global launch. This research project is very interesting because it can open up new commercial sourcing opportunities in addition to the already established method. As a company in development, we are constantly evaluating different alternatives to develop cost-effective solutions in all areas,” says Elin TrampeCEO of Dicot.

For more information, please contact:

Elin TrampeCEO
Tel: +46 739 80 14 08
Email: [email protected]

About Dicot AB

Dicot is developing the drug candidate LIB-01, which will be a powerful agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with a significantly longer effect and far fewer side effects, compared to those on the market. Today, at least 500 million men suffer from these sexual dysfunctions and the market is valued at 50 billion Swedish crowns. Research and development is conducted under its own auspices up to phase 2 studies. Thereafter, Dicot’s intention is to form strategic alliances, or alternatively make a commercial sale, with larger established pharmaceutical companies. to be able to introduce LIB-01 to the global market.

Dicot is listed on Stock market and has approximately 3,300 shareholders. For more information, go to www.dicot.se.

https://news.cision.com/dicot-ab–publ-/r/dicot-ab-enters-research-collaboration-with-uppsala-university-and-the-w–szafer-institute-of-botany ,c3577167


(c) Decision 2022. All rights reserved., sources Press Releases – English

University of Utah discovery with soft sea corals could lead to cancer treatment

Soft corals are thought to manufacture thousands of drug-like compounds that could work as anti-inflammatory agents, antibiotics, cancer therapeutics, and other drugs. University of Utah Health researchers have discovered how to duplicate a compound that could be used in cancer treatments; a study of their research was published on Monday. (Bailey Miller, Utah University of Health)

Estimated reading time: 3-4 minutes

SALT LAKE CITY – Researchers at the University of Utah Health have been able to duplicate a compound found in soft marine corals that is thought to be a natural chemical for cancer treatment.

“This is the first time we’ve been able to do this with any drug in mind on Earth,” said Eric Schmidt, professor of medicinal chemistry at the University of Utah.

Schmidt said his lab focuses on how bacteria in animals and the microbiome make compounds that can be used in medicines; their findings on these soft corals were published Monday in Nature Chemical Biology.

He said a postdoctoral fellow who is the paper’s first author, Paul Scesa, grew up in Florida and is interested in the local biodiversity there. He obtained the animal, brought it to the Utah lab and worked on the project.

“My hope is to hand them over to a doctor one day,” Scesa said. in a University of Utah article on health. “I think it goes from the bottom of the ocean to the bench at the bedside.”

Schmidt said the compound, called eleutherobin, was discovered about 25 years ago and researchers determined it might be beneficial for treating cancer, but there wasn’t enough to do. advance the process.

In this study, they learned how corals make the compound and solved the problem of how to reproduce it using organisms in a lab.

The ability to duplicate the compounds created by these corals will allow more research to be done to determine its effectiveness in treating cancer. Schmidt says their new goal is to produce enough to allow studies to determine effectiveness and lay the groundwork for further research.

This discovery could lead to research into thousands of other compounds found in corals. Schmidt said a group from the University of California, San Diego, which helped them with the study, is studying other compounds.

The University of Utah Health Article said these other compounds could work as anti-inflammatory agents, antibiotics or other drugs. Corals use compounds to ward off predators that try to eat them, so they produce edible compounds and the drugs created from them can probably be taken as pills rather than injected.

“These compounds are harder to find, but they’re easier to make in the lab and easier to take as medicine,” Schmidt said.

He said humans and animals usually get complicated chemicals from the food they eat or bacteria living in it, rather than producing them themselves, which means it’s unique and could open more opportunities for discovery.

“What was really amazing for us was to see that animals can make these complex, bioactive compounds. Normally these are associated with plants or microbes,” Schmidt said.

Schmidt said recent advances in synthetic biology made this discovery possible because marine corals could not be cared for and bred in the lab, which was previously necessary.

“What synthetic biology does is it allows us to rewrite the genes that are in these animals, you know, without having to go out and do these really long and difficult studies,” Schmidt said.

This discovery is far from a cure for cancer at this stage, but it is a step in the right direction.

Schmidt says they don’t know when an effective drug might come from this discovery, but he said if it all works out and it’s as promising as originally thought when the compound was discovered, a drug might come from the compound. in about five years. .


Emily Ashcraft joined KSL.com as a reporter in 2021. She covers court and legal affairs, as well as health, faith and religion news.

More stories that might interest you

NAFDAC, Iwu tea and detox

The coronavirus (Covid-19) outbreak in 2020 has pushed scientific research efforts around the world to the limit. Most of the developed countries, with their advancement in medical sciences, have been caught off guard by the devastation caused by this virus which has literally paralyzed the international community. There was the problem of understanding the nature of the virus to know how to manage its effect on humans.

The challenge he posed, however, brought out the best in humanity as a whole. It has also given rise to a kind of unprecedented response which has slowed its spread even if the virus itself, in its mutant form, still presents itself as a source of concern.

Many countries encourage local efforts to combat the virus and its impact on the health system, applying remedies that take due advantage of local resources that lead to people’s cultural and traditional particularities. Nigeria, through the Central Bank of Nigeria (CBN), has stepped in by making available large sums of money for research and development in the region.

It is in this context that we express our reservation on the position of the National Agency for Food and Drug Administration and Control (NAFDAC) on phytotherapy (IHP Detox) for Covid-19 developed by an internationally renowned Professor of Pharmacognosy, Professor Maurice Iwu. The former Chairman of the Independent National Electoral Commission (INEC) is currently Director General of Bioresource Development and Conservative Program.

In rejecting the herbal remedy, NAFDAC said it was the only agency authorized by law to rule on the safety and efficacy of all regulated products with satisfactory scientific evidence (clinical trial). This, certainly, is under no pretext. The problem is that, given the notorious delays of the country’s bureaucracy, or for that matter the unhealthy nuances within that official organization, the sample may either not come to light as quickly as it needs to, or become a useless, controversial tool that can kill it completely.

It is in this spirit that this newspaper must recall that the nation has already been there. Immediately after the civil war, cholera was then ravaging Central East State which was just emerging from a 30-month war that left all infrastructure in total disrepair. Professor of Medical Microbiology at the University of Nigeria (UNTH) Teaching Hospital, Enugu, Professor Augustine Njoku-Obi went to work in his lab and quickly developed a cholera vaccine.

In the same way that NAFDAC is trying to bring down Iwu’s product, certain figures in the Federal Ministry of Health, in collusion with the powerful Lagos-Ibadan press, have discredited Njoku-Obi’s scientific effort. A sample he submitted was allegedly tampered with on its way to the World Health Organization (WHO) for verification. Of course, he failed the WHO test.

Undeterred by the vile propaganda attached to it, and certain of the efficacy of the product of his scientific endeavor, Njoku-Obi continued to use the vaccine on his own people in the state and it was effective in the water bone disease control.

Interestingly, in our opinion, years later another country had an experience of cholera and the WHO referred it to Nigeria. Professor Olikoye Ransom-Kuti was then Minister of Health. He, in turn, referred this country to the same Professor Njoku-Obi and his product previously rejected by Nigerian health authorities. The vaccine made in Nigeria has become the saving grace of this foreign country in the fight against cholera.

We are sure to make this reference and wonder why there is this tendency to look at anything Nigerian with disdain and suspicion. Most of the first vaccines used in Nigeria against Covid-19 were given from abroad. Most of them were made in India. They were actually celebrated as a gift from God to the nation and a response to the rampaging virus. Authorities were eager to welcome such products which in some cases had reached their expiry date without subjecting them to the same scrutiny perceived as similar products by Nigerian scientists.

For the avoidance of doubt, we are in no way suggesting that standards should be compromised to satisfy the local sentiment at stake. Our argument is that Nigerian scientists deserve recognition for their concern to contribute to national development from their own point of view. seen.

Anyone who reads NAFDAC’s denial of Iwu’s detox will feel like poison is lying in wait. He barely acknowledges, let alone acknowledges, the fact that someone’s intellectual acumen must be acknowledged and respected before he rushes in to unduly ridicule him under the guise of protecting the imaginary public interest.

Topical ocular administration of progesterone may be a viable treatment for retinitis pigmentosa

Retinitis pigmentosa is a degenerative disease affecting the photoreceptor cells of the retina, called cones and rods. Of genetic origin, this disease first affects vision in low light conditions, then progressively affects peripheral vision and the central visual field until total loss of sight, as cells die. photoreceptors. Noting recent research on the role of hormones, particularly progesterone, in preventing cell death due to oxidative stress, the CEU UCH Drug Delivery Systems (DDS) research group has developed and successfully tested a range of methods to administration of this hormone to the eye to slow down the degenerative process characteristic of retinitis pigmentosa.

The research undertaken by the team is detailed in Dr. Adrián Alambiaga’s doctoral thesis, directed by Professor Alicia López Castellano and Dr. Aracely Calatayud, and which he successfully defended at CEU in April. His findings, already published in several journals, show that progesterone can be delivered in various forms, such as eye drops, micelles and inserts, in sufficient quantity to penetrate the surface of the eye and reach the neuroretina without causing toxicity or significant irritation.

The use of ocular inserts makes it possible to deliver progesterone in greater quantities than when using aqueous solutions. Although we have seen that aqueous solutions can also permeate the sclera and cornea, the inserts performed best in our tests, as they release progesterone for uptake by the neuroretina over a longer and greater period of time. amount.”

Dr Adrian Alambiaga

Topical administration, the best option

Progesterone is practically insoluble in water and dissolves only slowly and incompletely in gastrointestinal fluids. This means that when taken orally, it quickly becomes ineffective. Also, high levels of progesterone must be taken orally so that only a small amount can reach the eye. “That’s why it was important to study the different ways to deliver progesterone topically or locally in the eye, thus limiting the amount to be administered.”

During his doctoral research, Dr. Alambiaga, under the guidance of Prof. López Castellano and Dr. Calatayud, developed a range of pharmaceutical formulations of progesterone for topical administration to the eye. These included aqueous solutions, which increase the durability and diffusion of molecules on the ocular surface, and ocular inserts, which increase the contact time of the drug on the ocular surface, increase the availability of the drug in the body and allow controlled release, more precise dosages and less frequent administration.

New treatment strategies

For the principal researcher of the group, Professor Alicia López Castellano, specialized in pharmaceutical technology at the CEU UCH, Dr. Alambiaga’s thesis shows that “we have demonstrated for the first time that the topical administration of progesterone in the eye is viable. strategies for patients with retinitis pigmentosa and, by extension, for patients with other eye conditions in which oxidative stress is a risk factor, such as glaucoma, age-related macular degeneration, macular edema due to retinal vein occlusion, cytomegalovirus retinitis, posterior uveitis and diabetic retinopathy.”

Parts of Dr. Adrián Alambiaga’s thesis have been published as research articles in journals such as Pharmacythe Journal of Pharmaceuticals and Biomedical Analysis, and the International Journal of Pharmacy.


Journal reference:

Alambiaga-Caravaca, AM, et al. (2022) Topical ocular administration of progesterone decreases photoreceptor cell death in mice with slow retinal degeneration (rds). Medications. doi.org/10.3390/ph15030328.

ASU’s downtown campus in Phoenix will forego parking and retain multiple buildings

More than 15 years after Phoenix voters approved bonds to fund the construction of ASU downtown, the city will take control of several parking lots used by the university.

When the city made a financial commitment to support the state university, a detailed intergovernmental agreement and master lease was signed. The lease included six city-owned lots at the southeast corner of McKinley and First streets that ASU was to use for parking and future development. Now Phoenix wants them back and Councilwoman Yassamin Ansari has an idea.

“There’s no doubt in anyone’s mind that affordable housing is a huge need, especially downtown,” she said at a recent subcommittee meeting.

Christine Mackay, the city’s director of economic development, said city council would decide how the land would be used and ASU would no longer have any rights other than temporary parking. She told subcommittee members that her department could study the board’s preferences and options this summer and present the board with a request for proposal to consider this fall.

In exchange, ASU will retain six buildings that make up the Mercado at Fifth and Van Buren streets rather than transferring ownership to the city as originally planned.

“As it exists today, although Mercado in 2024 would come into city use, ASU still has the right to develop it and still has the right to continue moving forward and they would have rights to our McKinley lots “, Mackay said. “It allows them to have the right to develop on their own property that they own today and the council to make a different decision – the council today, with information that is now 17 years later to make a different decision for McKinley.”

The Mercado is home to various educational programs and is part of the Phoenix Biomedical Campus, limiting uses to accommodate the educational and healthcare environment.

Here’s how a city budget document explained the 2006 voter-approved bond plans:

The $237.9 million economic development program is funded through 2006 bonds, community reinvestment funds and non-profit corporate bond funding.

This program includes downtown and citywide economic development projects.

Downtown projects include land acquisition, renovation of three existing buildings, and design and construction of new facilities on a 20-acre downtown site for ASU Downtown, design of the new College of Pharmacy in the University of Arizona and the improvement of the infrastructures of the biomedical campus of Phoenix.

Land acquisition and site preparation near the city center for the expansion of the Life Sciences Research Park is also planned. Other projects include land acquisition for the Fillmore property, equipment acquisition for the Translational Genomics Institute (TGEN)/International Genomics Consortium (IGC) project, and downtown infrastructure improvements for sidewalks , landscaping and lighting, business redevelopment and artistic improvements.

The citywide economic development program is funded by 2006 bonds. Planned projects include revitalizing public infrastructure on the west side of the city, assisting small high schools targeted with specific career development and property acquisition for the relocation of the state fairgrounds.

Seven MBCC seniors get medical certifications – Press and Guide

Seven health science students at the Michael Berry Career Center have earned medical certifications. Students have passed their certification exams and leave their high schools with not just a diploma, but a nationally recognized credential.

Reame Alduais, Lara Nasseredine, and Nour Mazloum, all of Fordson High, earned their Certified Clinical Physician Assistant through the Michael Berry Career Center. (Photo courtesy of Dearborn Public Schools)

Students include:

• Ali Yassine, CPhT (Dearborn High)
• Reame Alduais, CCMA (Fordson High)
• Nour Mazloum, CCMA (Fordson High)
• Lara Nassereddine, CCMA (Fordson High)
• Zahraa Achi, CCMA (Fordson High)
• Shajan Alhilfi, CCMA (Dearborn High)
•Sarah Murshed, CCMA (Edsel Ford High)
Ali Yassine (DHS) completed the Allied Health the Pharmacy Technician program at MBCC and obtained the PTCB Certified Pharmacy Technician (CPhT) certificate which allows him to work in any pharmacy in the country.

He is continuing his studies at Henry Ford College next year and then plans to transfer to the biomedical engineering program at the University of Michigan – Ann Arbor.

Students sit on a bench
Sara Murshed (Edsel Ford), Shajan Alhilfi (Dearborn High), and Zahraa Achi (Fordson) all earned their Certified Clinical Physician Assistant certification through the Michael Berry Career Center. (Photo courtesy of Dearborn Public Schools)
Student in a classroom
Ali Yassine, a senior from Dearborn High, earned his Certified Pharmacy Technician certificate through the Michael Berry Career Center. (Photo courtesy of Dearborn Public Schools)

This is the first year that Advanced Allied Health – Medical Assisting students have qualified to take the Certified Clinical Medical Assistant (CCMA) exam offered by the National Healthcareer Association (NHA).

These six exceptional seniors have already obtained the certificate. (Juniors will take the exam during finals week in June.)

Notably, Shajan Alkilfi (Dearborn High used her 120 hours of clerkship in a physician’s office to land a physician assistant position while completing the course. After earning the certificate and becoming a certified physician assistant, she immediately received a increase of $2 and recognition of his accomplishment by his employer’s medical practice.

Michael Berry Career Center is a half-day program available to any qualified student attending one of our three traditional high schools – Fordson, Dearborn High or Edsel Ford. Bus transportation is provided between the secondary schools and the MBCC. Health is one of nine specialized career areas offered at MBCC.

All of these students plan to continue their studies in health or medicine in college and prepare for careers in these fields. These students represent the Michael Berry Career Center’s emphasis on “education with purpose.”

Source: Dearborn Public Schools

Anti-cancer compounds discovered in marine corals | News, Sports, Jobs

Jacquelyn Martin, Associated Press

In this July 20, 2010, file photo, a soft coral and brittle star, which were collected from the Gulf of Mexico, are displayed at the Smithsonian Museum Support Center in Suitland, MD.

Preserving the diversity of animals on Earth is extremely important because they contain a variety of compounds potentially vital to humans.

So said Eric Schmidt, a professor at the University of Utah, after his research team discovered that soft sea corals contain a promising anti-cancer compound.

Researchers have been looking for a natural chemical to treat cancer since the 1970s, Schmidt said. Now, they’ve discovered that easy-to-find soft corals are the elusive compound.

“This is the first time we’ve been able to do this with any drug on Earth,” Schmidt said. “Our breakthrough doesn’t treat cancer, but what it does do is provide the first step to really robustly delivering these compounds.”

Schmidt, a professor of medicinal chemistry at U of U Health and one of the lead researchers, said identifying the compounds allowed his team to find the DNA code in the animal. This then allowed them to perform the first steps of recreating the soft coral chemical in the lab, something that had never been done before.

This, he said, opens the door to further discoveries that could eventually produce the compound in quantities needed for extensive testing.

Another lead researcher and author, Paul Scesa, grew up in Florida where he spent a lot of time in the ocean.

Finding the compound — which ended up near his childhood playground — was one thing, Scesa said. Making a synthetic version in the lab was another.

“It’s like going into the dark and looking for an answer when you don’t know the question,” Schmidt said.

Researchers have found regions of coral DNA resembling genetic instructions for similar types of compounds from other species, according to a press release from U of U Health.

“After programming lab-grown bacteria to follow soft coral-specific coral DNA instructions, the microorganisms were able to replicate the first steps in transforming potential cancer into therapy,” the statement read.

The research has shown both that soft corals are the source of eleutherobin, a chemical that has been shown to have anticancer properties, and that researchers could make the compound synthetically in the lab.

“My hope is to hand them over to a doctor one day,” Scesa said.

Soft corals contain thousands of drug-like compounds, including anti-inflammatory agents and antibiotics, Schmidt said. While potentially life-saving, the findings weren’t entirely shocking – nature is teeming with millions of species known to have healing properties, including worms, snakes and even spiders.

“Half of all life-saving FDA-approved drugs come from nature,” Schmidt said. “What we’re doing right now is making sure that these compounds, using microbes in the lab, will provide enough to do the full evaluation to see if they really show promise in the fight against cancer.”


Join thousands of people who already receive our daily newsletter.

Design, synthesis, and evaluation of linker-optimized PSMA-targeting radioligands

This article was originally published here

Pharmacy. 2022 May 20;14(5):1098. doi: 10.3390/pharmaceutics14051098.


Prostate-specific membrane antigen (PSMA) is overexpressed in the majority of prostate cancer cells and is considered an important target for molecular imaging and treatment of prostate cancer. Here, we present the design, synthesis, and evaluation of 11 PSMA-binding radioligands with modified binding structures, focusing on the relationship between molecular structure and targeting properties. The linker design was based on 2-naphthyl-L-alanine-tranexamic acid, the binding structure of PSMA-617. X-ray crystal structure analysis of PSMA and structure-based design were used to generate the linker modifications, suggesting that tranexamic acid substitution may result in interactions with Phe546, Trp541 and Arg43 in the connecting cavity. After synthesis by SPPS, the analogs were labeled with indium-111 and evaluated in vitro for their specific binding, their affinity and their cellular retention. The selected compounds were then evaluated in vivo in mice bearing tumors expressing PSMA. Based on the results, 2-naphthyl-L-alanine appears to be crucial for good targeting properties, while tranexamic acid could be replaced by other substituents. [111In]In-BQ7859, consisting of a 2-naphthyl-L-alanine-L-tyrosine linker, demonstrated favorable targeting properties. The substitution of tranexamic acid for L-tyrosine in the linker led to an improvement in the tumor-to-blood ratio, highlighting [111In]In-BQ7859 as a promising radioligand targeting PSMA.

PMID:35631684 | DO I:10.3390/pharmaceutical14051098

Black Buffalo Determined to Rebuild While Facing Heartbreak and Grief

The national media packed their bags and moved on to America’s next mass shooting. But residents of East Buffalo, where 85% of the population is black, are still grieving — while trying to figure out how to rebuild.

“This is not one of those situations where we can just go about our daily lives,” said Jillian Hanesworth, Buffalo’s first Poet Laureate and social justice activist working for the Open Buffalo organization.

The May 14 massacre amplified the plight of a community that had long been underprivileged before 10 black people were gunned down by a white supremacist in a supermarket.

Through the horror and grief – and in some ways, inspired by it – Black Buffalonians see a desperate need for substantial community-wide change that goes beyond reopening the Tops Friendly Market.

Through tears, they say they view the massacre as an inflection point to expose and repair the city’s many black community deficits. And they blame Buffalo’s first black mayor, Bryon Brown, for being at the forefront of that revitalization.

Hanesworth said Open Buffalo is working to meet people’s immediate needs, “but at this point, it’s life or death for this community. A lot of things have to happen on the other side of that.

The targeted attack took place in what was Buffalo’s only Black neighborhood grocery store for nearly 20 years. This dubious distinction aside, the store became the center of the neighborhood, a gathering place, amplifying the impact of the butcher’s shop.

“Tops not only served as a grocery store, but there was a pharmacy there where the community got prescriptions filled,” said Thomas Beauford, president of the Buffalo Urban League. “A lot of people were cashing their paychecks there. And they were using Tops to buy money orders to pay a bill. All that has disappeared.

The fact that the store is now closed – and will be for some time – makes it more difficult for the region to recover because so many people relied on this one resource.

Despite the crucial market position in the neighborhood, the feeling was that Tops on Jefferson “didn’t have the same level of investment” as stores in Buffalo’s white neighborhoods, Beauford said. “It was already lower, but that’s all we had.”

Hanesworth said she has been on the ground since the shooting, working in various capacities to help heal and fill in the gaps created by the shooting. “People here are fed up,” she said.

“Our people are starving, and they were starving before May 14, 2022,” she said. “I’m glad the community is pulling together. We keep people eating not only through donations and graciously helping organizations, but also by providing shuttles to take customers to other grocery stores in town.

“But,” Hanesworth added, “we shouldn’t have to be kicked out of our community to buy groceries.”

The median income in East Buffalo is $42,681, according to the 2021 U.S. Census, and many East Buffalo residents do not own cars and rely on public transportation to get around. The census indicates that the median income of black households in Buffalo has increased by only $2,650 from 1990 to 2020.

In all social categories – services, wages, transportation, job opportunities and health disparities – blacks in East Buffalo lag far behind white residents and have seen little progress in 30 years. according to The Harder We Run, a 2021 study by Henry Louis Taylor, professor of urban studies at the University at Buffalo.

“Dr. Taylor’s study says it all,” said Dorothy Hill, an 87-year-old native who remains active in social issues. “We’ve been so demoralized in East Buffalo for years, decades. And It’s just not acceptable. It has to stop now.”

Beauford stressed the need to continue supporting and developing Buffalo’s east side. “And because of how the community has been ignored in the past, there is a lot of concern about whether the right investment will be made in recovery from this tragedy.”

That’s where Brown comes in, say community leaders. He served as mayor of Buffalo for 16 years, “and we’re in the state we’re in under his tenure,” Hanesworth said. “That says a lot.”

She credits the mayor with developing the Northland Workforce Training Center, which prepares residents for employment and provides other services, as well as hiring more black workers from sanitation. “But when you look at the general status of the community,” Hanesworth said, “the answer is that people today are just as hungry as they were before he was mayor.

“He inherited a very racist system. But once you inherit something, you have two choices: you can change it or you can keep it as it is. So while there have been some bright spots in our community, it hasn’t even been enough to confront the systemic oppression black people face in the city of Buffalo. We need more commitment from him.

The mayor’s commitment

For his part, Brown told NBC News that he and his family live in East Buffalo and that he was and remains committed to improving the area. He added that he had been assured by the chairman of Tops that the store would be fully renovated and eventually reopen.

Additionally, Brown said he plans to use the U.S. East Buffalo bailout money to create “training programs where we can help people get up to speed quickly, where people will go from training for living-wage, family-supporting jobs. We will make record investments in improving infrastructure on the east side of Buffalo and throughout the city.

Buffalo Mayor Byron Brown leaves the funeral of Aaron Salter Jr. at Crosspoint Chapel in Buffalo, NY May 25, 2022.Joshua Thermidor / Getty Images

He cited several accomplishments during his tenure, including building the Jefferson Library and a local police station, hiring the “most diverse staff in the city’s history,” tearing down thousands of vacant buildings conducive to crime and drugs and an increase in the annual budget. on youth employment.

Still, he said the burden of building or rebuilding the community should not fall on him alone.

“Everyone should be on deck,” he said. “The city, the state, businesses, associations, everyone. But it also has to be the people of East Buffalo. People need to be more aware that government cannot be the only actor. People must also be involved in their upliftment.

The community and many others responded to immediate needs. Organizations large and small have been invaded by volunteers, from Buffalo, the state and beyond. More than $3 million worth of food has been donated to the city’s east end, Brown said.

“A terrific response to help with healing and to help us move the community forward,” he added.

There’s a lot going on in the field. At the Resource Council of West New York, FeedMore WNY, a regional food bank, provided milk, potatoes, produce and other goods to more than 1,100 people a day in tents. People often congregate and grind at the site, as they did at Tops.

The daily gatherings that take place to remember or mourn the victims are moving, but also uplifting. Hanesworth, author of The Revolution Will Rhyme, performs inspirational and uplifting poems for residents.

Dorothy Hill and her son Michael Hill, the director of the Langston Hughes Arts Center, organize local artists to mount exhibits in the area around the store to inspire, uplift and even entertain the community.

For those who need professional help coping with the shooting, the Buffalo Urban League has brought in a cache of black therapists to serve those looking to make sense of the senseless for a community that prefers counselors black for reasons of comfort and cultural competence.

The organization has set up a makeshift office that welcomes mourners. Melissa Archer, a board-certified psychiatric nurse and native of Buffalo, leads a team of 15 people who have administered counseling to more than 1,000 people, she said.

“People walk into our office and start crying,” Archer said. “They’re scared. They’re angry and tired of being tired. Very scary, depressed, anxious, especially the last few days now that the media is gone and things have calmed down for Jefferson. Are they going to be left alone here? How are they going to eat? How are they going to put the pieces back together? How are they going to stay safe? How are they going to do this on their own?

“We met a lot of people who had just left their homes for the first time since it happened. They are frustrated,” Archer said. “They feel that we are not doing enough to protect them. But we work to build that resilience, that community resilience, individual resilience, and family resilience.

Rita Hubbard-Johnson said she cried the first time she passed by Tops after the shooting. A staple of the community, she and others — like Curtis Haynes, an associate professor of economics at Buffalo State College, who proposed a food co-op for the city that was rejected — have for years pushed the local government to invest. in creating healthy food options in the community. The tragedy made her more determined to do so.

“I have to be,” said Hubbard-Johnson, owner of NeuWater and Associates, a firm that focuses on population health and the social determinants of health conditions. “This horrific event has shown that we cannot survive in just one grocery store, especially one that operates on corporate thinking about who black people are and what they are and what they deserve or what they can obtain.”

Pressed on whether the east side would have another supermarket, Brown stopped short of committing.

“After so many years, an infrastructure plan or reinvestment in this community should have happened by now,” Hubbard-Johnson said. “But I would like to think that this was a wake-up call for all the influential people in city hall, county government and state government – ​​and even federal halls – because the kind of improvements needed here have been a long time coming.

Follow NBCBLK on Facebook, Twitter and instagram.

The surprising partnership of the binding histone with single-stranded DNA

An artistic depiction of the interaction between single-stranded DNA and the H1 binding histone, featured on the cover of the journal in which the new findings were reported. 1 credit

To maintain order in the tight quarters of the cell nucleus, our DNA is carefully held in place around a central disk by the binding histone H1, which helps guide DNA into the tidy chromatin fibers that make up the chromosomes. However, the binding histone is much more than just a protein clip. Without enough H1, the gene transcription process fails and the complex dance of DNA repair comes to a screeching halt. Perched unassumingly atop our nucleosomes, the humble binding histone somehow seems to drive several processes critical to genome maintenance.

Now a new study in Nature Structural and Molecular Biology suggests that the binding histone can distinguish between different forms of nucleic acids, with a clear preference for the formation of condensates with single-stranded DNA rather than double-stranded DNA. This discriminating feature provides further evidence that the role of H1 extends far beyond that of chromatin compaction and may help explain the protein’s contribution to DNA repair and a number of human diseases.

“It changes the paradigm of H1 function in the cell and offers a new perspective in understanding different H1 variants and disease-associated mutations,” says Rockefeller’s Shixin Liu, head of the Laboratory of Biophysics and Biochemistry at the nanometer scale.

Scientists have long suspected that histone binding plays a key role in multiple genomic processes. Besides the evidence that H1 is involved in DNA repair and transcription, the existence of many different types of histone binding in our cells implies an expanded role for the protein. “We wouldn’t need 11 different histone binding subtypes if its role was purely structural,” says Rachel Leicher, a former graduate student in Liu’s lab who led the study with one of the students. Liu’s current graduate, Gabriella Chua.

Motivated by this suspicion, Liu, Leicher and Chua formed a collaboration with a team at Memorial Sloan Kettering Cancer Center led by Yael David, who had pioneered the purification of recombinant histone binding proteins. They relied on the laboratory’s area of ​​expertise, the detection and manipulation of single molecules, to closely study how H1 interacts with DNA.

By shooting double-stranded DNA between focused laser beams known as optical tweezers, Liu and his colleagues stretched a sample until parts of it melted into single-stranded DNA. The binding histone, to their surprise, flooded the single-stranded region. Further investigations have demonstrated that H1 and single-stranded DNA accumulate in a viscous gel-like droplet, distinct from the more fluid droplet created when H1 reluctantly fuses around double-stranded DNA. And the accompanying computer simulations performed by Bin Zhang’s lab at MIT, as well as cellular imaging of histone binding function in the nucleus performed by the David lab, were consistent with the in vitro findings from the Liu lab. .

“We did not accept this hypothesis – our hypothesis was that H1 would only interact with double-stranded DNA and nucleosomes,” says Leicher. “But when we stretched the DNA, we happened to observe the accumulation of H1 around the portions of the molecule that had broken into single strands. That’s when we realized that H1 not only binds single-stranded DNA, but likes it better than double-stranded DNA.

Since one of the hallmarks of DNA damage is the breakdown of double strands into frayed single strands, the results fit well with the proposed role of H1 in DNA repair. If H1 is involved in the DNA damage response, one would expect it to show particular affinity for single-stranded DNA. The current study focused on a particular H1 subtype, also one of the most abundant. Future studies will investigate how other binding histone subtypes interact with damaged DNA, continuing to capitalize on the optical tweezer technique that has allowed the lab to study the material properties of molecular condensates of a way that traditional techniques cannot.

In the long term, a better understanding of histone binding could inform research on several cancers associated with H1 mutations. “Our work opens up a new way of thinking about the function of histone binding,” Liu says. “It’s not purely an architectural factor, but a protein that plays a diverse and dynamic role. And since we know that H1 mutations can cause certain cancers, we are particularly interested in studying the impact of histone binding on genome stability and gene expression.

Researchers use laser ‘tweezers’ to study chromatin structure and dynamics

More information:

Rachel Leicher et al, Binding and coacervation of single-stranded nucleic acid by the binding histone H1, Nature Structural and Molecular Biology (2022). DOI: 10.1038/s41594-022-00760-4

Provided by
Rockefeller University

Surprising partnership of histone binding with single-stranded DNA (2022, May 27)
retrieved 28 May 2022
from https://phys.org/news/2022-05-linker-histone-partnership-single-stranded-dna.html

This document is subject to copyright. Apart from any fair use for the purpose of private study or research, no
any part may be reproduced without written permission. The content is provided for information only.

bleeding heartland

Bleeding Heartland welcomes guest posts advocating for Democratic candidates in competitive primaries for local, state or federal office. Please read these guidelines and contact Laura Belin if you are interested in writing.

I want to introduce myself to the readers of Bleeding Heartland. I am Michael Andreski, Democratic candidate for District 31 of the Iowa House of Representatives.

Why am I running for this office? The short answer is because the opportunity was there, and I was encouraged by several people, including Democratic State Representative John Forbes of Urbandale.

But the long answer is that as a fifth generation Iowan, I couldn’t stay away for long and see the state where I was born, raised, educated, started a career and raised a family continue to become a place I no longer recognize as the Iowa I know and love.

KU awards 73 MPhil, 36 doctorates in various disciplines

The Council for Advanced Studies and Research of the University of Karachi has awarded 73 master’s degrees and 36 doctoral degrees in various disciplines.

Acting KU Registrar Prof. Dr. Maqsood Ali Ansari said that the ASRB at the meeting under the chairmanship of Acting KU Vice-Chancellor Prof. Dr. Nasira Khatoon awarded these degrees, reads the statement posted here on Friday.

According to him, MPhil degrees were awarded to Khalid Gulab and Rimsha Munir (Agriculture and Agribusiness Management), Dr. Rais Ahmed (MBBS) (Anatomy [BMSI]), Zahrah Mohammad Rafique and Syed Immad Uddin Hussani (Applied Economics [AERC]), Humaira Sharif (Biochemistry), Razim Ali (Biotechnology), Hira Yaqoob and Muhammad Rizwan (Biotechnology [KIBGE]), Hafsah and Hira Anwer (Botany), Muhammad Hamza Khan (Botany [ISHU]), Khansa Fauq, Shazia Ghaffar, Hidayat Bibi, Alveena Saghir, Fahad Ahmed Hassan, Ghazala Aftab, Muneera and Saima (chemistry), Shafia Sagheer, Samina Karim and Farzeen Ghazal (chemistry [HEJ]), Binish Nighat, Rushna Siddiqui, Rabiea Faruqi and Zarlish Zafar (clinical psychology), Sadia Perveen and Syed Salman Ali (business), Muhammad Bilal and Rozi Ali (criminology), Sharmeen Ismail (English [ELT and Applied Linguistics]), Nilofar Yaqeen (environmental studies), Syeda Mehreen Naeem (food science and technology), Sanober Rafi, Hafiz Muhammad Tariq Zaman Khan and Umair Majeed (geology), Iram Iqbal Shamsi (health, physical education and sport), Niaz Fatima, Sumaira Ashraf, Faiza and Ayesha Faheem (Islamic learning), Muhammad Shoaib, Muhammad Noor Mustafa Barkati and Syed Zaki Ahmed (Islamic studies with computer technology (SZIC), Anis Fatima (marine biology), Muhammad Zubair and Sumayya Akhtar (mass communication studies), Maria Aman and Muhammad Illyas (mathematics), Mamona Mushtaq, Tooba, Maria and Shaista Qayyum (molecular medicine), Sami Ullah (nematology [NNRC]), Ali Qasim and Qamraz Bibi (Pakistani studies), Hira Arif, Asiya Farheen, Syeda Abiha Rizvi and Farah Batool (pharmaceutical chemistry), Sadia Iqbal (pharmacy), Sobia Gul and Asma Noor (pharmacognosy), Sadaf Alam and Aisha Rizvi ( Pharmacology), Mushtaque Ahmed (Psychology), Madiha Erum (Quran and Sunna), Naseer Ahmed (Sindhi), Muhammad Asad Khan (Social Work), Muhammad Tayyab (Usooluddin), Tayba Khalid (Women’s Studies) and Muhammad Kamil Nadeem ( Zoology).

Kennesaw State senior earns spot in exclusive chemistry research program

KENNESAW, Georgia (May 27, 2022) — Kaia Ellis, a chemistry major at Kennesaw State University, is one of nine undergraduate students chosen from hundreds of applicants for a prestigious 10-week summer research program in chemistry at Northeastern University in Boston.

Kaia Ellis

The research opportunity is part of the National Science Foundation’s Research Experiences for Undergraduate Students (REU). During his REU program, Ellis will study and discuss the chemistry of catalysis across the spectrum, from small molecule catalysts to enzymes. Catalysis is an important aspect of organic chemistry for medicinal chemistry, which she described as a possible career path.

“I saw that Northeastern had research in medicinal chemistry and I’ve been interested in it for a year,” said Ellis, a senior from Atlanta. “Not many schools have a dedicated medicinal chemistry research lab, so when I found the REU program at Northeastern University, I decided to apply. I accepted the offer to join the program over the summer to see if this is what I really want to pursue after I graduate.

Seeking enrichment opportunities has become second nature to Ellis, who joined the lab of Kennesaw State Assistant Professor of Organic Chemistry Carl Saint-Louis in the fall of 2021.

St. Louis research focuses on the discovery and characterization of new fluorescent organic materials widely used in the fields of materials and imaging technologies due to their potential applications in molecular sensors, laser optical recordings and materials. organic light-emitting diodes (OLED). Ellis thrived in her lab, and she credited St. Louis for encouraging her, both to improve her knowledge of organic chemistry and to apply for Northeastern’s REU program.

“At first, even joining Dr. Saint-Louis’ lab, I was anxious because I had never worked in a lab before,” Ellis said. “He kept reminding me that science is a process and learning science is a process. It was the same applying for the research opportunity, but I’m really glad he continued to encourage me to apply.

St. Louis said Ellis is a shining example of how students grow through the experience of working in a lab.

“Kaia joined my lab excited about organic chemistry,” he said. “She discovered that we were working on projects that interested her and she immersed herself in the work. Now she will gain even more lab and research experience over the summer.


This summer, Ellis can expect 10 weeks of immersion in the study of catalysis, which studies the effects of using a catalyst to create a chemical reaction. She said her group will have weekly seminars and classes. More importantly, Ellis said experiences like these are within the reach of any Kennesaw State undergraduate student interested in research.

“Research enhances the learning process and helps connect classroom work to practical application,” she said. “It can really help people understand what they want to do in science.”

—Dave Shelles
Photo by David Caselli

Related stories

A leader in innovative teaching and learning, Kennesaw State University offers undergraduate, graduate, and doctoral degrees to its nearly 43,000 students. With 11 colleges on two metro Atlanta campuses, Kennesaw State is a member of the University System of Georgia. The university’s vibrant campus culture, diverse population, strong global connections, and entrepreneurial spirit attract students from across the country and around the world. Kennesaw State is a Carnegie-designated (R2) doctoral research institution, placing it among an elite group of only 6% of US colleges and universities with R1 or R2 status. For more information, visit kennesaw.edu.

The Opportunity in the Freeze Drying Services Market

London, May 26, 2022 (GLOBE NEWSWIRE) — Root analysis announced the addition of “Lyophilization Services Market for biopharmaceuticals (2nd edition)2022 – 2035” report to its list of offers.

In order to achieve longer and commercially viable shelf lives, lyophilization has become the preferred approach, allowing the manufacture of stable, dry biopharmaceutical formulations. Currently, a number of biopharmaceutical companies outsource their freeze-drying operations to contract service providers who have dedicated facilities, equipment and production lines for this purpose. Additionally, technological advancements in this area have improved the productivity and efficiency of the overall process.

To order this 220+ page report, which includes over 80 figures and over 140 tables, please visit

Key market information

More than 105 companies claim to offer lyophilization services for biopharmaceuticals worldwide
The majority (48%) of industry players are based in North America, followed by those headquartered in Europe (42%). In addition, more than 40% of service providers have the capacities required to perform protein freeze-drying, followed by companies offering freeze-drying services for antibodies (32%) and vaccines (21%).

More than 55% of partnership agreements were signed in 2020 and 2021
The majority of agreements related to the lyophilization of biopharmaceuticals were observed as examples of acquisitions, representing more than 60% of the total partnerships. Additionally, most intercontinental deals, as well as intracontinental ones, have been signed by players based in North America.

Expansion activity in this area grew at a CAGR of approximately 28%, between 2018 and 2021
Approximately 55% of initiatives focused on adding freeze drying capacity, followed by examples of facility expansions (32%) and new facility additions (14%). More than 85% of reported expansions in this area were local initiatives, followed by international initiatives (12%).

North America and Europe are expected to capture more than 70% market share by 2035
Also, the market in Asia-Pacific is expected to grow at a relatively faster rate (7.8%), in the long term. Moreover, in 2035, the majority share (52%) of the global biopharmaceutical lyophilization market will probably be captured by antibodies.

To request a copy / brochure of this report, please visit

Answers to key questions

  • Who are the major players engaged in offering freeze drying services for biopharmaceuticals?
  • What is the relative competitiveness of freeze drying service providers for biopharmaceuticals?
  • What types of partnership models are commonly adopted by players in this industry?
  • What are the different types of expansion initiatives undertaken by freeze drying service providers for biopharmaceuticals?
  • What are the key market trends and driving factors that are likely to impact this market?
  • How is the current and future market opportunity likely to be distributed across key segments?

The financial opportunity in the lyophilization services market for biopharmaceuticals has been analyzed in the following segments:

Type of organic freeze-dried

  • Antibody
  • Cell and gene therapies
  • Vaccines
  • Other organic products

Type of primary packaging system

  • Vials
  • Syringes
  • Cartridges
  • Bulbs
  • Others

Key geographic regions

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and North Africa
  • Rest of the world

The report also features contributions from eminent industry players, according to which the continued growth of biologic therapeutics pipeline and growing preference for outsourcing is likely to drive the growth of the overall Freeze Drying Service Provider market, in the near future. The report includes detailed transcripts of discussions held with the following experts:

  • Brian Sasaki (Director of Business Development) and Thomas Ingallinera (Vice President of Technical Support, Pharmaceutical International)
  • Doreen Coull (Regional Sales Manager, Curia)
  • Patrick DePalma (Former CMO Business Development Manager, BioDefense Division, Emergent BioSolutions)
  • Rocio Gonzalez Rodriguez (CDMO Project Management Manager, Liof Pharma)
  • John Shaw (former Head of Business Development and Marketing, Vibalogics)
  • Sophia Kim (Commercial Director of Sales (Filing Participant) / Group Head, Samsung Biologics)
  • Marianna Tcherpakov (Head of Business Development, Bioserv)
  • Adam Inche (Marketing Director, Symbiosis Pharmaceutical Services)
  • Adam Viverette (Freeze Drying Manager, Patheon)
  • Steven Nail (Principal Researcher, Baxter BioPharma Solutions)

The search includes profiles of key players (listed below); each profile presents a brief overview of the company, its financial performance (if available), recent developments and informed future prospects.

  • Baxter BioPharma Solutions
  • BioZed Engineering
  • CinnaGen
  • Corden Pharma
  • Coriolis Pharmaceuticals
  • Curia
  • Emerging BioSolutions
  • Manufacturing under LSNE contract
  • Freeze-drying technology
  • MabPlexComment
  • Northway Biotech
  • Pharmaceutical Project
  • Samsung Organics
  • Vetter Pharma
  • WuXi Organic Products

For more details, please visit
https://www.rootsanalysis.com/reports/view_document/lyophilization-services-market-for-biopharmaceuticals/161.html or email [email protected]

You might also be interested in the following titles:

  1. Pharmaceutical secondary packaging Market: industry trends and global forecasts, 2022-2035
  2. Continuous manufacturing (small molecules and biologics) Market (2nd edition): industry trends and global forecasts, 2022-2035
  3. Live biotherapeutics and microbiome manufacturing Market: industry trends and global forecasts, 2022-2035
  4. Peptide Therapeutics: API Contract Manufacturing Market: industry trends and global forecasts, 2022-2035
  5. Manufacture of biopharmaceutical excipients Market: industry trends and global forecasts, 2022-2035
  6. Companion diagnostics development services Market: industry trends and global forecasts, 2022-2035


Texas and Mental Health Care Under the Microscope After Uvalde School Shooting

Democratic gubernatorial candidate Beto O’Rourke interrupted the press conference to blame Abbott for his inaction, saying Texas ranked 50th in the nation for mental health in an apparent reference to a report published in 2020.

An updated report currently places Texas 33rd in adults with mental illness and access to health care, according to this now-updated report. However, Texas ranks 41st when it comes to young people with mental illness. When it comes to overall access to mental health care, Texas ranks dead last at #51 (the District of Columbia is included with the 50 states in the ranking).

For fiscal year 2022, Texas reduced its general revenue fund contributions to community adult, pediatric, and crisis mental health services provided through health and human services by $237,163. However, community mental health grant programs saw their funding increase by $2,910,409. For the same budget period, federal funding increased by $41,103,876.

The Texas House rejected a proposal last April that would have used billions of dollars in federal funding to expand Medicaid to some of Texas’ estimated 5 million uninsured residents and potentially improve access to mental health care.

According to the Kaiser Family Foundation, only 9.7% of adults with mental illness reported having access to Medicaid in 2018 and 2019, compared to 21.6% of adults nationally. Medicaid covers most mental health treatments. There were 3.3 million adults who reported having a mental illness in Texas, and 59.6%, or 1,960,000, of that figure did not receive treatment, according to a 2021 ranking from Mental Health America. .

From 2018 to 2019, 69.8% (1,268,000) of adults with mild mental illness in Texas did not receive care, according to the Kaiser Family Foundation. For adults with serious mental illness during the same period, 44.7% (375,000) of those adults in Texas did not receive care.

Families lay flowers near a memorial at Robb Elementary School in Uvalde, Texas on Wednesday.

Jerry Lara/San Antonio Express-News

Break down the barriers

Residents of Uvalde have access to mental health services through Community Health Development Inc., which also serves Real, Edwards and Zavala counties.

CEO Mayela Castañon says CHDI receives grants from the state Health Resources and Services Administration, as well as funding from the City and County of Uvalde for indigent health care. Real, Edwards and Zavala counties do not contribute to the organization, she says, and there is only one psychiatrist and one licensed clinical social worker for the four counties – a total population of 38,527 according to the 2021 census estimates.

The town of Uvalde has contributed $65,000 annually to the CHDI for the past five years, according to its recent budget. Uvalde County budgeted $2.7 million for indigent health services in fiscal year 2021, but it was not immediately clear how much of that sum went to the organization.

CHDI posted on Facebook on Wednesday announcing plans to provide bereavement counseling to families affected by the shooting. Castañon says other mental health professionals come from surrounding areas to lend their services.

Over the next two months, mental health services will be available to all members of the community, with no immediate plans to charge for services for the bereaved community, she said.

“I just want to make sure we break down all the barriers and make it available to everyone who needs it,” Castañon says. “It doesn’t matter income, insurance, whatever⁠ – all we want to do is provide the services to the community.”

CHDI offers mental health services including counselling, clinical assessments, therapies, medication management and on-site pharmacy services, as well as in-person and virtual visits. All of these services are offered with a “variable fee discount” available to families earning less than 200% of the federal poverty guidelines, which is based on family sizes ranging from 1 to 8 and with incomes ranging from $13,590 to $46,630.

In Uvalde, the median household income in 2020 was $45,936, while the median personal income was $21,036, according to the US Census Bureau. Census data from July 2021 estimates that Uvalde is 72.7% Hispanic or Latino.

Patients requiring services must provide a driver’s license or government-issued ID and either: their last four pay stubs; their most recent tax return if you are self-employed; proof of residence such as a utility bill; insurance card or proof of Medicare or Medicaid if available. The typical minimum fee is $20 for mental health services, according to Castañon.

For immigrants or residents without ID, accessing this discount or other mental health services could be difficult. Castañon says for those who don’t have ID or proof of income, they have a self-certification process where those who need it can claim their income and identity. Castañon says CHDI doesn’t know whether or not any of its patients are living in the country without legal permission because the organization doesn’t specifically request that information.

Dangerous counterfeit drugs put millions of US consumers at risk, new study finds

Courtesy of C. Michael White, University of Connecticut

The research summary is a brief overview of interesting scholarly work.

The big idea

The Food and Drug Administration took 130 enforcement actions against counterfeit drug rings from 2016 to 2021, according to my new study published in the journal Annals of Pharmacotherapy. Such actions may involve arrests, confiscation of products, or the disbanding of counterfeit rings.

These counterfeit operations involved tens of millions of pills, over 1,000 kilograms (2,200 pounds) of active ingredient powder that could be made into pills in the United States, and hundreds of millions of dollars in sales. Unfortunately, with over 11,000 rogue pharmacy sites selling drugs on the internet, these actions only scratch the surface.

The FDA’s Office of Criminal Investigations conducts and coordinates criminal investigations of manufacturers and individuals who violate federal drug laws. The agency maintains a database with links to press releases for their enforcement actions. Overall, in 64.6% of cases over this five-year period, counterfeit products were sold over the Internet, and in 84.6% of enforcement actions taken, products were obtained without a prescription. .

Many counterfeit drugs involved controlled substances such as opioids such as oxycodone and hydromorphone and stimulants such as those commonly used to treat attention deficit/hyperactivity disorder, as well as benzodiazepines, which are used to anxiety and sleep. China, India, Turkey, Pakistan and Russia were the most common countries supplying American consumers with counterfeit drugs.

why is it important

The World Health Organization reports that about 11% of medicines sold in developing countries are counterfeit, resulting in 144,000 additional deaths per year from antibiotics and antimalarials alone. My previous study also documented 500 child deaths attributed to diethylene glycol – a common additive in antifreeze – added to cough suppressants as a sweetener.

In addition, from November 2021 to February 2022, counterfeit versions of drugs used for chronic conditions – such as the transplant drug tacrolimus, sold under the brand name Limustin, and the blood thinner rivaroxaban, or Xeralto – were found. on the shelves of Mexican pharmacies.

In the United States, the Drug Quality and Security Act of 2013 secures the drug supply through a national electronic track and trace system that tracks a specific drug from the manufacturer to the pharmacy. While drugs in licensed US pharmacies are safe, a Kaiser Family Foundation survey found that 19 million people in America obtained prescription drugs that are likely counterfeit through licensed non-US internet pharmacies or while traveling to the stranger. The National Association of Boards of Pharmacy found that 96% of the 11,688 online pharmacies analyzed did not comply with US federal or state laws. Of these, 62% did not reveal their physical location and 87% were affiliated with “rogue internet drug outlet networks”.

The FDA offers guidance to help consumers determine if an online product is legitimate.

How counterfeit drugs can end up in your medicine cabinet.

Opioids, benzodiazepines and stimulants are highly addictive and dangerous when taken improperly or when used together. Although these counterfeit drugs may appear legitimate, the active ingredients believed to be in these controlled substances are frequently replaced with more dangerous alternatives such as fentanyl. Four out of 10 counterfeit opioid pills containing fentanyl contain a potentially lethal dose.

According to the Drug Enforcement Administration, the United States confiscated 9.5 million counterfeit pills from April 2020 to April 2021, more than the previous two years combined. This is likely a driver of the 100,306 drug overdose deaths in the United States during this period.

Fraudulent online pharmacies frequently use social media platforms to reach potential customers. This suggests that online platforms like social media, online forums and search engines need to do more to identify and stop illegitimate online prescription drug sellers.

People who buy controlled substances over the Internet usually try to circumvent the doctor’s control over the drugs or the quantities they can receive. However, most people who access counterfeit drugs of uncontrolled substances are simply trying to buy them at an affordable price. These trends clearly show that the United States needs a long-term strategy to reduce the cost of prescription drugs in order to reduce the demand for counterfeit drugs, although there are money-saving strategies that can be used in the short term.

C. Michael White, Professor of Pharmacy Practice, University of Connecticut

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Raman Spectroscopy Sales Market Size and Forecast

New Jersey, United States – Raman Spectroscopy Sales Market The 2022-2029 report has been prepared based on an in-depth market analysis with input from industry experts. The Raman Spectroscopy Sales market study sheds light on the significant growth momentum that is expected to prevail during the assessment period 2022-2029. The study offers statistics on key segments in important geographies, along with detailed mapping of the global competitive landscape. Additionally, the market report tracks global Raman Spectroscopy sales in 25+ high growth markets, while analyzing the impact COVID-19 has had on the current industry and the Raman Spectroscopy sector in particular.

Main Drivers and Obstacles:

The high-impacting factors and renderers have been studied in the Raman Spectroscopy Sales market report to help readers understand the overall development. Additionally, the report includes constraints and challenges that can be stumbling blocks in the players’ path. This will help users to be attentive and make informed decisions related to business. Specialists also focused on future business prospects.

Get Sample Full PDF Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.verifiedmarketreports.com/download-sample/?rid=509505

(Use company email id to get higher priority)

In its latest report, Verified Market Reports offers a comprehensive overview of the Raman Spectroscopy Sales Market with a focus on key dynamics including drivers, restraints, opportunities, trends and detailed information on the structure of the Raman spectroscopy sales market. The sales of Raman spectroscopy sales market across the world will increase with the growing adoption of R&D activities and advanced technologies. With the outbreak of COVID-19, businesses have become heavily dependent on digital platforms for their survival.

Top Key Players in Raman Spectroscopy Sales Market Research Report:

Horiba Jobin Yvon, Renishaw, Thermo, B&W Tek, Bruker, Kaiser Optical, Ocean Optics, Smiths Detection, JASCO, Sciaps, TSI, Agilent Technologies, Zolix, GangDong

Key Segments Covered in the Raman Spectroscopy Sales Market – Industry Analysis by Types, Applications and Regions:

Raman Spectroscopy Sales Market – Type Outlook (Revenue, USD Million, 2017 – 2029)

• Benchtop Raman spectroscopy
• Portable Raman spectroscopy

Raman Spectroscopy Sales Market – Application Outlook (Revenue, USD Million, 2017-2029)

• Pharmaceutical
• R&D in academia
• Industrial sector
• Others

For more information or query or customization before buying, visit @ https://www.verifiedmarketreports.com/product/raman-spectroscopy-sales-market-size-and-forecast/

Scope of the Raman Spectroscopy Sales Market Report

UNITY Value (million USD/billion)
SECTORS COVERED Types, applications, end users, and more.
REPORT COVER Revenue Forecast, Business Ranking, Competitive Landscape, Growth Factors and Trends
BY REGION North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
CUSTOMIZATION SCOPE Free report customization (equivalent to up to 4 analyst business days) with purchase. Added or changed country, region and segment scope.

Raman Spectroscopy Sales Market Regional Analysis:

The Raman Spectroscopy Sales market research report details current market trends, development outline, and several research methodologies. It illustrates the key factors that directly manipulate the market, for example, production strategies, development platforms, and product portfolio. According to our researchers, even minor changes in product profiles could lead to huge disruptions in the factors mentioned above.

➛ North America (United States, Canada and Mexico)
➛ Europe (Germany, France, United Kingdom, Russia and Italy)
➛ Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
➛ South America (Brazil, Argentina, Colombia, etc.)
➛ Middle East and Africa (Saudi Arabia, United Arab Emirates, Egypt, Nigeria and South Africa)

What insights does the Raman Spectroscopy Sales market report provide readers?

➜ Raman Spectroscopy Sales fragmentation based on product type, end-use and region
➜ Comprehensive assessment of upstream raw materials, downstream demand and current market landscape
➜ Collaborations, R&D projects, acquisitions and product launches of each actor Raman Spectroscopy Sales
➜ Various regulations imposed by governments on the consumption of Raman Spectroscopy Retail Sales
➜ Impact of modern technologies, such as big data and analytics, artificial intelligence and social media platforms on Raman spectroscopy sales

Get a discount on the purchase of this report @ https://www.verifiedmarketreports.com/ask-for-discount/?rid=509505

Visualize the Raman Spectroscopy Sales Market Using Verified Market Intelligence:-

Verified Market Intelligence is our BI platform for market narrative storytelling. VMI offers in-depth forecast trends and accurate insights on over 20,000 emerging and niche markets, helping you make critical revenue-impacting decisions for a bright future.

VMI provides a global overview and competitive landscape with respect to region, country and segment, as well as key players in your market. Present your market report and results with an integrated presentation function that saves you more than 70% of your time and resources for presentations to investors, sales and marketing, R&D and product development. products. VMI enables data delivery in Excel and interactive PDF formats with over 15+ key market indicators for your market.

Visualize the Raman Spectroscopy Sales Market Using [email protected] https://www.verifiedmarketresearch.com/vmintelligence/

Most Popular Reports

Global Fully Automatic Inserting Machines Sales Market Size and Forecast

Global Radome Sales Market Size and Forecast

Global 3D Metrology Systems Sales Market Size and Forecast

Global Digital Microscope Sales Market Size and Forecast

Global Microscope Sales Market Size and Forecast Insights

Global Heating Cost Allocator (HCA) Market Size and Forecast

Global Exhaust Gas Purifiers Sales Market Size and Forecast

Global Raman Spectroscopy Market Size and Forecast

Global Electrolyte Analyzer Market Size and Forecast

Global Industrial Monitor Sales Market Size and Forecast

About Us: Verified Market Reports

Verified Market Reports is a leading global research and advisory company serving over 5000 global clients. We provide advanced analytical research solutions while delivering information-enriched research studies.

We also provide insight into the strategic and growth analytics and data needed to achieve business goals and critical revenue decisions.

Our 250 analysts and SMEs offer a high level of expertise in data collection and governance using industry techniques to collect and analyze data on over 25,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research.

Our research spans a multitude of industries, including energy, technology, manufacturing and construction, chemicals and materials, food and beverage, and more. Having served many Fortune 2000 organizations, we bring a wealth of reliable experience that covers all kinds of research needs.

Contact us:

Mr. Edwyne Fernandes

USA: +1 (650)-781-4080
UK: +44 (753)-715-0008
APAC: +61 (488)-85-9400
US toll free: +1 (800)-782-1768

E-mail: [email protected]

Website: – https://www.verifiedmarketreports.com/

Building inspired by fire goddess wins award for UH Hilo College of Pharmacy

The late U.S. Senator Daniel K. Inouye, the college’s namesake, was the driving force behind the establishment of the school.

Vigorous Kīhoʻihoʻi, the new home of the Daniel K. Inouye College of Pharmacy (DKICP) at the University of Hawaii in Hilo, was recognized at the 25th Annual Kukulu Hale Awards, which honor excellence in Hawaii’s commercial real estate sector.

The two-story, 45,000 square foot structure completed in December 2019 received an award from NAIOP Hawaii in the category of public/government projects. Vigorous Kihoʻihoʻi houses lecture halls, pharmaceutical compounding labs, simulated pharmacy practice skills and dispensing labs, as well as meeting rooms and innovative spaces for the college.

“With its beautiful open design, Hale Kīhoʻihoʻi is a very welcoming place that offers so many great spaces for learning, research and educational collaboration,” said Miriam Mobley, DKICP acting dean. “The structure also represents a significant commitment and investment by the State of Hawaii at university and the training of health professionals.

With its beautiful open design, Hale Kīhoʻihoʻi is a very welcoming place that offers so many great spaces for learning, research and educational collaboration.
—Miriam Mobley

In ʻōlelo Hawaii (Hawaiian language), kīhoʻihoʻi refers to the rapid restoration of land after a lava flow. According to Hawaiian naming protocol, anything from this new building and the college it houses is intended to promote the restoration of Hawaii’s natural environment and its inhabitants.

Oʻahu-based company, WCIT The architecture has integrated Hawaiian culture and themes into the building’s modern design, from the undulating roofline that represents the goddess Pele and her lava shaping the landscape.
flux, to floor-to-ceiling interior murals that depict the blending of traditional and contemporary healing practices. The design of the building also followed LEED principles that called for environmentally friendly building materials and practices.

Hilo-based Isemoto Contracting served as the general contractor on the three-year construction project, which sits above the main uh Hilo campus and overlooks the city of Hilo and the bay.

Related uh News stories:

(Photo credit: Tracy Niimi)

Drug Discovery Services Market 2020 Analysis with Detailed Competitive Outlook by 2026 | Key Players Thermo Fisher Scientific, Inc. (USA), Albany Molecular Research

Drug Discovery Services Market: Introduction

The global drug discovery services market has witnessed continuous development over the past couple of years and is expected to develop significantly more during the period 2020-2026. Exploration introduces an overall assessment of the Drug Discovery Services Market and contains future patterns, current growth factors, conscious sentiments, certainties, chronicle information, and factually backed and industry-approved market information.

The global drug discovery services market was valued at USD 9649.12 million in 2019 and is projected to grow at 14.0% CAGR during the forecast period.

Competitive analysis

The report contains an in-depth analysis of the vendor’s profile, including financial health, business units, key business priorities, SWOT, strategies and opinions.

Thermo Fisher Scientific, Inc. (USA)
Albany Molecular Research, Inc. (USA)
Charles River Laboratories International, Inc. (USA)
Evotec AG (Germany)
Domains (UK)
GenScript Biotech Corporation (China)
Laboratory Corporation of America Holdings (USA)
WuXi AppTec (China)
Pharmaceutical Product Development, LLC (USA)
Jubilant Biosys Ltd. (India)
Eurofins Scientific SE (Luxembourg)
Piramal Enterprises Ltd. (India)

Suppliers were identified based on portfolio, geographic presence, marketing and distribution channels, revenue generation and significant R&D investments.

Request Sample Report of Global Drug Discovery Services Market @ https://straitsresearch.com/report/drug-discovery-service-market/request-sample

Vendors across different verticals are planning major investments in this market and hence, the market is expected to grow at an impressive rate in the coming years. The major players are adopting various organic and inorganic growth strategies such as mergers and acquisitions, collaboration and partnerships, joint ventures, and few other strategies to gain a strong position in the global market.

Market Segmentation Analysis

The report provides an extensive assessment of the market, providing in-depth qualitative insights, historical data and justifiable projections along with assumptions about the Drug Discovery Service market size. The projections presented in the report have been derived using proven research methodologies and assumptions based on vendor portfolio, blogs, white papers, and vendor presentations. Thus, the research report represents all aspects of the Drug Discovery Service Market and is segmented on the basis of regional markets, offerings, applications, and end-users.

By type

Drug metabolism
Biology services
Medical chemistry
By process

Target validation
Target selection
Hit-To-Lead Identification
Validation of candidates
Lead Optimization
By type of drug

Organic Products
small molecules
By therapeutic area

Respiratory diseases
Cardiovascular illnesses
Per end user

Hospitals & Clinics
Pharmaceutical companies
Biotechnology companies
research Institute

Regional analysis

North America held the largest drug discovery service market share in 2018 and is expected to dominate the market over the forecast period. The market will witness a strong rise in the following regions covered: North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.


Companies in the drug discovery services industry provide business continuity with powerful protection by constantly checking the report and representing attractive growth opportunities for the businesses. Drug Discovery Service meets all the needs of operators by allowing them to improve their services and focus on their core business. Drug Discovery Service Market Research aims to increase business agility and reduce operational and capital expenditures through improved technology deployments and capacity planning. The report examines service types and regions related to this Drug Discovery Service market. Additionally, the report provides details about the major challenges affecting the growth of the market.

Buy now: https://straitsresearch.com/buy-now/drug-discovery-service-market/global/

Other report features:

  1. Provides an in-depth analysis of key strategies with a focus on corporate structure, R&D methods, location strategies, production capacities, sales and performance of various companies.
  2. Provides valuable product portfolio insights including product planning, development and positioning.
  3. Analyzes the role of major drug discovery services market players and their partnerships as well as mergers and acquisitions.

Thank you for reading this article; you can also get individual chapter wise sections or region wise report versions like North America, Europe or Asia.

Trend Report:


About Us:

StraitsResearch.com is a leading research and intelligence organization specializing in research, analysis and advisory services, as well as the provision of market intelligence and research reports.

Contact us:
E-mail: [email protected]
Address: 825 3rd Avenue, New York, NY, USA, 10022
Such : +1 6464807505, +44 203 318 2846

Website: https://straitsresearch.com/

Starved of funding by pending Cuomo exclusion, safety net providers consider layoffs – troyrecord

By Perry Junjulas

Albany’s failure to repeal a pre-pandemic cash grab has left community health and social services centers like mine in a precarious financial vacuum, threatening both jobs and the care we provide to residents. New York’s most vulnerable, the majority of whom are black and brown communities.

The exclusion from Medicaid drug benefits proposed by former Governor Andrew Cuomo, which diverts money from safety net providers to state coffers, will not take effect until April 2023. But the reality is that providers like mine operate under very strict conditions. margins and desperately need predictability.

This 30-year-old federal drug pricing program, known as 340B, allows safety net providers to buy drugs at discounted prices and use the savings to fund services for our clients who don’t are not covered by Medicaid, such as food, housing assistance, transportation, mental health counseling, medical care, and medication adherence assistance.

In April 2021, implementation of the exclusion was delayed by the Legislative Assembly until 2023 after an outcry from lawyers. We hoped that the exclusion plan would be permanently repealed after Governor Hochul took office and pledged to bolster the state’s pandemic-ravaged health care system.

But the governor and legislative leaders missed the opportunity to permanently end exclusion in the 2022-23 state budget. They can still act before the end of the session next month by passing and signing the proposed repeal law. Failure to do so will undoubtedly hurt the 2.3 million New Yorkers who rely on our services, 71% of whom are people of color and 89% low-income.

Excluding Cuomo will prevent safety net clinics from accessing more than $250 million in funding. Those of us with calendar year budgets will soon begin working on the year budget. Without knowing if we can rely on this essential funding stream, we will be forced to consider program cuts and staff cuts at all levels to make ends meet.

The Damien Center alone would lose 20% of our annual budget. Overall, it is estimated that nearly 80% of health centers would lay off or lay off staff, and at least 32 community clinics would be forced to close entirely, according to a survey by the Community Health Care Association of New York.

In the fall of 2020, the Damien Center faced the same dilemma as we prepared our 2021 budget. The proposed exclusion weighed heavily, with no repeal in sight. In December, we reduced our staff by 20%, eliminating eight of 40 positions, and imposed service cuts to all programs.

The ban was extended months later, but the damage was already done. For the first time in 34 years, the Damien Center was forced to conduct a mid-year review of its budget. But we could not, in good conscience, fully restore all cut jobs and services because a delay in implementation is not a total repeal. We were still in limbo.

The whole process was extremely disruptive for staff and customers. And we will have to repeat this painful exercise unless the governor and the legislature act now.

The state maintains that the carve-out will generate significant savings. But based on New York’s Medicaid funding, the state would be required to transfer more than 70% of the funding from the dismantling of the safety net system to the federal government, diverting resources away from communities in need. It does not mean anything.

The world has turned upside down since this ill-conceived plan was put forward. The budget deficit disappeared, thanks in large part to an unprecedented influx of federal pandemic aid. And the need for our services has only increased due to the COVID crisis and worsening economic conditions amplifying health inequities.

Governor Hochul and state legislators are playing a game of chicken with our community health centers, making a decision as we plan our budgets. They must stop torturing safety net facilities with indecisiveness and immediately repeal Cuomo’s exclusion so that we can continue to keep vulnerable New Yorkers safe and healthy.

— Perry Junjulas is executive director of the Albany Damien Center, a non-profit HIV/AIDS service organization and a person living with AIDS.